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ABSTRACT 
 
 
 
 
LSD1, the first identified Lysine specific demethylase that removes methyl groups 
from mono- or di-methylated Histone 3 Lys4 (H3K4), has a mammalian-restricted 
neuronal isoform (LSD1-E8a), generated by the alternative inclusion of the 12-bp 
neurospecific exon E8a. LSD1 general function is to inhibit the expression of 
neuronal genes in non-neuronal cells, but LSD1-E8a isoform is characterized by a 
less gene repressing action. Indeed, the 4 aa coded by the exon E8a, which form a 
protruding loop in the LSD1 catalytic domain, contain a Threonine residue that can 
be phosphorylated and that is required to induce neuronal maturation, neurite 
outgrowth and the abrogation of LSD1-8a repressive activity. 
Using a Minigene reporter assay, we demonstrate that the exon E8a is surrounded 
by a highly conserved 800-bp intronic region that is sufficient per se to regulate 
exon E8a alternative splicing, containing at least in part the necessary cis-acting 
elements. Among them there are the binding sites for NOVA1 and nPTB, that  we 
found to be exon E8a positive trans-acting splicing regulators. Exon E8a, indeed,  
is very tightly modulated and it is present only in neuronal brain tissues and not in 
cell line. Along with positive trans-acting factors, we identified an exon E8a 
complementary/inverted sequence with a very strong negative regulatory effect on 
exon E8a inclusion. Here we show that this sequence acts by forming a double 
strand pre-mRNA pairing in which exon E8a is masked. Indeed, the deletion of the 
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12 core nucleotides of such complementary region promotes a strong exon E8a 
inclusion, allowing binding of trans-acting factors that recognize single-strand 
cis-acting motifs. Furthermore, downstream of exon E8a we identified a new 77-bp 
human-restricted LSD1 alternative exon, that we called “exon E8b”. Its inclusion in 
mature transcripts is regulated by FOX1 and occurs in many different tissues,  
although these transcripts are present at a very low level. This is probably due to 
the fact that exon E8b, by introducing a premature STOP codon inside LSD1 
mature transcripts, causes their degradation by the cellular Non-sense mRNA 
Mediated Decay (NMD) pathway. Exon E8b very low endogenous expression level 
makes it difficult to study its functional role. At the moment we can only say that its 
inclusion into LSD1 transcripts could be a tool at cells disposal to finely tune LSD1 
RNA amount, providing a new human-restricted LSD1 level of regulation.  
Since the epigenetic function of the neurospecific LSD1 isoform has not been 
completely elucidated in-vivo, we generated a knock-out mouse model by replacing 
the sole LSD1 exon E8a with the Neomycin resistance cassette, flanked by two 
loxP sites. LSD1-E8a knockout animals are fertile, survive embryogenesis and 
show no histological differences as well as no obvious developmental defects. 
Interestingly, specific behavioral differences were detected in the exon 
E8a-deficient mice in response to a pharmacologically induced epileptic treatment, 
where they display a longer time of latency and a reduced number of seizures, in 
addition to a more restrained expression-burst of the two immediate early gene 
Egr-1 and c-Fos. From the immunohistological point of view, significative 
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differences were observed in Calbindin, V-GLUT2 and Sox-2 expression and 
distribution, although the characterization is not completed yet.  Our results indicate 
that, in vivo, neuronal LSD1 isoform is not strictly required for normal development 
but it may became relevant to later functional events inside the Central Nervous 
System. 
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1.EPIGENETICS AND ITS RELEVANCE IN        
NEURONAL PLASTICITY 
 
 
1.1 THE LURE OF EPIGENETICS IN THE BRAIN 
 
Our phenotype is the product of continuous gene–environment interactions. 
Environmentally regulated intracellular signals constantly modulate gene 
transcription in order to obtain cellular plasticity. The interaction of such signals with 
regulatory DNA sequences is dynamic and cannot explain instances in which 
extracellular inputs program enduring effects on gene expression and cellular 
function [1]. This issue is of particular interest in the brain, where persistent 
alterations in cellular function are essential for normal activity  [1]. Indeed, the value 
of the brain is to guide the function of the organism in accordance with its life 
history. The capacity to mastermind such adaptation to circumstances relies on the 
possibility of neurons and glia to change their genomic structure in  a replication 
independent manner (Fig. 1.1.1). But how does the life experience re -program 
gene expression in the brain [1]?  
A great number of accumulating evidences suggests that there is much more than 
DNA sequence that permits the brain to reorganize itself, and one way that such 
phenotypic plasticity can be established is through epigenetic mechanisms [2]. 
Epigenetics refers to heritable changes in gene expression that are unrelated to 
variation in DNA sequence [1]. The main instruments at epigenetics disposal are 
DNA methylation and core histone proteins modifications. These epigenetic ‘marks’ 
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can be remodelled by environmentally induced alterations and they are variable 
over time, for this reason they are considered the best tools to obtain the 
phenotypic plasticity shown by neurons throughout life [4]. During all the lifehood, 
indeed, the brain remains flexible and responsive to the outside world [3], so in the 
brain, heritable maintenance is less of an issue than replication independent 
methylation change or chromatin marks remodeling [1]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1.1 The epigenetic interface. 
Epigenetic states lie at the interface between environmental signals and genome, serving to govern dynamic changes in 
transcriptional activity through extra- and intra-cellular mediators. In a multistep process, the epigenetic template attracts specific 
effectors that determine the responsivity of specific genomic regions to environmentally induced intracellular signaling path ways, thus 
leading to more stable effects on the potential of transcriptional activation and variation in neural function (color-graded region). 
 
 
 
1.2 CHROMATIN OVERVIEW 
 
Chromatin is the intimate association of genomic DNA with histone proteins and  
represents the physiological form of our genome and the substrate of the 
epigenetic processes related to gene expression [5].  
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The fundamental unit of chromatin is the nucleosome: a 146 bp-long supercoiled 
DNA wrapped around the radial surface of an octamer, composed of two copies of 
each highly conserved core histone protein H2A, H2B, H3, and H4 [6]. The 
histones H3 and H4 form a tetramer, whereas the histones H2A and H2B form two 
dimers. Each of these histone protein consists in a main globular body (that 
contributes to the central protein mass of the nucleosome) and in a N-terminal tail 
that contains sites for post-translational modifications that influence chromatin 
structure and function [7]. Histone H1 has not been isolated within the 
nucleosomes, because it is located on the top of the structure, keeping in place the 
DNA  wrapped around the core proteins (Fig.1.2.1). In addit ion, histone H1 binds 
to the "linker DNA" region between nucleosomes (from 8 to 114 nucleotides in 
length), helping the stabilization of the chromatin fiber [8].  
 
Fig. 1.2.1 Nucleosome 
Structure. 
The arrangement of the eight 
histone proteins in the 
nucleosome is shown 
schematically. 146 base pairs of 
DNA are wrapped around the 
histone core. Histone H1 seals 
the nucleosome separating each 
nucleosome unit from the  
other.  
 
 
In general terms, there are three levels of chromatin organization (Fig 1.2.2): 
1. the "beads on a string" structure, consisting of DNA wrapped around histone 
proteins (euchromatin);  
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2. the 30 nm fiber: multiple nucleosomes organized in their most compact form 
(6 nucleosomes for each turn) (heterochromatin); 
3. the metaphase chromosome, a higher level of the 30 nm fiber packaging 
during mitosis and meiosis [9]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2.2 Chromatin packing occurs on several levels . 
Schematic drawing shows some of the orders of chromatin packing that give rise to the highly condensed mitotic chromosome.  
 
The overall chromatin structure depends on the stage of cell cycle: during 
interphase the chromatin architecture is lost to allow RNA and DNA polymerases to 
access, transcribe or replicate DNA [9]. The local structure of chromatin during 
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interphase depends on the genes present on the DNA: DNA coding genes that are 
actively transcribed ("turned on genes") is more loosely packaged and is 
associated with RNA polymerases (euchromatin), while DNA coding inactive genes 
("turned off genes") is associated with structural proteins and is more tightly 
packaged (heterochromatin) [9]. 
 
 
1.3 THE BUILDING BLOCKS OF THE EPIGENOME: HISTONE MODIFICATIONS 
AND DNA METHYLATION 
  
Within the cells, regulation of biological processes can be achieved via genetic and 
epigenetic programs. Epigenetic control operates either on DNA, via DNA 
methylation, and on chromatin, by post-translational modifications (PTMs) of 
histones or by the exchange and replacement of the major histones with 
specialized variants. All of this mechanisms act together and define the so called 
'epigenetic code'. While in one individual the genetic code in each cell is the same, 
the epigenetic code is tissue and cell specific (Fig. 1.3.1) [2]. 
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Figure 1.3.1 Genetic versus Epigenetic Control. 
Regulation of biological processes can be achieved via genetic and epigenetic programs. Variation in genetic information is o btained 
by mutagenesis of the DNA sequence that irreversibly changes the encoded message. Epigenetic control operates either on DNA , via 
DNA methylation, or on chromatin. Variation in the chromatin template can be brought about by posttranslational modifications  
added to histones, by the exchange and replacement of the major histones with specialized variants or by ATP -dependent 
nucleosome remodeling, which alters histone:DNA contacts.  
 
 
 
HISTONE MODIFICATIONS 
 
The N-terminal tails of histones contain flexible and highly basic 15-30 aa-long 
sequences that are generally conserved across eukaryotic organisms and it is well 
established that they act as substrates for several types of post-translational 
modifications, including acetylation, methylation, ADP-ribosylation, ubiquitylation, 
and phosphorylation (Fig. 1.3.2) [10]. Histone modifications are proposed to affect 
chromosome function through at least two distinct mechanisms. The first 
mechanism suggests that modifications may alter the electrostatic charge of the 
histone, causing structural changes or alteration of its DNA  binding affinity. The 
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second mechanism proposes that these modifications represent binding sites for 
protein recognition modules, such as the bromodomains or chromodomains, that  
bind acetylated lysines or methylated lysine, respectively [11]. 
 
Fig. 1.3.2 Histone modifications. 
All histones are subject to post-translational modifications, which mainly occur in histone tails. The main modifications are depicted in 
this figure: acetylation (green), active lysine methylation (pink), arginine methylation (l ight blue), repressive lysine methylation 
(yellow), phosphorylation (orange) and ubiquitylation (grey).  
 
 
 HISTONE ACETYLATION mainly occurs on ε-amino groups of Lysine 
residues. The aa surrounding the preferred Lys/Arg are important for the 
identification of the specific binding site by the modifying enzyme. The 
enzymes that transfer an acetyl group from an Acetyl- CoA molecule to the 
Lys/Arg residues are generally called Histone Acetyl Transferases (HATs)  
while the ones acting on the Lys ammonium group are specifically called 
Lysine Acetyl Transferases (KATs) [2,7]. Since this modification is 
reversible, some enzymes that remove the acetyl group have been 
identified. They are generally called Histone Deacetylases (HDACs). 
Histone acetylation occurs mainly in two circumstances: during DNA 
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replication and during active gene expression. During the S phase of the cell 
cycle, before its incorporation in the nucleosome, the tetramer H3-H4 is 
transiently acetylated. The modification is probably required for the 
assembly of the new chromosome. After S phase, histone acetylation is 
correlated with gene expression. On the contrary, the N-terminal tails of 
histones H3 and H4 are not acetylated in heterochromatic regions [7]. 
Histone Lysines acetylation in the promoter region is often associated with 
gene activation, and the acetylated state is maintained until the gene is 
active (Fig. 1.3.3). This post-translational modification also represents a 
platform for  binding of other effector proteins that regulate transcriptional 
activity [14].  
 
 
 
 
 
 
 
 
 
 
Fig. 1.3.3 Histone acetylation and deacetylation effects.  
Acetylation occurs on specific Lys and Arg residues on histones H3 and H4, leading to an open chromatin conformation.  
 
 
 HISTONE METHYLATION: also the histone methylation occurs on ε-amino 
groups of H3 and H4 Lysine and Arginine residues. The enzymes that 
transfer the methyl group from the molecule S-adenosyl methionine to the 
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Lys/Arg residues are generally called Histone MethylTransferases (HMTs). 
For many years histone methylation was thought to be a permanent 
modification, but very recently two families of Histone Demethylase 
enzymes (HDM) were discovered: the Flavin-dependent and the Jumonji     
C-containing (JmjC) HDMs. Unlike acetylation, methylation doesn’t alter the 
protein charge, so it probably functions recruiting other effector proteins 
acting in a trans- mechanism. Figure 1.3.4 shows that distinct histone Lys 
residues have different functions when they are methylated, but also 
different degrees of methylation may have different functions, relating to 
positive or negative roles in transcription and other reactions. Also Arg 
methylated residues can play either a positive or negative role in 
transcription [15]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3.4 Major Lysine methylation points.   
The numbers refer to the methylated aa residue on each histone. Depending on the number and the position of the methyl group 
added, they exert different functions.  
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 HISTONE SUMOYLATION and UBIQUITINATION have been observed at 
the same way. Sumoylation appears to be associated with transcriptional 
repression, whereas ubiquitylation has been suggested to play a role in 
transcriptional activation and elongation [15].  
 
 HISTONE PHOSPHORYLATION: histone phosphorylation occurs on 
Serine, Threonine or Tyrosine residues. Also in this case, the modification of 
different histones or different aa residues in the same histone, has opposite 
effects on chromatin structure. The phosphorylation of histone H1 has been 
associated to a particular chromosome conformation during mitosis. This led 
to speculation that histone phosphorylation might be connected with the 
condensation of the chromatin. On the contrary, phosphorylation of H3S10 
is associated with gene transcription and consequently to chromatin 
decondensation, probably due to the addiction of negative charges to the 
DNA environment [15]. 
 
In addition to the great number of histone modifications described above, 
epigenetic studies have led to the discovery of a large number of enzymes wich  
interact physically and functionally with them (Fig. 1.3.5) [2]. These enzymes are 
classified in:  
 'writers', that modify specific substrates by adding phosphate, acetyl or 
methyl groups. They are represented by kinases, histone acetyltransferases 
Introduction 
14 
(HATs) and histone methyltransferases (HMTs); 
 'erasers', that catalyze the removal of specific histone modifications, such as 
histone deacetylases (HDACs) and histone demethylases (HDMs); 
 'readers’, that are regulatory proteins containing unique domains that 
recognize acetyl or methyl or phosphate groups, etc. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3.5 Distinct c lasses of chromatin remodeling molecules.   
Specific marks on the N-terminal tails of core histones are PTMs elicited by chromatin remodeling machineries that include a large 
variety of regulatory molecules, many of which interact physically and functionally. The regulators may be indicated as follo ws. (1) 
Writers. These are enzymes such as kinases, HATs, and HMTs that modify specific substrates adding phosphate, acetyl, or methyl 
groups. (2) Readers. These include a large variety of regulatory proteins that share unique domains implicated in recogni zing acetyl 
or methyl groups.  (3) Erasers. These enzymes include phosphatases, HDACs, and DMTs, which directly remove PTMs.  
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DNA METHYLATION 
 
DNA methylation is a chemical process that adds a methyl group to DNA. It is 
highly specific and always occurs at the 5-position of Cytosine residue (m5C), in a 
DNA region called CpG island where a Cytosine nucleotide is located next to a 
Guanine. CpG islands are methylated by one of three enzymes called DNA 
methyltransferases (DNMTs), which use S-adenosyl-L-methionine as donor of 
methyl groups. The CpG islands are mainly located within the first exon and the 
promoter of many genes. In higher eukaryotes, DNA demethylation is associated 
with euchromatin. DNA regulatory sequences are generally demethylated. The 
presence of m5CpG dinucleotides in the promoter can affect gene transcription in 2 
ways: in the direct mechanism the methylated dinucleotides interfere with 
transcription factors binding; in the indirect mechanism the dinucleotides are 
recognized by a binding protein that blocks the interaction with other transcription 
factors. It has also been suggested that DNMTs can “read” the histones 
modifications, recognizing the regions that should be methylated. Moreover, 
post-translational modifications such as acetylation, phosphorylation and 
methylation, can influence their catalytic activity. DNA methylation is also used in 
some genes to differentiate which copy is inherited from father and which one from 
mother, a phenomenon known as imprinting [16]. 
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Fig. 1.3.6 Methylation of DNA at the 5-carbon position of cytosine, induced by DNMTs. 
Accomplished by the transfer of a methyl group from S-adenosylmethionine (SAM) to the 5-carbon position of the pyrimidine ring of 
cytosine, DNA methylation contributes to the epigenome by covalently modifying the structure of DNA.   
 
 
 
1.4 HISTONE H3 POST TRANSLATIONAL MODIFICATIONS (PTM) 
 
The amino-terminal tail of histone H3 has the highest density of post-translational 
modiﬁcations mapped among all histones [17]. Several enzymes that modify 
specific residues on the N-terminal tail of histone H3 have been identified and 
characterized. LSD1 belongs to this category. For this reason, before focusing on 
the specific residue targetted by LSD1, it may be useful to have a panoramic view 
of the different histone H3 post-translational modiﬁcations and their effects on  
gene expression. 
The major challenge in chromatin biology is connecting specific modiﬁcations with 
distinct biological functions and vice-versa. One of the better-understood histone 
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modiﬁcation is the acetylation. It is now generally accepted that hyperacetylated 
histones are mostly associated with active genomic regions, at both local and 
global levels. By contrast, deacetylation (leading to hypoacetylation) mainly results 
in gene repression and silencing. Concerning histone methylation, it appears to 
have multiple effects on chromatin function in a system- and site-speciﬁc manner. 
Methylation of H3K9 is largely associated with gene silencing and repression while 
methylation of H3K4 is most often associated with active or permissive chromatin 
regions. Methylation of H3K36 has been suggested to be involved in transcriptional 
repression, but the corresponding modifying enzyme, Set2, has been found in 
complex with actively transcribing RNA pol II. Also H3S10 phosphorylation has a 
dualistic effect, since it has been implicated not only in transcriptional activation but 
also in mitotic chromosome condensation. These results suggest that a single 
histone modiﬁcation may have distinct biological effects, depending from its 
epigenetic context. The ﬁnding that a particular post-translational modiﬁcation 
mediates separate and sometimes opposite physiological effects, led to the 
suggestion that the multiple readout of a certain covalent mark depends from 
various combinations of different modiﬁcations in the same chromatin region [17] 
[18].  
At the level of N-terminal tail of H3 a great number of PTMs have been identiﬁed: 
serine and threonine residues are well-known phospho-acceptor sites, while lysine 
and arginine residues have multiple choices of post-translational modiﬁcation 
possibilities (Fig. 1.4.1). 
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Fig. 1.4.1 Schematic diagram of the covalent post-translational modifications (PTMs) of the histone 
H3 N-terminal tail.  
The different Histone H3 modifications are indicated (P, phosphorylation, shown in orange; Ub, ubiquitylation, shown in purpl e; Ac, 
acetylation, shown in blue; S, sumoylation, shown in yellow; N, neddylation, shown in pink). Methylation (Me) is shown on top, with 
green and red indicating the methyl marks that are associated with activation or repression, respectively.  
 
H3-lysines can be modiﬁed by acetylation, mono-ubiquitination or mono-, di- and 
tri-methylation. Similarly, H3-arginines may be mono- or di-methylated. Concerning 
this, it is well documented that H3-K9 and H3-K14 can be either acetylated or 
(mono-, di-, tri-) methylated. Obviously, different marks on the same site cannot 
co-exist and an acetyl group, for example, must be removed before a methyl group 
can be added. Nevertheless, we now also know that the exact state of methylation 
(mono-, di- or tri-methylation) of a single lysine residue has an impact on 
physiological processes. For example, it was recently shown that dimethylation of 
H3-K4 occurs at both inactive and active euchromatic genes, whereas 
tri-methylation is present exclusively at active genes [18].  
Many of the enzymes that post-translationally modify histones display a high 
degree of speciﬁcity not only towards a particular site, but also towards the 
pre-existing modiﬁcation-state of their substrate. So far the N-terminal tail of H3 has 
the highest intricate combination of marks (Fig. 1.4.2). 
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Fig.1.4.2 Local cross-talk on the human H3 amino-terminal tail domain.  
The sequence of the amino-terminal tail of H3 (amino acids 1–40) and the four a-helices (represented by boxes) of the globular 
domain of H3 are shown. Sites of known modifications are listed (M, mono-, di- or tri-methylation). K9 and K14 have been found to be 
methylated or acetylated (yellow box). ARKS repeats that contain two sites of methylation (K9 and K27), as well as known site s of 
phosphorylation (S10 and S28), are highlighted. Primary modifications that positively (green, ‘go’ or permissive) or negatively (red, 
‘stop’ or repressive) influence the modification of other sites in in vitro enzymatic assays are listed on the left.  
 
Methylation on H3-K9, for example, appears to trigger sequential events leading 
ultimately to transcriptional repression. This mark can inhibit acetylation of the H3 
tail (on K14, K18 and K23) mediated by histone acetyltransferases, and 
methylation of H3 on K4. By contrast, H3-K4 methylation inhibits K9 methylation 
but promotes acetylation of H3. Remarkably, the choice of methylating H3 on K9 
could be dictated by H3-S10 phosphorylation. In mammalian cells, this mark not 
only inhibits methylation on K9, but also precedes and promotes acetylation on 
K14, following specific signals [17].  
Perhaps, more fascinating than the direct synergism/antagonism or 
‘communication’ of adjacent modiﬁcations in the same histone tail (‘cis’ effects), is 
the unexpected discovery that modiﬁcations on different histones can affect each 
other (‘trans’ effects). These effects might be restricted to a single nucleosome or 
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might affect larger nucleosomal arrays or domains (Fig. 1.4.3).  
 
 
 
 
 
 
 
 
Fig.1.4.3 Cross-talk at the level of nucleosomal domains. 
In an array of nucleosomes, different modifications on separate histones (X or Y) might influence each other in a positive or  negative 
way. For example, it has been postulated that methylation of H3 on K9 could be spread over larger domains by recruitment of an 
HP1-Su(var)3-9 complex to sites of H3-K9 methylation. Similarly, boundaries for modification spreading could be established by 
inhibition/exclusion of different modifications. On another level, a single modification could regulate the modification pattern of a larger 
region of nucleosomes (‘master control switch’, Z). Ubiquitination of H2B in budding yeast could be such a ‘master control sw itch’ 
because of its relatively low abundance in comparison with the methylation on H3-K4 and H3-K79, which are both dependent on this 
modification. Since histone ubiquitination might be less stable than histone methylation, it is also possible that ubiquitin is removed 
after a methylation event on the same nucleosome. 
 
 
For instance, in vitro studies using histone acetyl-transferases p300 showed that 
this HAT acetylates both H3 and H4 especially in nucleosomes where H3 is 
methylated on K4. By contrast, methylation of H3 on K9 signiﬁcantly inhibits the 
activity of p300 towards nucleosomal histones H3 and H4 [17]. 
Besides cross-talk between different covalent modiﬁcations, another way of 
‘communication’ within the nucleosomes could be the disulﬁde-bond-mediated 
dimerization. It may not be a coincidence that H3 is the only core histone containing 
a single cysteine (C110), which is conserved in all species except for budding 
yeast. Formation of a disulﬁde bond between the two H3 molecules of each 
nucleosome might place severe conformational restraints on the structure of 
individual nucleosome, nucleosomal arrays or chromosomal domains [17].  
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It is clear from this roundup on H3 PTMs that we are only beginning to understand 
and appreciate the far-reaching implications of this non-DNA-encoded information 
for human biology and disease. The ﬁrst level of the complexity of chromatin 
cross-talk originates from the modular organization of chromatin itself. Obviously, 
each core histone can be post-translationally modiﬁed in a remarkably large 
number of ways, thus generating a vast number of possible combinations of marks 
for any chromatin domain. Besides a direct input from various signal transduction 
pathways on local and global chromatin levels, the modiﬁcations on a single 
histones seem to be dependent on each other and to be interconnected via various 
mechanisms [17, 18]. Deciphering even only a small aspects of the proposed 
‘histone and chromatin cross-talk’ represents a signiﬁcant and exciting challenge.  
 
 
1.5 H3K4 METHYLATION PATTERN 
 
In this section I will focus only on the methylation pattern of Histone H3 Lysin 4 
(H3K4) since this specific epigenetic mark is directly regulated by LSD1.  
H3K4 methylation was ﬁrst discovered in the trout testes. In subsequent studies, 
methylation of H3K4 has been linked to transcriptional activation in a variety of 
eukaryotic species. As I said before Lysine residues can be mono-, di-, or 
trimethylated at the z-amine in vivo. Recent genomic-scale analysis of histone 
modiﬁcations allows for general corre lations between different H3K4 methylation 
states, their genomic loci, and gene expression levels. The emerging consensus is 
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that high levels of H3K4 trimethylation are associated with the 5' regions of virtually 
all active genes and that there is a strong positive correlation between this 
modiﬁcation, transcription rates, active polymerase II occupancy, and histone 
acetylation. In contrast, pattern of dimethyl H3K4 differs signiﬁcantly between yeast 
and vertebrate chromatin: in S. Cerevisiae, dimethylated H3K4 appears to spread 
throughout genes, peaking toward the middle of the coding region, and is 
associated with a transcriptionally ‘‘poised’’ gene as well as active chromatin.   
Monomethylation, on the contrary, is most abundant at 3' ends of the genes. In 
vertebrates, the majority of H3K4 dimethylation colocalizes with H3K4 
trimethylation in discrete zones, about 5–20 nucleosomes in length, close to highly 
transcribed genes. On the contrary, H3K4 monomethylation is associated with 
silenced euchromatin regions of the genome and it has a function in gene 
repression [20]. 
The first H3K4 methylase complex, COMPASS, was identified in the yeast S. 
Cerevisiae and consists of Set1/KMT2 and seven other polypeptides (named 
Cps60-Cps15). Set1/KMT2 alone is not enzymatically active, but works within 
COMPASS and is capable of mono-, di-, and trimethylate H3K4. Following the 
identification in S. Cerevisiae of Set1/COMPASS as H3K4 methylase, it was 
demonstrated that its mammalian homologues, the MLL proteins, MLL1-4 and 
hSet1A and B, were found in COMPASS-like complexes capable of methylating the 
fourth Lysine of histone H3. SET1, SET7/9, Ash1, ALL-1, MLL, ALR, Trx, and 
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SMYD3 are the other histone methyltransferases that catalyze methylation of 
histone H3 at lysine 4 (H3K4) in mammalian cells (Fig. 1.5.1) [20].  
Fig. 1.5.1 The known enzymatic machineries involved in the methylation of lysine residues of 
his tones H3. 
The N-terminal amino acid sequences of histones H3 and H4 are shown along with the positions of specific methylation of lysines (in 
red) and arginines (in green) sites and the known enzymatic machinery responsible for the corresponding lysine modifications.  
 
For many years histone methylation was thought to be a permanent modification 
but very recently two families of histone demethylase enzymes  were discovered: 
the Flavin-dependent monoamine oxidase and the Jumonji domain-containing 
(JmjC) histone demethylases. The first are inactive on tri-methylated lysines while 
the latter are able to demethylate mono-, di-, or tri-methylated H3K4 [19]. LSD1 
belongs the Flavin-dependent family and it represents the first discovered 
monoamine oxidase . 
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2. HISTONE DEMETHYLASE LSD1/KDM1 
 
2.1 FLAVIN-DEPENDENT AND JUMONJI DOMAIN-CONTAINING HISTONE 
DEMETHYLASES 
 
The discovery of  Lysine Specific Demethylase 1 (LSD1) introduced a new 
concept in the field of the histone methylation,  clearing the way for the idea that 
histone demethylation is possible. After LSD1 finding, many studies have been 
done and mechanisms for direct histone demethylase reactions have been 
proposed.  
Depending on the catalysis reaction, histone demethylases are subdivided in two 
main families: Flavin-dependent histone demethylases and Jumonji 
domain-containing demethylases [21]. 
As shown in figure 2.1.1, the Flavin-dependent histone demethylases, cause the 
oxidative cleavage of the C-N methyl group bond, coupling it with a two-electron 
reduction of the Flavin Adenine Dinucleotide (FAD) cofactor. This reaction 
produces an imine intermediate that is then non-enzymatically hydrolyzed. The 
methyl group is released as formaldehyde. This proteins exhibit specificity in the 
Lysine substrate, indeed they preferentially demethylate mono- and di-methyl 
Lysines. Since LSD1 is a good model for this protein family, their structure and 
function will be discussed later [21]. 
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Fig 2.1.1 Catalytic mechanisms of FAD-dependent demethylase enzymes.   
The FAD-dependent demethylation of Lys-4 of histone H3 proceeds through the hydrolysis of an iminium ion following a two-electron 
oxidation of the amine by the flavin. R, ribosyl adenine dinucleotide.  
 
 
Differently, the JmjC histone demethylases are a group of Fe2+-dependent 
dioxigenases proteins, that involve the oxidative decarboxylation of α-ketoglutarate 
coupled to the hydroxylation of the histone methyl group. This reaction creates an 
unstable hydroxymethyl ammonium intermediate, which is released as 
formaldehyde. The catalytic centre requires Fe2+ and oxygen, as shown in figure 
2.1.2 [22]. 
 
Fig. 2.1.2 Catalytic mechanisms of Jumonji demethylase enzymes. 
The iron(II)-dependent demethylation of trimethyl -lysine substrates proceeds through an iron(II), α-ketoglutarate, and O2 derived 
hydroxyl radical oxidation of the methyl C–H bond.  
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These proteins are involved in the demethylation of trimethyl Lysines. The structure 
of these proteins consists of:  
 Jmj N-terminal domain; 
 Jmj C-terminal domain, the catalytic core that contains 2 Histidine and 1 
Glutamate residue, which chelate the catalytic iron atom;  
  C-terminal zinc finger motif;  
 a hairpin and a mixed domain to connect JmjN and JmjC domains.  
Most of the interactions with the substrate are mediated by hydrogen bonds 
between the main chains of both the enzyme and the histone tail; for this reason a 
number of residues is important for the interaction with the peptide. Many Jmj 
proteins also contain a PHD finger motif. Interestingly, different studies show that 
the Jmj proteins can hydroxylate histones or other proteins, suggesting their 
function in alternative reactions.  
Every histone demethylases protein has however to be considered as part of a 
macro-molecular complex that also contains other functionally complementary 
enzymes that modify histones methyl state, and histone modification “readers”. The 
presence of auxiliary factors, such as proteins or non-coding RNA, can influence 
the histone demethylases activity [22].  
 
 
 
 
 
Introduction 
27 
2.2 LYSIN SPECIFIC DEMETHYLASE 1 
 
Lysine Specific Demethylase 1 (LSD1, also named KMD1A or AOF2), is a 
flavin-dependent histone demethylases, that specifically acts on mono- or 
dimethylated lysine 4 on histone 3 (H3K4).  
Its function is predominantly related to gene repression, in fact it is required for 
downregulation of neuronal genes in non-neuronal cells. LSD1 demethylases 
function can also be related to different biological processes, such as development, 
cancer and neurological disorders.  
The human LSD1 protein is 852 aa long and consists of different domains (Fig. 
2.2.1):  
 N-terminal domain, composed of the SWIRM domain (involved in proteins 
interactions) and of an unstructured region made of linear motifs that might 
represent functional sites responsible for the association of LSD1 with 
different transcriptional protein complexes; 
 C-terminal amine oxidase domain (AOD), composed of a substrate -binding 
portion and a FAD-binding portion. The enzyme active site is located 
between these two regions;  
 “Tower Domain”, made of two long antiparallel α- helices that project away 
from the globular AOD. This domain provides the interface for CoREST 
binding. 
 
Introduction 
28 
Fig. 2.2.1 Structure of LSD1-CoREST in complex with H3 peptide. 
Ribbon diagram of the structure. LSD1 is in blue, CoREST in red, and the peptide in green. The FAD cofactor is shown as a yellow 
ball-and-stick. The final model consists of residues 171–836 of LSD1, residues 308–440 of CoREST, and residues 1–16 of pLys4Met 
peptide.  
 
 
 
The histone tail adopts a folded conformation when bound to the enzyme and 
slides into the substrate-binding domain cavity, establishing a network of specific 
interactions with the active site residues. These interactions are important to 
correctly position the Lys4 in front of the FAD [22,14].  
The LSD1 core complex contains LSD1, the proteins HDAC1, HDAC2 and 
CoREST. CoREST is a co-repressor protein that binds the neuronal Responsive 
Element RE1 Silencing Transcription factor (REST). Indeed LSD1 complex  is 
recruited by REST through the direct binding to CoREST, resulting in the 
repression of neuronal genes in non-neuronal cells. The presence of CoREST in 
the complex is also important for the substrate binding and recognition:  the 
C-terminal SANT domain of CoREST facilitates the association with chromatin by 
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directly interacting with DNA. HDAC 1 and 2 deacetylate histone H3, allowing the 
binding of CoREST to the nucleosome and the LSD1 recruitment. Thus, the 
presence of HDAC1 and 2 suggests a coordinate modification of histone tails [23]. 
Even if the active site of LSD1 is large enough to accommodate also H3K4me3, 
LSD1 demethylates only mono-or dimethylated H3K4, suggesting that the methyl 
state selectivity is not structurally inhibited but is chemically constrained, as 
predicted by its enzymatic mechanism. Some studies demonstrated that certain H3 
tail modifications (such as acetylation on Lys 9 or phosphorylation on Ser 10) affect 
LSD1 activity, suggesting that LSD1 could act after the addiction or removal of 
other charge-altering histones modifications. Moreover, these findings suggest also 
that LSD1 complex is capable to read the histone code.  
It has also been demonstrated that LSD1 complex function is not limited to 
REST-regulated neuronal genes, but it can be extended to other contexts. Thus, 
LSD1 can either repress or activate target genes through interacting with a variety 
of co-factors. For instance, there are some evidences that LSD1 can demethylate 
H3K9me2/me1, with an activating function. Indeed, it has been demonstrated that 
LSD1 directly binds the androgen receptor, and in this molecular complex is able to 
demethylate H3K9, functioning as a transcription activator. Anyway, it is still 
unclear how LSD1 changes its demethylase specificity when it engages different 
interacting partners [22]. It's a given that LSD1 also interacts with other proteins, 
including Carboxyl-terminal binding protein (CtBP), HMG domain containing protein 
BRAF35 and PHD-finger containing protein BHC80 [23]. These proteins can  
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enhance the HDAC1-2 activity, adding  further  regulatory  steps to the LSD1 
activity [24].  
 
2.3 NEURONAL LSD1 ISOFORM: EXPRESSION AND ACTIVITY  
 
Given the central role of LSD1 in chromatin remodeling, few years ago in my 
laboratory the process of LSD1 alternative splicing was investigated in order to find 
out an additional mechanism of LSD1 regulation. This approach led to the 
discovery of 4 different LSD1 splicing isoforms (Fig. 2.3.1), deriving from 
combinatorial retention of two alternative exons: exon E2a and exon E8a. E2a is 
60-bp-long and encodes for 20 aa, whereas the E8a is 12-bp-long and is translated 
into 4 aa with sequence Asp-Thr-Val-Lys [12]. 
 
 
 
 
 
 
 
 
Fig. 2.3.1 Structure of the four LSD1 variants. 
Single or double inclusion of two alternati vely spliced exons, E2a and E8a,  generates 4 different mammalian specific splicing 
variants. 
 
 
The inclusion of the two exons does not alter the reading frame and results in a 
protein of 876 aa. In this isoform, the amino acids coded by the exon E2a localize 
between the N-terminal disordered region and the SWIRM domain; whereas the 
four residues of the exon E8a immediately precede the CoREST-binding tower 
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domain, which is inserted within the amine oxidase domain (Fig. 2.3.2). Both the 
two alternatively spliced introns present a very high conservation degree between 
human and mouse, a typical feature of alternatively spliced exons.  
Fig. 2.3.2 Genomic organization of human LSD1 gene.  
Schematic representation of the human LSD1 protein domains together with its exons ranging from 1 to 19; asterisks indicate t he 
location of annotated alternative exons (E2a and E8a). Different colors  indicate functional domains. N-terminal unstructured region 
coded by exons 1–2, SWIRM domain coded by exons 2– 4,  the SWIRM-oxidase connector  coded by exon 5, the amine oxidase 
domain coded by exons 6–9 and exons 13–19, and the tower domain coded by exons 10 –12.  
 
 
The isoforms containing exon E2a are ubiquitously expressed, as the wild type 
isoform is, whereas the isoform containing the sole exon E8a is restricted to the 
nervous system. Finally, the LSD1-E2a/8a isoform is expressed both in human 
brain and testis. It is interesting to note that while the E2a isoform is present in 
different species, such as lizard, chicken and mammals, the E8a isoforms are 
expressed only in mammals. Moreover, while the epigenetic factors are mostly 
ubiquitous, LSD1-E8a is one of the very few factors restricted exclusively to 
neurons. All the 4 splicing variants retain the ability to generate functional proteins 
and to form an active complex with CoREST and HDAC1-2.  Biochemical in vitro 
assays using histone H3 peptides as substrate revealed that all three LSD1 
isoforms bound to CoREST can demethylate Lys4 of histone H3 with a catalytic 
efficiency virtually identical to that displayed by wild type LSD1. Such unchanged 
enzymatic activity and  substrate specificity is supported  by a very similar 
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three-dimensional structure, indeed even in the presence of exon E2a  the 
N-terminal region of LSD1 remains unstructured, at least in the crystalline state. 
Also the overall conformation of LSD1-E8a is very similar to that of the native 
protein, since the neurospecific E8a residues Asp-Thr-Val-Lys form a sort of 
protrusion that emerges from the amino-ossidase domain of the protein but doesn't 
contact  the histone peptide and CoREST (Fig. 2.3.3). From a functional point of 
view, the presence of the neuronal mini-exon E8a determines a significantly 
reduced repression of the Luciferase reporter gene activity [12]. 
Moreover it was demonstrated that a fine balance of LSD1 isoforms allows 
differentiating neurons to acquire a proper morphology. Indeed, the expression of 
LSD1 splice variants is dynamically regulated during mammalian brain 
development and synaptic maturation, in particular during the perinatal stages. At 
early all the splicing isoforms are detectable, but the preponderal ones are LSD1 
and LSD1-E2a. During the perinatal window, however, a rapid inversion of the 
proportions occurs, with a notable increase of the neuronal exon E8a containing 
isoforms and a decrease of the exon E2a isoforms. Exon E8a expression increases 
concomitantly with early stages of synaptogenesis, suggesting its implication 
during morphogenesis, possibly regulating the proper timing of neurite maturation. 
Nevertheless, after day P7, all LSD1 isoforms reach comparable levels, as it is 
possible to detect in adult mouse brain. Thus, LSD1 expression profile suggests a 
possible implication of neurospecific E8a-containing isoforms in neuronal 
development. 
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Fig. 2.3.3 Structural analysis of LSD1 and the LSD1-8a splice variant.  
Overall crystal structure of LSD1-8a–CoREST in complex with a histone peptide. LSD1-8a (residues 171-840) is in light blue, 
CoREST (residues 308-440) in red, and te histone H3 peptide (residues 1-16) in green. The FAD cofactor is in the orange 
ball-and-stick representation. The insertion site of E8a (residues Asp369A-Thr369B-Val369C-Lys369D) is highlighted. 
 
 
 
 
To infer the function of the different LSD1 isoforms within neurons, they were 
knocked down differentially by short hairpin RNAs (shRNAs) specific for each 
variant and 3 typical phenotypic parameters of neuronal morphogenesis during in 
vitro maturation were evaluated. Only the change in the amount of neurospecific 
LSD1-8a isoform is able to alter neurite morphogenesis in terms of  cumulative 
neurite arborization, number of secondary branches and average neurite width 
[12]. 
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2.4 EXON  E8a PHOSPHORYLATION AND ITS EFFECTS 
 
As I said before, mammalian neurons have a specialised chromatin remodelling 
complex resulting from the presence of a neurospecific LSD1-8a splice variant, 
whose expression is developmentally regulated. Only this isoform is capable of 
selectively inducing morphogenic effects in cortical neurons, which indicates that 
the sole presence of the 4 amminoacids coded by exon E8a is pivotal to acquisition 
of neuro-specific function. 
The mini-exon E8a forms a loop, protruding from the surface of the protein, that is 
close to the enzyme active site and, more importantly, it is accessible to enzymes 
for possible post translational modifications (PTM). Indeed Thr 371, inside D-T-V-K 
aa sequence, can be phophorylated both in neuronal and in non-neuronal cells by a 
set of unknown enzymes. Although phosphorylation of Thr371 per se does not 
interfere with the intrinsic catalytic activity of the enzyme in vitro, this PTM further 
decreases repression of the Luciferase reporter gene activity much more than 
unmodified LSD1-8a and enhances morphogenic properties exerted by neuronal 
isoform. To investigate if the neuronal LSD1-8a repressive activity likewise that one 
of LSD1, involves the activity of associated factors, demethylase-null isoforms were 
generated and repressive activity was evaluated. In a condition of total 
demethylase inactivity, conventional LSD1 shows a slight reduction in repressor 
strength in the SH-SY5Y cell line while LSD1-8a completely abolished its 
repressive activity. Since conventional LSD1 is incorporated in multiprotein 
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complexes consisting of an equimolar ratio of CoREST, HDAC1 or HDAC2, the 
differences observed in neuronal LSD1 activity could be ascribe to one of such 
factors. Interestingly,  immunocomplexes from the clones expressing 
HA-LSD1-E8a shows reduced HDAC1 protein levels in comparison with those 
expressing HA-LSD1, with  no significant differences in CoREST and HDAC2.  
Altogether these results highlight an intrinsic difference in the mechanisms by 
means of which the two LSD1 isoforms exert their repressive activity and suggest 
that, in neuronal cells, phosphorylation turns off repressive activity of neuronal 
LSD1-E8a interfering with demethylase activity directly or mediating recruitment of 
additional regulatory factors that could interfere with the substrate 
binding/recognition [13]. 
 
 
 
2.5 LSD1-RELATED EPIGENETIC MECHANISMS IN THE BRAIN 
 
Modulation of histone methylation and transcriptional repression in the brain is 
crucial in the control of various neurological functions, however limited knowledge 
exists regarding the significance of LSD1 in the brain.  As I said before, in my 
laboratory a neurospecific chromatin remodeling enzyme, arising from a splice 
variant of LSD1, was identified. Its demethylase activity on Lys4 of histone H3 is 
related to gene repression but so far little is known about neurospecific LSD1 target 
genes or pathways selectively regulated by this neuronal  isoform.  
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In literature, LSD1 is reported to be involved in a number of neuronal processes. 
Among them, the regulation of neural stem cells proliferation, the control of 
pyramidal cortical neurons  development and the modulation of long-term memory 
formation are the most investigated ones.  
In 2010 Y. Shy and his group demostrated for the first time that  LSD1 is a key 
regulator of neural stem cell proliferation. Thanks to the recruitment by nuclear 
receptor TLX to the promoter of its target genes, LSD1 is able to co-repress their 
expression. TLX, indeed, is an essential neural stem cell regulator and  its most 
well-known tagret genes are pten and p21 [26], which are positive modulators of 
neural stem cell proliferation. Thus, through the recruitment by TLX and the 
co-modulation of its repressive activity, LSD1 exerts a strong control on neural 
stem proliferation [26]. 
On the side of the cortical neurons development, last year a paper was published 
that revealed the importance of epigenetic control in the execution of neural 
development programs, specifically in the cerebral cortex.  In fact the transition of 
newborn cortical pyramidal neurons between multipolar and bipolar stage results 
markedly deleyed by depletion of CoREST, a corepressor strongly associated to 
LSD1. The function of CoREST in this process is independent from REST but 
requires the activity of LSD1. Indeed, the loss of CoREST/LSD1 complex 
profoundly affects the onset of radial migration of the cortical pyramidal neurons 
and also perturbs the dynamic of neuronal precursor cell populations, transiently 
increasing the fraction of cells that remain in progenitor states [27].  
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Finally, also the issue of long-term memory consolidation mediated by LSD1 is 
worthy of note. One years ago J.M. Hooker generated two selective LSD1 
inhibitors, RN-1 and RN-7, that exhibited good blood-brain-barrier penetration and 
retention. Systemic administration of RN-1 to rodents revealed for the first time that 
the inhibition of LSD1-mediated histone demethylation in the brain is implicated in 
long-term memory formation. Indeed, a memory test, called “novel object 
recognition”, demonstrated that rodents treated with RN-1 were significantly 
impaired in long-term memoryzation but not in short-term one [28]. 
Together these results highlight the importance of LSD1 demethylase activity in the 
brain in different pathways, but they also reveal that a lot of work has still to be 
done in order to deeply understand all the neuronal processes regulated by LSD1 
and its splicing isoforms.         
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3. ALTERNATIVE PRE-mRNA SPLICING  
 
3.1 MECHANISM OVERVIEW 
 
Alternative splicing is the major contributor to protein diversity in metazoan 
organisms. Estimates of the minimum number of human gene products that 
undergo alternative splicing are as high as 60% [29].  
In a typical multiexon mRNA, the splicing pattern can be altered in many ways (Fig. 
3.1.1). Most exons are constitutive, this means that they are always spliced or 
included in the final mRNA. Besides, there are the so called “cassette exons”, 
which are regulated exons that are sometimes included and sometimes excluded 
from the mRNA, in a tissue- or condition-specific manner (Fig. 3.1.1 A, B). This is 
the case of the LSD1 exon E8a. Exons can also be lengthened or shortened by 
altering the position of one of their splice sites (Fig. 3.1.1 C, D). The 5'-terminal 
exons of an mRNA can be switched through the use of alternative promoters and 
alternative splicing (Fig. 3.1.1 E). Alternative promoters are primarily an issue of 
transcriptional control. Similarly, the 3'-terminal exons can be switched by 
combining alternative splicing with alternative polyadenylation sites (Fig. 3.1.1 F). 
Finally, some important regulatory events are controlled by the failure to remove an 
intron, a splicing pattern called intron retention (Fig. 3.1.1 G) [29]. This is what we 
observed with the intron E8b-E9. Particular pre-mRNAs often have multiple 
positions of alternative splicing, giving rise to a family of related proteins from a 
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single gene (Fig. 3.1.1 H). Changes in splice site choice can have different effects 
on the encoded protein. Small changes in peptide sequence can alter ligand 
binding, enzymatic activity, allosteric regulation, or protein localization. Genetic 
switches based on alternative splicing are important in many cellular and 
developmental processes, including sex determination, apoptosis, axon guidance, 
cell excitation and contraction, and many others. Errors in splicing regulation have 
been implicated in a number of different disease states [29]. 
 
Fig. 3.1.1 Patterns of alternative splicing. 
Constitutive sequences present in all final mRNAs are gray boxes. Alternative RNA segments that may or may not be included in the 
mRNA are hatched boxes. (A) A cassette exon can be either included in the mRNA or excluded. (B) Mutually exclusive exons occur 
when two or more adjacent cassette exons are spliced such that only one exon in the group is included at a time. (C, D) Alternative 
5'and 3' splice sites allow the lengthening or shortening of a particular exon. (E, F) Alternative promoters and alternative poly(A) sites 
switch the 5- or 3-most exons of a transcript. (G) A retained intron can be excised from the pre-mRNA or can be retained in the 
translated mRNA. (H) A single pre-mRNA can exhibit multiple sites of alternative splicing using different patterns of inclusion. These 
are often used in a combinatorial manner to produce many different final mRNAs.  
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The excision of the introns from a pre-mRNA and the joining of the exons is 
directed by special sequences at the intron/exon junctions called splice sites. The 
5' splice site marks the exon/intron junction at the 5' end of the intron. This includes 
a GU dinucleotide at the intron end encompassed within a larger, less conserved 
consensus sequence. At the other end of the intron, the 3' splice site region has 
three conserved sequence elements: the branch point, followed by a 
polypyrimidine tract, followed by a terminal AG at the extreme 3'  end of the intron 
(Fig.3.1.2) [29]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.2 Splicing takes place in two trans-esterification steps. 
The first step results in two reaction intermediates: the detached 5' exon and an intron/3'-exon fragment in a lariat structure. The 
second step ligates the two exons and releases the intron lariat.  
 
 
Splicing is carried out by the spliceosome, a large macromolecular complex that 
assembles onto these sequences and catalyzes the two trans-esterification steps 
of the splicing reaction. In the first step, the 2-hydroxyl group of a special A residue 
at the branch point attacks the phosphate at the 5' splice site.  
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This leads to cleavage of the 5' exon from the intron and the concerted ligation of 
the intron 5' end to the branch-point 2-hydroxyl. The second trans-esterification 
step is the attack on the phosphate at the 3' end of the intron by the 3'-hydroxyl of 
the detached exon. This ligates the two exons and releases the intron, still in the 
form of a lariat (Fig. 3.1.2) [29]. 
The spliceosome assembles onto each intron from a set of five small nuclear 
ribonucleoproteins (snRNPs) and numerous accessory proteins (Fig. 3.1.3). During 
assembly, the U1 snRNP binds to the 5' splice site via base pairing between the 
splice site and the U1 snRNA. The 3' splice site elements are bound by a special 
set of proteins. SF1 is a branch-point binding protein. The 65-kDa subunit of the 
dimeric U2 auxiliary factor (U2AF) binds to the polypyrimidine tract. In at least some 
cases, the 35-kDa subunit of U2AF binds to the AG at the intron/exon junction. The 
earliest defined complex in spliceosome assembly, called the E (early) or 
commitment complex, contains U1 and U2AF bound at the two intron ends. The E 
complex is joined by the U2 snRNP to form the A complex. The A complex is joined 
by the U4/U5/U6 tri-snRNP to form te B complex. The B complex undergoes a 
complicated rearrangement to form the C complex, in which the U1 snRNP 
interaction at the 5' splice site is replaced with the U6 snRNP and the U1 and U4 
snRNPs are lost from the complex. It is the C complex that catalyzes the two 
chemical steps of splicing (Fig. 3.1.3) [29]. 
Changes in splice site choice arise from changes in the assembly of the 
spliceosome. In most systems, splice site choice is thought to be regulated by 
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altering the binding of the initial factors to the pre-mRNA and the formation of early 
spliceosome complexes. By the time the E complex is formed, it appears that the 
splice sites are paired in a functional sense and the defined intron is committed to 
being spliced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1.3 The spliceosome contains five small nuclear ribonucleoproteins that assemble onto the 
int ron. 
The Early (E) complex contains the U1 snRNP bound to the 5' splice site. Each element of the 3' splice site is bound by a specific 
protein, te branch point by SF1 (BBP), the polypyrimidine tract by U2AF 65, and the AG dinucleotide by U2AF 35. This complex also 
apparently contains the U2 snRNP not yet bound to the branch point. The A complex forms when U2 engages the branch point via 
RNA/RNA base-pairing. This complex is joined by the U4/5/6 Tri -snRNP to form the B complex. The B complex is then extensively 
rearranged to form the catalytic C complex. During this rearrangement the interactions of the U1 and U4 snRNPs are lost and the U6 
snRNP is brought into contact with the 5' splice site.  
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The splice site consensus sequences are generally  not sufficient informations to 
determine whether a site will assemble a spliceosome and function in splicing. 
Other information and interactions are necessary to activate their use. Introns can 
range in size from less than 100 nucleotides to hundreds of thousands of 
nucleotides. In contrast, exons are generally short and have a fairly narrow size 
distribution of 50–300 nucleotides. Commonly, spliceosomal components binding 
on opposite sides of an exon can interact to stimulate excision of the flanking 
introns. This process is called “exon definition” and apparently occurs in most 
internal exons. On top of this process, there are many non–splice site regulatory 
sequences that strongly affect spliceosome assembly. RNA elements that act 
positively to stimulate spliceosome assembly are called splicing enhancers. Exonic 
splicing enhancers are commonly found even in constitutive exons. Intronic 
enhancers also occur and appear to differ from exonic enhancers. Conversely, 
other RNA sequences act as splicing silencers or repressors to block spliceosome 
assembly and certain splicing choices. Again, these silencers have both exonic and 
intronic varieties. Some regulatory sequences create an RNA secondary structure 
that affects splice site recognition, but most seem to be protein binding sites [29].   
In the following paragraphs I will consider the role of cis-acting sequences and 
neurospecific trans-acting factors, as well as the putative function of the RNA 
secondary structure, in the alternative exon choise. 
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3.2 CIS-ACTING ELEMENTS INVOLVED IN SPLICING REGULATION  
 
Accurate and efficient removal of introns from pre-mRNAs is essential to ensure 
correct gene expression. However, the information content present in the canonical 
splice signals (5′ splice site, branch site and 3′ splice site) is not sufficient to 
precisely define exons, indeed a large excess of sequences that conform to these 
weakly defined consensus elements is present in introns but these sequences are 
never used [30]. 
Studies of the molecular basis of splicing reveal the existence of exonic and intronic 
cis-acting regulatory sequences, which bind trans-acting factors and thus inﬂuence 
splice-site selection. These cis-acting elements are relatively short, usually 4–18 
nucleotide, and  they are classiﬁed as exonic or intronic splicing enhancers 
(ESE/ISE) and silencers (ESS/ISS) (Fig. 3.2.1). These elements become 
particularly important in the presence of weak splice sites or when alternative 
splicing is involved. An important goal toward defining the functions of AS events is  
to understand the mechanisms by which these cis-acting sequences in pre-mRNA 
combine with each other and with trans-acting splicing factors to define global 
splicing patterns.  
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Fig. 3.2.1 Alternative splicing regulatory elements. 
In addition to the splice-site consensus sequences, a number of auxil iary elements can influence alternative splicing. These are 
categorized by their location and activity as exon splicing enhancers and silencers (ESEs and ESSs) and intron splicing enhan cers 
and silencers (ISEs and ISSs). Enhancers can activate adjacent splice sites or antagonize silencers, whereas silencers can repress 
splice sites or enhancers. Exon inclusion or skipping is determined by the balance of these competing influences, which in  turn might 
be determined by relative concentrations of the cognate RNA-binding activator and repressor proteins.  
 
Speaking about exonic splicing regulators, it is now well established that ESEs 
include a diverse range of sequences, and many if not all exons contain internal 
ESE sequences. Most ESEs function by recruiting members of the SR protein 
family. These factors usually regulate splicing by binding ESEs through their 
N-terminal RRM domains and mediating protein–protein interactions that facilitate 
spliceosome assembly through C-terminal RS domains [31]. ESSs, on the contrary, 
are often bound by splicing repressors of the hnRNP class, a diverse group of 
proteins containing one or more RNA-binding domains and sometimes splicing 
inhibitory domains such as glycine-rich motifs. hnRNPs function by a wide variety 
of mechanisms. For example, PTB (hnRNP I) can block essential interactions 
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between U1 and U2 snRNPs, whereas hnRNP A1 can inhibit splicing by binding on 
either side and “looping out” exons or by directly displacing snRNP binding [31]. 
Beyond molecular genetics, global approaches, including both computational and 
experimental methods, have been developed to identify ESEs and ESSs on a large 
scale. ESEs have been identified experimentally by in vitro and in vivo SELEX 
approaches. ESEs have also been computationally identified based on their 
enrichment in authentic exons versus introns and in exons with weak splice sites, 
and by their enrichment in authentic exons versus pseudoexons and 5′ UTRs of 
intronless genes. Additional exonic SREs have been predicted based on sequence 
conservation, but the activities of these elements as either splicing enhancers or 
silencers or neutral sequences were observed to depend heavily on their exonic 
context [31].  
A number of intronic SREs are also known but fewer large-scale screenings have 
been conducted for intronic elements, and many more intronic elements likely 
remain to be identified. One well characterized ISE is the G triplet (GGG) or G run 
(Gn; n ≥ 3), which often occur in clusters and can enhance recognition of adjacent 
5′ss or 3′ss. This ISE is common in GC-rich introns and is conserved between 
human and mouse. Intronic CA repeats in several cases can enhance splicing of 
upstream exons, probably through binding of hnRNP L. UGCAUG hexanucleotides 
or slight variations often occur downstream of neuron-specific exons and function 
as ISEs by binding to the brain- and muscle-specific splicing factors Fox-1/Fox-2. 
Pairs of YCAY motifs (Y = C or U) are recognized by the  neuron-specific Nova 
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family of splicing factors to regulate a large number of splicing events in the brain. 
Interestingly, depending on their relative location in pre-mRNA, YCAY pairs can 
also function as either ESSs or ISSs [31]. Such context dependence will be 
discussed in more a detail way below. Intronic elements (ISS and ISE) are likely of 
primary importance in regulating AS events, as the intronic regions surrounding 
alternative exons are far more conserved in mammals than those surrounding 
constitutive exons, out to a distance of 150 bp or more. Such increased 
conservation has been used to predict unannotated alternative exons, and to 
predict intronic SREs. Splicing enhancers and silencers often function additively, 
with additional copies increasing their effect on splicing regulation , either because 
they increase the affinity of the associated factor or because they increase the copy 
numbers of the factor that are recruited, sometimes in synergistic fashion. Different 
SREs may also function cooperatively to regulate alternative splicing. For example, 
exonic UAGG motifs and intronic GGGG motifs overlapping the 5′ss can function 
cooperatively to silence the brain-specific CI cassette exon (exon 19) of the 
glutamate NMDA R1 receptor gene [31]. 
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3.3 NEUROSPECIFIC TRANS-ACTING SPLICING MODULATORS 
 
Alternative pre-mRNA splicing has the potential to greatly diversify the repertoire of 
transcripts in multicellular organisms. This expansive layer of gene regulation plays 
a particularly important role in the development and function of the nervous system. 
The nervous system, indeed, exhibits particularly high levels of alternative splicing 
[32]. 
Even if there are many ways to regulate alternative splicing, protein-RNA 
interaction is considered the primary elements of splicing regulation [33]. Several 
neuro-specific splicing factors are involved in the inclusion of neuronal alternative 
exons. Few of them will be described below.  
 
NOVA1 AND NOVA2 
 
The Nova RNA binding proteins are among the first tissue-specific regulators of 
alternative splicing to be identified. They were initially identified as the target 
antigens in the POMA disease, a rare immune-mediated disorder characterized by 
abnormal motor inhibition [40]. Studies in knock-out mice indicate that Nova-1 plays 
a critical role in the maintenance of brain stem and spinal cord neurons, likely 
through the regulation of alternative splicing in these cells [34]. Nova expression is 
indeed restricted to the central nervous system: Nova1 acts primarily in the spinal 
cord while Nova2 is expressed mostly in the brain [41].  
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Studies utilizing splicing-sensitive microarray profiling in mice lacking Nova proteins 
identified a network of brain-specific splicing events coordinated by these factors.  
Importantly, transcripts with Nova-regulated exons encoded proteins that were 
significantly enriched in functions associated with the synapse [35]. The integration 
of such alternative splicing regulatory network with genome-wide cross-linking and 
immunoprecipitation (CLIP) studies identifying in vivo Nova binding sites in the 
transcriptome, provided two key advances [36, 37] First, these data sets have 
enabled the formulation of “RNAmaps” correlating cognate Nova YCAY cis-element 
locations in pre-mRNA transcripts with effects on splicing regulation, leading to 
mechanistic insights into how the Nova proteins modulate alternative splicing [38]. 
Second, these networks identify target isoforms and pathways that likely contribute 
to aspects of neuronal physiology. 
Nova factors recognize the cis-acting nucleotide motif YCAY (where Y indicate a 
pyrimidine), usually in clusters of multiple tetramers [42]. The positions of 
protein-RNA interactions play a major role in splicing regulation. Indeed, if the 
YCAY cluster lays inside an alternatively spliced exon or in the upstream intron 
Nova triggers the skipping of that exon, whereas if the YCAY cluster lays in the 
intron downstream of the regulated exon, Nova would promote its inclusion [39]. 
Nova effects on alternative splicing are due to its ability to physically block or 
promote the assembly of the spliceosome. One possible mechanism for the 
enhancing exon inclusion is that Nova can enhance the U1 snRNP recruitment to 
the 5’ splice site of the preceding exon. This would restrict the temporal window 
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available for splicing inhibitory proteins to assemble to the alternative exon. On the 
contrary, Nova binding to an exonic YCAY cluster blocks U1 snRNP binding and 
exon inclusion. These observations suggest that Nova interacts with the pre-mRNA 
before snRNPs binding, to alter the composition of the pre -spliceosome complex 
[39]. 
It was also demonstrated that Nova1 can regulate the alternative splicing of the 
exon E4 in the Nova1 pre-mRNA itself, promoting both exon inclusion or exclusion. 
This exon encodes for a domain that contains a number of potential sites for 
phosphorylation by serine/threonine protein kinases. Indeed, Nova regulated 
alternative exons encode putative phosphorylation sites more often than 
constitutive or other alternative exons [43].  
Numerous studies have revealed that tissue specific splicing factors act in concert 
to regulate alternative splicing. In fact, Nova can also work in a cooperative manner 
with other splicing factors; for instance, it was suggested a functional interaction 
between the neuronal splicing factor Fox and Nova proteins when they both bind 
the two sides of an intron [39]. Another example can be the interaction between 
Nova1 mRNA and nELAV splicing factors. nELAV proteins bind Nova1 mRNA at 
the AU-rich elements (ARE) in the 3’ UTR region, increasing its stability and 
translation. Thus, the nELAV proteins are able to indirectly influence the splicing 
activity of Nova1, by controlling Nova1 gene expression and protein content at the 
post-transcriptional level [44].  
Several studies demonstrated that splicing may be mechanistically coupled to 
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mRNA localization in the cytoplasm. It was indeed observed a significant amount of 
Nova in both nuclei and cytoplasm of mouse neurons. It has been also 
demonstrated that Nova and its nuclear RNA targets co-localize in dendrites closed 
to synaptic contacts. Within dendrites, Nova was mainly located peripherally, along 
the plasma membrane, in the proximity of synaptic contacts. In fact, Nova is able to 
bind 3’ UTR elements and also contains NES and NLS elements, necessary to the 
transport through the nucleus. These observations suggest that the role of Nova in 
RNA regulation goes beyond its action in the nucleus [45].  
 
 
nSR100/SRRM4  
 
The neural-specific SR-related protein of 100 kDa (nSR100/SRRM4) was found to 
regulate alternative splicing decisions. Microarray profiling experiments in mouse 
neuroblastoma cells and tissues revealed that depletion of nSR100 results in 
increased skipping of alternatively spliced exons normally included in the brain, 
suggesting that it mainly acts to promote the inclusion of alternative exons. A 
significant fraction of genes containing these regulated exons are known to be 
important for neuronal differentiation, raising the possibility that specific splice 
variants modulated by nSR100 could contribute to this process. Consistent with this 
notion, nSR100 was found to play a critical role in neuronal differentiation and 
neurites extension in vitro as well as nervous system and sensory organ 
development in zebrafish embryos in vivo [46]. The specific mechanism by which 
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nSR100 regulates alternative splicing in the nervous system remains to be 
elucidated. It was  found that the introns flanking alternative exons regulated by 
nSR100 are enriched in pyrimidine rich motifs [46]. The majority of these motifs are 
likely recognized by the polypyrimidine tract binding protein PTBP1 and its 
tissue-specific paralog PTBP2 (also called neural- or brain-enriched n/brPTB). 
Consistent with a link between these regulators in modulating neural-specific 
alternative splicing, many nSR100-dependent alternative splicing events are also 
regulated by PTBP1 and PTBP2.  
More recently, it was discovered that nSR100 indirectly controls the steady-state 
abundance of a network of transcripts in neuronal cells distinct from the population 
of mRNAs that it regulates at the level of splicing. Depletion of nSR100 in mouse 
neuroblastoma cells led to decreased levels of hundreds of transcripts, and a 
subset of these changes were shown to be dependent on repressor element 1 
silencing transcription factor (REST, also known as NRSF), a transcriptional 
repressor of genes involved in neurogenesis [47]. In neuronal cells, REST 
transcripts include an additional exon that results in the introduction of a STOP 
codon and production of a truncated protein lacking domains required for its 
repressive activity. Raj et al. found that nSR100 plays a critical role in promoting 
the inclusion of this alternative exon, suggesting that the expression of nSR100 in 
neurons contributes to the reduced activity of REST upon differentiation to the 
neural lineage. Importantly however, REST was also found to directly repress 
nSR100 transcription in non-neuronal cells and thus indirectly inhibit neural-specific 
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alternative splicing. This negative feedback loop between two gene regulatory 
levels was found to be important for developmental outcomes in the nervous 
system, as inhibiting nSR100 expression in mouse brain disrupted cortical 
neurogenesis, preventing neuronal precursor cells from committing to a neuronal 
fate [47].  These results are in agreement with previous studies showing that loss 
of REST derepresses neuronal transcripts in non-neuronal tissues, while REST 
overexpression inhibits the expression of transcripts in neuronal tissues, which in 
one study was shown to result in axon pathfinding errors in chick embryos [48].  
 
 
PTBP1 AND PTBP2 
 
PTBP1 and PTBP2 display mutually exclusive patterns of expression in the 
developing brain, with PTBP1 found in glial and non-neuronal cells, and PTBP2 in 
neurons [49]. This non-overlapping pattern of expression is established by an 
elegant cross-regulatory network where PTBP1 normally suppresses the inclusion 
of an exon in PTBP2 transcripts, leading to a non-functional isoform degraded by 
the non sense-mediated mRNA decay (NMD) pathway [49, 50]. In neurons 
however, PTBP1 is silenced by miR-124, a neuron-specific microRNA, leading to 
the derepression of PTBP2. [51] The consequences of modulating the  relative 
levels of PTBP1 and PTBP2 in neuronal cells have been initially revealed through 
splicing-sensitive microarray profiling of mouse neuro-blastoma cells depleted of 
these factors. Analogous to the Nova-regulated alternative splicing network, 
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PTBP1-and PTBP2-dependent alternative splicing events are frequently found in 
transcripts expressed from genes with known roles in neuronal differentiation and 
physiology. [49] A role for PTBP1 and PTBP2 in regulating the expression of 
PSD-95, an important scaffolding protein essential for synaptic maturation and 
plasticity of excitatory neurons, has recently been identified. Overexpression of 
PTBP1 and PTBP2 in cultured  hippocampal neurons was shown to repress 
synaptic activity, dendritic spine formation, and reduce levels of PSD-95 
transcripts. This reduced mRNA abundance is caused by PTBP1 and PTBP2 
binding to a pyrimidine rich cis-element upstream of PSD-95 exon18, leading to 
increased exon skipping and the production of a transcript containing a premature 
termination codon that is targeted for degradation by the NMD pathway. 
Importantly, the increased expression of PSD-95 in developing neurons in the 
cortex was found to correlate with three distinct phases of PTBP1 and PTBP2 
expression. At the neural progenitor stage, when PTBP1 levels are high, PSD-95 
expression is at its lowest. In embryonic neurons, the weaker repressor PTBP2 is 
more highly expressed while PTBP1 expression is lost, leading to intermediate 
levels of PSD-95. Finally, in post-natal cortical neurons, PTBP2 is no longer 
expressed, allowing PSD-95 abundance to reach its highest levels. These results 
indicate that the sequential changes in relative expression of PTBP1 and PTBP2 
can allow for distinct splicing regulatory programs to be established at different 
stages in neuronal maturation [52]. 
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RBFOX1 AND RBFOX2 
 
Members of the Rbfox family of RNA binding proteins display enriched or highly 
specific expression patterns in the neuro-muscular system, and regulate alternative 
splicing decisions through interactions with the highly conserved cis-element 
(U)GCAUG. Focused biochemical studies and several genome-wide analyses 
have demonstrated that the Rbfox proteins can function as activators or repressors 
of splicing, depending on the location of (U)GCAUG elements in target pre-mRNA 
transcripts. When Fox proteins bind intronic regions downstream from the 
alternative exon they promote its inclusion; on the contrary, when the binding sites 
are present in upstream intronic regions, Fox acts as an alternative splicing 
repressor, blocking the formation of the early-spliceosome complex and inhibiting 
the recruitment of splicing factors. Together, these studies have begun to shed light 
on the relevant networks of transcripts modulated by these factors, although the 
role of the Rbfox proteins in nervous system development and function in vivo has 
remained somewhat unclear [53].  
Two recent studies from the Black laboratory using Rbfox knockout mice have 
provided further insight toward the functional importance of this protein in the 
nervous system [54, 55]. Deletion of Rbfox1 specifically in the nervous system of 
transgenic mice did not seem to have any effects on neuronal development or 
morphology in  the brain. However, loss of Rbfox1 did lead to spontaneous 
seizures, increased sensitivity to induced seizures, and increased excitability in 
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neurons of the dentate gyrus. Integration of splicing-sensitive microarray profiling  
and CLIP-Seq data sets identified alternative splicing events differentially regulated 
in the brains of Rbfox1-/- mice. Several of which were linked to genes known to be 
associated with epilepsy and others with roles in synaptic function [54].   
In contrast to loss of Rbfox1 in the nervous system, deletion of the gene encoding 
Rbfox2 in the nervous system led to pronounced defects in cerebellar 
development. Rbfox2 -/- animals have much smaller cerebella than wild-type 
littermates, defects in Purkinje cell migration and dendritic arborization, and 
reduction in the migration and number of granule cells [55]. Again, 
splicing-sensitive microarray profiling experiments were performed, revealing 
alternative splicing events displaying significant  changes upon loss of Rbfox2. 
Genes with affected exons were  associated with neuronal developmental 
disfunctions, and a subset of Rbfox2-dependent alternative splicing events were 
also regulated by Rbfox1, suggesting partial redundancy between the two factors. 
In agreement with these data, double knockout mice displayed far more severe 
phenotypes than those observed in either  single knockout mutant [55]. Finally, in 
an attempt to separate a possible role for both Rbfox proteins in the mature 
nervous system from their collective role in development, transgenic animals were 
generated that deleted these two factors specifically in Purkinje cells. Intriguingly, 
these double knockout  mice possess no gross morphological or developmental 
abnormalities, but display impaired motor skills and significant reductions in 
spontaneous firing frequency of Purkinje cells, demonstrating that the Rbfox 
Introduction 
57 
proteins also play an important role in mature neural circuitry in addition to their 
contribution to development [55]. 
 
SAM-68 
Sam68 is a nuclear RNA binding protein implicated in various aspects of mRNA 
metabolism, including splicing, nuclear export, somatodendritic transport, and 
translation. Sam68 belongs to the family of GSG (GRP33, Sam68, GLD1) or STAR 
(signal transduction and activation of RNA) domain proteins. This domain includes 
a central KH ( hnRNP K homology) RNA binding domain flanked by conserved N- 
and C-terminal. The GSG domain in Sam68 binds to RNA motifs that are rich in A 
or U, such as UAAA or UUUA, and also mediates homodimerization. Sam68 
contains a variety of other protein domains that allow its interaction and 
modification by multiple signaling pathways. These many regulatory interactions 
and posttranslational modifications affect the RNA binding activity and localization 
of Sam68 and make it an appealing molecule for transducing information from 
signaling systems to pathways of mRNA metabolism [56]. Sam68 is localized 
primarily in the nucleus as observed by immunofluorescence, consistent with its 
role in alternative splicing. Sam68 helps regulate the splicing of CD44 variable 
exon v5 in response to phosphorylation by extracellular signal-regulated kinase in T 
lymphoma cells [57].  Sam68 also regulates the alternative splicing of the 
apoptotic regulator Bcl-x, where it cooperates with hnRNPA1 to induce a switch 
from the antiapoptotic (Bcl-xL) to the proapoptotic (Bcl-xS) isoform [58]. 
The small number of confirmed Sam68 pre-mRNA targets has limited the 
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understanding of both its mechanisms of action and its cellular role. A recent paper 
shows that changes in Sam68 expression during neuronal differentiation affect a 
large number of specific splicing events. Such genes, carrying Sam68 target exons, 
are involved in a variety of cellular processes important in neurogenesis, including 
cytoskeletal organization (Numa1, Clasp2, and Sgce), organellar biogenesis and 
transport (Bin1, Ktn1, Kifap3, and Opa1), and synaptogenesis (Cadm1, Dlgh4, and 
Sorbs1 ). Sam68 controls splicing of its targets through direct binding to RNA 
elements but also through its interactions with other factors, such as PTB or hnRNP 
A1 [58]. Loss of Sam68 in P19 cells eliminates their ability to form neurons. 
Similarly, Sam68 knockdown in neuronal progenitor cells reduces the number of 
TuJ1-positive neurons that differentiate in  culture. However, Sam68 null mice do 
not show a neurogenesis defect but instead show defects in bone mesenchymal 
cell differentiation. Only about one-third of Sam68−/−mice survive to adulthood, 
with the survivors showing defects in motor coordination [59]. Sam68 is widely 
expressed and plays roles in multiple cell types. It is possible that the neurogenesis 
defect we observed in vitro results from the loss of a general function that is not 
specific to neurons, possibly through Sam68 effects on the cell cycle [60]. 
Alternatively, it may be that in vivo other Sam68 family members, such as Slm-1 
and Slm-2, can substitute Sam68 during neurogenesis. In the future it will be 
important to understand how this protein can coordinate splicing of certain 
pre-mRNAs in the nucleus and then follow these RNAs to the cytoplasm to see 
their interactions with a variety of signaling pathways.  
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3.4 PRE-mRNA SECONDARY STRUCTURE AND SPLICING REGULATION 
 
There are two properties of RNA molecules that cannot be denied: their natural 
tendency to form highly stable secondary and tertiary structures in vitro and in vivo, 
and the observation that alterations in these structures represent a well-known 
mechanism to regulate the alternative splicing of many pre-mRNA molecules [61]. 
Three are the possible experimental situations in which pre-mRNA secondary 
structures are engaged. The first one is represented by the view that hnRNP 
proteins bind the RNA as it gets transcribed by RNA polymerase II and keep it in a 
largely linear conformation. In this case, binding of specific factors is regulated only 
by the competitive advantage provided by sequence-specific interactions over the 
generic RNA binding affinities of all hnRNP proteins (Fig. 3.4.1 A). The opposite 
situation is when the drive to form RNA secondary and tertiary structures is 
stronger than the ability of RNA-binding proteins to prevent it. In this case, the role 
played by generic RNA-binding proteins is severely reduced and specific 
complexes can bind through a mix of sequence-specific and structure-specific 
recognition (Fig. 3.4.1 B). Between these two models there is a situation that 
should encompass many cellular RNAs. In this case, the potential “ironing” of the 
RNA by its weak or aspecific interactions with hnRNPs can indeed maintain the 
mRNA in a largely linear conformation. However, in particular regions the mRNA is 
still able to form localized RNA structures which might represent, together with the 
nucleotide sequence, preferential binding sites for specific nuclear complexes   
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(Fig. 3.4.1 C). Hence, the predictive ability in the search for novel RNA binding 
targets for well-known proteins can be greatly enhanced if secondary structure is 
taken into consideration [61].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.1 Experimental models of pre-mRNA secondary structure. 
(a)  hnRNP proteins bind the RNA as it gets transcribed by RNA polymerase II and keep it in a largely linear conformation. (b)   
RNA secondary and tertiary structures are stronger than the ability of RNA-binding proteins to prevent it. (c)  In particular regions the 
mRNA is able to form localized RNA structures which might represent, together with the nucleotide sequence, preferential binding 
sites for specific nuclear complexes. 
 
 
With regard to specific factors capable of affecting the splicing process, it has to be 
noted that the binding of several positive (B52, SRp55, and NOVA-1) and negative 
(hnRNP) regulators of splicing have been shown to depend on RNA secondary 
structures as well as on the target nucleotide sequences. For obvious reasons, the 
earliest and most numerous reports regarding the ability of RNA secondary 
structures to affect the splicing process concern conserved key regions that define 
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an exon: 5′ splice site, 3′ splice site, and branch site.  The most common case is 
represented by the presence of structural elements which may hinder the 
accessibility of such conserved sequences by basic splicing factors.  Depending 
on the system analyzed, this alterated accessibility has been observed to involve 
only the acceptor site, the donor site, or both. With special regard to the 3′ splice 
site, it should be noted that recent attempts to correlate the presence of loosely 
defined secondary structures in 3′ splice site definition have resulted in a small (5 
to10%) but significant improvement in predictive ability, indicating that this region 
may be particularly sensitive to the presence of structured RNA. Another 
mechanism by which pre-mRNA secondary structures may indirectly affect 
pre-mRNA splicing involves a change in the relative distance between conserved 
cis-acting splicing sequences. These changes can indeed determine considerable 
variation in splice sites usage or efficiency (Fig. 3.4.2 A). Finally, structural 
constraints may also have an effect on the branch site, indirectly promoting its use 
by keeping it in a single-stranded configuration (Fig. 3.4.2 B).  
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Fig. 3.4.2 RNA structural elements and splicing efficiency.  
(a) Hairpins can change the relative distances of splicing regulatory elements and thus affect the final outcome. The functio n of this 
structure would be two fold: to bring the BPS into working range of the correct 3'ss and to sequester the silent 3'ss, preventing its use 
by the splicing machinery. (c ) Hairpin structure formation near the branch point of the gene  has been recently proposed to play an 
active role in splicing through a distinct mechanism. In this case, hairpin formation forces the branch point sequence (BPS) into an 
unpaired conformation that is better recognized by the splicing machinery.   
 
 
In addition to splicing consensus sequences, there is also cases where structural 
constraints affect less-defined cis-acting sequences such as exonic/intronic 
splicing enhancers (ESE/ISE) or silencer elements (ESS/ISS). For example, in the 
case of  fibronectin EDA exons, secondary structural elements can stabilize the 
conformation of the ESE sequence and enhance its SR protein binding capabilities 
(Fig. 3.4.3 A).  Alternatively, RNA secondary structures can also function on 
ESE/ESS regulatory regions indirectly.  In FGFR2 gene, the function of the stem 
structure formed by the intronic activating sequence 2 (IAS2) and intronic splicing 
activator and repressor (ISAR) elements would be that of approximating an 
inhibitory intronic sequence (a GCAUG-rich sequence) relative to the distal intronic 
splicing silencer (DISS) element, which would normally repress exon IIIb inclusion. 
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Inactivation of this element would then lead to activation of exon IIIb splicing in 
epithelial cells (Fig. 3.4.3 B) [61]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4.3 Effects of RNA secondary structure on exonic/intronic enhancer or silencer elements.  
(a) Mutations that do not directly affect the ESE sequence cause a conformational change in this region (from a loop to a stem) wh ich 
hinders SF2/ASF protein binding  abolishing exon recognition. (b) In FGFR2 gene the function of the stem structure formed by the 
intronic activating sequence 2 (IAS2) and intronic splicing activator and repressor (ISAR) element is that of approximating an 
inhibitory intronic sequence (a GCAUG-rich sequence) relative to the distal intronic splicing silencer (DISS) element, which would 
normally repress exon IIIb inclusion. Inactivation of this element would then lead to activation of exon IIIb splicing in epi thelial cells.  
  
 
Considering the advancement in the study of RNA structure within the last few 
years, it is becoming increasingly apparent that RNA structure provides important 
supplementary information for any RNA function, that needs to be taken into 
account alongside the primary sequence information. 
It is now evident that non-coding RNAs are functionally relevant, and it is very likely 
that the secondary and tertiary structures they adopt play an important role. 
Furthermore, there are several examples showing that mutations affecting mRNA 
structural features are related to human disease, and it is likely that more will 
Introduction 
64 
follow. A common effect is that binding of regulatory RNA binding proteins (RBP) is 
altered, and it has recently been shown that mRNA secondary structure can serve 
as a prediction tool for RBP binding sites. While this is useful in understanding the 
interaction between RBPs and mRNA in general, it will be particularly helpful in 
providing novel therapeutic targets in human disease. This potential has already 
been explored in tauopathies, and further small molecule drugs that can stabilize or 
destabilize specific mRNA structures could provide a powerful therapeutic tools 
[62]. RNAs are already used as drug targets and are generally preferred over DNA 
drug targets since they are more accessible. These drugs are the so-called 
“antisense drugs”, which target single-stranded mRNA sequences and bind them 
through complementary base pairing, thus blocking translation. In conclusion we 
can say that a full understanding of the functionality of mRNA structures will allow a 
finer tuned manipulation of gene expression,  providing a tool for targeted and 
personalized therapy [63]. 
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Alternative splicing is the major source of proteome diversity in humans. In our 
laboratory a new splicing isoform of LSD1 was identified containing the 
mini-alternative exon E8a. This isoform is selectively expressed in the nervous 
system during the whole life, but plays an important role in brain development and 
synaptic maturation. In such critical phases, a fine modulation of LSD1-E8a 
expression allows differentiating neurons to acquire proper morphology [12]. 
Furthermore, the presence of the mini-exon E8a introduces a new phosphorylation 
site at Thr371 that modulates neuronal LSD1 epigenetic function. Indeed,  in 
cortical neurons Thr371 phosphorylation was found in our group to be pivotal in 
enhancing neurite outgrowth and in hampering the transcriptional repressive 
activity of neuronal LSD1 [13].  
In the light of these data, the aim of my project is on the one hand to study how the 
alternative splicing of exon E8a is regulated and on the other hand to clarify the 
biological function of LSD1-8a isoform in vivo and its possible involvement in 
neurological disorders. Concerning exon E8a inclusion into LSD1 mature transcript, 
we want to investigate the function of the cis-acting regulatory sequences present 
in the introns flanking the exon E8a, as well as the role of the trans-acting factors 
directly acting on splicing regulation. 
On the side of neuronal LSD1 biological relevance, we intend to study in-vivo the 
function of LSD1-E8a isoform by generating a knock-out mouse model for the sole 
exon E8a of LSD1. By different approaches, ranging from anatomical and 
behavioural studies to biochemical assays and transcriptional profiles, we propose  
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to characterize the mutants versus wild-type mice in order to identify physiologic or 
pathologic pathways involving neurospecific LSD1- E8a isoform. 
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1. DNA CLONING 
DNA cloning, also known as recombinant DNA technology, refers to the process of 
creating multiple copies of a DNA fragment by in vitro methods. There are various 
procedures of DNA cloning, but some steps are constant for all. The process   
begins with the isolation of a DNA stretch, using restriction enzymes or Polymerase 
Chain Reaction (PCR) with chemically synthesized oligonucleotides. The isolated 
fragment is then linked to a molecule that is capable of replicate and propagate 
both itself and the fragment linked to it. To this aim, a restriction enzyme cuts the 
self-replicating molecule so that the isolated DNA can be linked by a ligation 
procedure. The DNA  stretch  artificially linked to a backbone vector is called 
recombinant DNA. The new-born plasmid is then inserted into host bacterial or 
mammalian cells to obtain its replication and the increasing in the number of copies. 
To this aim different techniques like chemical sensitivation or electroporation can 
be used. The plasmid usually contains selectable antibiotic resistance markers 
and/or color selection markers which make it easier to know if the cells have been 
successfully transfected with the plasmid. The antibiotic resistance markers allow 
only cells in which the plasmid has been transfected to grow up. Transfected cells 
are then cultured, and proliferation of the recombinant DNA takes place. The 
resulting clones are genetically identical organisms containing the recombinant 
DNA. This can be confirmed by using PCR, restriction fragment analysis, or DNA 
sequencing methods. Cloning DNA is helpful in getting an insight into an organism 
genetic make-up and how this affects and influences the organism life processes. 
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     1.1 POLYMERASE CHAIN REACTION   (PCR) 
 
PCR is one of the best known and useful technique that allows any stretch of DNA 
to be amplified in vitro. It requires a DNA template, two DNA primers, and a 
particular DNA polymerase isolated from Thermus aquaticus, a bacterium that 
grows at 70°C. The main properties of this polymerase are that it is capable of 
synthesizing DNA at 70°C and that it is stable at even higher temperatures. 
The template used in PCR is a double-stranded DNA but the two strands have to 
be separated before DNA synthesis taking place. To denature DNA, the PCR 
reaction mix is first placed at 90–95°C, then temperature is lowered to ~50–68°C to 
allow primers to anneal to the single-strand template and finally the temperature is 
raised again to 70-72°C to allow DNA to be elongated. This cycle of denaturation, 
annealing and elongation  is repeated between 25 and 35 times for each PCR 
reaction. The DNA primers used in PCR are chosen so that only the stretch of DNA 
of interest is amplified and they are chemically synthesized in vitro. If the PCR 
products have to be cloned, the 5' ends of each primer contain a restriction site so 
that the resulting fragment is digested with the corresponding  enzyme and cloned 
into the appropriate vector. The template DNA can derive from any source and for 
each reaction only a small amount is needed. DNA replication that takes place in 
PCR, like in vivo DNA replication, is not 100% accurate and occasionally a mistake 
occurs: if the amplified fragment has to be cloned, the resulting clones must be 
sequenced to ensure that they carry the wild-type copy of the gene, while if the 
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amplified fragment has to be used as a probe, a few mutant copies in a mixture 
containing a large number of wild-type copies will not represent a problem. 
The thermal procedure we perform is the standard one, even if it may change in the 
annealing temperature (Ta) and in the number of cycles, according to the amplified 
sequence. Ta  temperature is calculated by decreasing 8-10°C from the melting 
temperature (Tm). Tm = [4*(G+C)+2*(A+T)]. In every cycle, each new DNA 
fragment works as template for Taq polymerase.  Final amplicons number will be 
2n (n=cycle number). PCR products are then loaded on agarose gel, in order to 
verify the correct amplification. 
 
For each PCR reaction we used the following reagents: 
                  Final Concentration 
DNA     < 50 ng                              
Buffer 5X    1X   Cycle 1   95°C x 5'  Initial. Denaturation                
MgCl2  25 mM   2 mM       95°C x 30''      Denaturation 
Forward Primer 10 µM  0,2 µM Cycle 2     Tm x 30''    Annealing              
Reverse Primer 10 µM    0,2 µM    x 30    72°C x 30''      Elongation              
dNTPs 10 mM     0,2 mM   Cycle 3   72°C x 7’     Final Elongation       
Taq Polymerase 5 U/µl   1,25 U                
H2O to 25 or 50 µl 
  
Primers used in PCR reactions: 
hLSD1 cloning intron FW                      
GGAATTCCATATGTCACTGCTTTCTGACACTTCCCC          
hLSD1 cloning intron RV 
GGAATTCCATATGACACAAGTGTGCAAATGGTACAGAT 
FW AseI hLSD1-MG 
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GGGAATTCATTAATTCACTGCTTTCTGACACTTCCCCCTCACTCC 
RV AseI hLSD1-MG 
CCCTTAAGATTAATCTGAAAATCCGAAGTATAGCAGAGTTGGTCC 
New 2 del pal hLSD1 RV 
AGAGAAATATTTAAAGGGTTAGAGGGACCAAATTTG 
New 3 del pal hLSD1 FW 
CAAATTTGGTCCCTCTAACCCTTTAAATATTTCTCT 
 A2-3 FW Fluo 
[6-FAM] CAACTTCAAGCTCCTAAGCCACTGC 
 BraII RV 
CACCAGGAAGTTGGTTAAATCA 
FN1 FW 
TGGAATTATTAAAAGCATTGCTGA 
FN1 RV 
GTTGCCACACAGCAAAGAGA 
hB-actin FW 
GCGGGAAATCGTGCGTGACATT 
hB-actin RV 
CTAGAAGCATTTGCGGTGGA 
NOVA1 BclI FW 
TCAGAATGATCAACATGATGGCGGCAGCT 
NOVA1 HindIII RV 
TCGAAGCTTCAACCCACTTTCTGAGG 
FOX-1  cloning FW 
GCTCTAGAATGGCTCAGCCTTACGCTTC 
FOX-1 cloning RV 
CGGGGTACCTTAGTATGGAGCAAAACGGTTGTAT 
P3 
ACGCGTCGACTCTTCAGTGCTTTCTCACTCCCA 
P6 
ATAGTTTAGCGGCCGCCCTCTATTTTCTGAGCAGCC 
Neo PL451 BamHI screening (PB) 
CAGCTGGGGCTCGACTAGAGCTTGC 
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hLSD1 8b FW 
CTTTGAGGGGAAGCCAGATACC 
hLSD1 8b RV 
CTGAGGACCTTCCAAGAATAAGG 
mLSD1 8b FW 
TCATCCTTGAGCAGGTAAC 
mLSD1 8b RV 
CAGGTTTATTATTGAGGACG 
m/rRT-Bact-FW 
GCCTTCCTTCTTGGGTAATGG 
m/rRT-Bact-RV 
AATGCCTGGGTACATGGTGG 
hmrFAMex8 LSD1FW 
[6FAM] GAAAAGGAAACTATGTAGC 
hFAMex2 LSD1FW 
[6FAM] GTGAGCCTGAAGAACCATCG 
hLSD1ex9 RV 
CTACCATTTCATCTTTCTCTTTAGG 
mrFAMex2 FW 
[6FAM]AGTGAGCCGGAAGAGCCGTCTG 
mrLSD1ex9 RV 
CTACCATTTCATCTTTTTCTTTTGG 
m/rNOVA1 FW 
CATTGAACTATATGGACTCTTCA 
m/rNOVA1 RV 
TGAGTCCTACTCTTACAGTTTG 
hmr PTBP2 FW 
TAAGTTGGTGCTGTATTGAAG 
hmr PTBp2 RV 
AGATCAGGTCGAGTATAATCC 
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1.2 AGAROSE GEL ELECTROPHORESIS                                
Electrophoresis is a process which enables the sorting of DNA molecules 
depending on their size. Using an electric field, DNA can be made to move through 
a gel composed of agarose. DNA molecules are dispensed into different wells in 
the gel material together with 1X loading dye. The most common dyes are 
bromophenol blue (Sigma B8026) and xylene cyanol (Sigma X4126): the former 
migrates at a rate equivalent to 200–400bp, while the latter migrates at 
approximately 4kb. DNA density is provided by glycerol or sucrose. The gel is 
placed in an electrophoresis chamber, which is then connected to a power source. 
We always run agarose gels in an electrical field of about 100 mV, in 
Tris-Borate-EDTA (TBE) buffer 0,25X (Tris-borate 0,089M, Boric Acid 0,089M and 
EDTA 0,002M). When the electric current is applied, the larger DNA fragments are 
slower to migrate than small molecules, which in turn move faster. Thus, molecules 
of different weight form distinct bands on the gel. Molecular weight markers are 
available that contain a mixture of molecules of known sizes. We always use about 
500 ng of pUC9 vector, digested with HaeIII enzyme, or Lambda DNA,  digested 
with PstI enzyme. After the electrophoresis is complete, DNA molecules in the gel 
can be stained using ethidium bromide (EtBr) 0,5 mg/ml,  that becomes 
fluorescent under ultraviolet light. We use 3 µl of EtBr (Sigma Aldrich) in 40 ml of 
final gel volume. We make agarose gels with 0.7-2% of agarose powder dissolved 
in TBE electrophoresis buffer. 0.7% gels perform good separation (resolution) of 
large DNA fragments (5–10kb) while a 2% gels are able to better resolve small 
fragments (0.2–1kb). 
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1.3 DIGESTION WITH RESTRICTION ENZYMES 
 
Once DNA has been purified, it must be cut to ligate the ends of the DNA fragment 
to the ends of the DNA plasmid. A group of enzymes, called Restriction Enzymes, 
are used to this purpose. The restriction enzyme recognizes a specific DNA 
restriction site, typically four, six, eight, ten, or twelve nucleotides-long, and it 
cleaves the DNA by introducing breaks in specific phosphodiester bonds. The 
cleavage is on both the DNA strands so that a double-stranded break is made. 1 U 
of enzyme is necessary to digest 1 μg of DNA, but to improve the performance of 
the reaction it is better to use an excess of 3-4 U of enzyme for each μg of DNA. 
However, it is important not to use more enzyme than 10% of the final reaction 
volume because the enzyme storage buffer contains glycerol that inhibits the 
digestion. Each enzyme requires a specific reaction buffer, with a peculiar salt and 
Magnesium concentration (high or low) and pH. These 10X buffers are sold with 
the restriction enzyme. Most companies have about 4 different kinds  of buffer 
(called A,B,C,D or 1,2,3,4 etc.) and the enzyme/buffer compatibility has to be 
check in the enzyme company informations. A few enzymes require special 
conditions, such as BSA (bovine serum albumin) added to the mixture. This is 
usually provided  with the enzyme at 100X concentration. 
A typical reaction is conducted for 2-3 hours or overnight and the temperature 
varies, according to the enzyme. If suggested by manufacters the enzyme has to 
be heat-inactivated, generally at 65°C or 80°C for 20 min. 
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1.4 DEPHOSPHORYLATION OF LINEARIZED PLASMID DNA FOR LIGATION 
 
Dephosphorylation of linearized plasmids is a method to prevent self-ligation of 
vectors with blunt-ends or with ends digested with a single restriction enzyme. This 
property can be used to decrease the vector background in cloning strategies but 
after ligation and transformation, it is necessary to perform a diagnostic experiment 
(e.g. colony PCR with suitable primers) to ensure that clones contain DNA 
fragment in the correct orientation. 
Calf Intestinal alkaline Phosphatase (CIP) is the most frequently used enzyme to 
remove 5' phosphate groups from cloning vectors. The reaction is conducted at 
37 °C for 3-4 hours, using the following protocol. 
 
DNA                       100-1000ng 
Buffer 10X                      1X 
CIP   10.000 U/ml             10 U 
H2O to 20 ul 
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1.5 DNA PURIFICATION FROM GEL SLICE 
 
Agarose contains various impurities which may inhibit downstream reactions if not 
efficiently removed from DNA. Spin-column kits are very efficient in removing these 
kind of contaminants. To this purpose we use The Wizard® SV Gel and PCR 
Clean-Up System (Promega) which extracts DNA fragments from 100-bp to 10kb 
from the agarose gels, or purifies PCR products directly from amplification 
reactions. This membrane-based system can bind up to 40μg of DNA, taking 
advantage from the ability of DNA to bind silica membranes in the presence of 
chaotropic salts. Purified DNA can be used for different applications without further 
manipulation. 
This method requires the band to be cut from the gel. To visualize DNA band the 
trans-illuminator has to be set to long-wavelength UV (or low-power) and the time 
of exposure has to be minimized, because UV mutagenesis DNA in a measurable 
rate. Using a scalpel blade to cut around the band, it can be removed from the gel 
and placed in a 1.5mL microfuge tube. The basic protocol of DNA extraction 
requires: 
- Addition of Membrane Binding Solution to the gel slice in a ratio of 10 μl of 
solution per 10 mg of gel slice: 
- Incubation at 60 °C to dissolve the gel: 
- Transfer of the mixture to the SV Minicolumn and centrifugation to discard the 
liquid solution; 
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- Washing of the column for 2 times with the Membrane Wash Solution (containing 
Ethanol), ensuring that no Ethanol residue remains in the column; 
- Elution of the DNA in at least 30μl of Nuclease-Free Water; 
 
1.6 DNA PRECIPITATION FROM PCR REACTION 
 
Another commonly used protocol to purify PCR products from the amplification 
reaction  makes use of salt and ethanol added to the aqueous solution to force the 
nucleic acids to precipitate. The positively charged salt neutralizes the DNA 
negatively charged backbone and in particular the (PO3)- groups of the nucleic 
acid, making it far less hydrophilic and much less soluble in water. On the other 
hand, ethanol has a much lower dielectric constant compared to the water, making 
the interaction of the salt with (PO3)-groups easier. Thanks to this property, ethanol 
shields acid nucleic charges and causes its dropping out of the solution. 
Centrifugation of the precipitated nucleic acids isolates it from the rest of the 
solution. The pellet is then washed with cold 70% ethanol to remove all the salt. A 
second centrifugation step is used to separate the nucleic acid from the ethanol, 
allowing it to be removed. The nucleic acid pellet is then dried and  re-suspended 
in  aqueous TE ( Tris EDTA) buffer or nuclease-free water. 
The classic PCR products precipitation protocol involves: 
1 Volume of Ammonium Acetate (2M final conc.) 
2 Volume of cold isopropanol. 
In this step it is possible to add also 1 μl of glycogen, making the nucleic acid 
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heavier and visible. 
- Incubation at -20 °C over night or 30' in ice; 
- Precipitation by centrifugation; 
- Washing with 100 ul of 70% cold EtOH; 
- Resuspension in 30 ul of TE or water. 
 
1.7 LIGATION 
 
DNA ligation allows two DNA molecules to be joined together, through the 
generation of a phosphodiester bond between the 3' hydroxyl group of a nucleotide 
and the 5' phosphate of another. This reaction is usually catalyzed by a DNA ligase 
enzyme which is able to join DNA fragments having blunt or 'sticky' ends. T4 DNA 
Ligase (New England Biolabs), from T4 bacteriophage, is the most commonly used 
enzyme for this purpose. It is supplied with its specific 10X reaction buffer 
supplemented with 1mM ATP, which ensures the optimal activity of the enzyme. 
Ligation may be done at room temperature (20-25°C), in 10 minutes for cohesive 
ends and in 2 hours for blunt ends, or over-night at 16°C. At the end of the reaction 
T4 DNA Ligase has to be inactivated at 65°C for 20' min. Before using DNA for 
bacterial transformation it has to be dialyzed to remove buffer salts. To this aim we 
use Millipore Membrane Filters. 
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We always perform ligation protocol like this: 
DNA                              100 ng 
Buffer 10X                           1X 
T4 Ligase 400U/ul (NEB)             400U 
H20 to 20 ul 
 
1.8 GENERATION OF COMPETENT BACTERIAL CELLS ( TOP10) 
 
The procedure to prepare competent cells can sometimes be tricky. Bacteria are 
not very stable when they have holes in their membrane and they easily die. A 
poorly performed procedure can result in cells that are not very competent to take 
up DNA, while a well-performed procedure will result in very competent cells. The 
competency of a stock of cells is determined by calculating how many E. Coli 
colonies are produced per 1 μg of DNA added: a good preparation of competent 
cells will give at least 108 colonies per 1 μg of DNA, a poor preparation will be 
about 104/ug or less. First of all it is necessary to streak out a frozen glycerol stock 
of TOP 10 bacterial cells onto an LB plate without antibiotics and let the plate grow 
overnight at 37°C. To prepare the starter culture, we select a single colony of E. 
Coli from the fresh TOP 10 LB plate and we inoculate it overnight in 3-4 mL of LB at 
37°C in a shaker. This is the protocol to follow the day after: 
- Inoculate 0,5 L of LB media with the starter culture and grow at 37°C in a shaker. 
Measure the OD600 every hour, then every 15-20 minutes when the OD gets 
above 0,2; 
Materials and methods 
79 
 
- When the OD600 reaches 0.4-0.5, immediately put the cells on ice. It is also very 
important to keep the cells at 4°C for the remainder of the procedure. The cells and 
any bottles or solutions that they come in contact with the cells must be pre-chilled 
to 4°C; 
- Split the 0,5 L culture into two 250 mL  centrifuge bottles; 
- Harvest the cells by centrifugation at 800g for 30-40 minutes at 4°C; 
- Decant the supernatant and resuspend each pellet in 200 mL of ice cold ddH2O; 
- Harvest the cells by centrifugation at 800g for 30 minutes at 4°C; 
- Decant the supernatant and resuspend each pellet in 100 mL of ice cold ddH2O; 
- Combine resuspensions into one centrifuge bottle and harvest the cells by 
centrifugation at 800g for 20 minutes at 4°C. At this step, rinse two 50 mL conical 
tubes with ddH2O and chill on ice; 
- Decant the supernatant and resuspend each pellet in 40 mL of ice cold 10% 
glycerol; 
- Harvest the cells by centrifugation at 1000g for 20 minutes at 4°C; 
- Carefully aspirate the supernatant with a sterile Pasteur pipette and resuspend 
each pellet in 1 mL of ice cold 10% glycerol by gently swirling; 
- Aliquot into sterile 1.5 mL microfuge tubes and store in the -80°C freezer; 
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1.9 TRANSFORMATION BY ELECTROPORATION 
 
Electroporation is a very basic technique used to transform bacterial cells. In this 
procedure, an electric pulse temporarily disturbs the phospholipid bilayer, allowing 
molecules like DNA to pass into the cell. Since the phospholipid bilayer of the 
plasma membrane has a hydrophilic external side and a hydrophobic internal one, 
any polar molecules, including DNA, are unable to freely pass through the 
membrane. The concept of electroporation capitalizes on the relatively weak 
nature of the phospholipid bilayer hydrophobic/hydrophilic interactions and its 
ability to spontaneously reassemble after disturbance. Thus, a quick voltage shock 
may temporarily disrupt areas of the membrane, allowing polar molecules to pass 
through, but after the electric shock plasma membrane may reseal quickly, leaving 
the cell intact. 
The electroporation apparatus is typically commercially produced and purchased. 
We use Bio-Rad Gene Pulser II Electroporator , set up at these conditions: 2,5kV, 
25mF, 200Ω. 
Electroporation is performed as described here: 
- Add up to 10 ng of plasmid DNA to a tube containing 40 μl of fresh or thawed 
bacterial competent cells in ice. Mix by swirling with pipette; 
- Transfer DNA and cells to a pre-chilled electroporation cuvette (0.2 cm electrode 
gap) using a narrow pipette tip. Wipe any ice or water from sides of cuvette and 
place the cuvette into the sample chamber; 
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- Energize the electroporation apparatus and deliver the pulse by pushing both 
charging buttons simultaneously and holding until a short beep is heard; 
- Remove the cuvette from the sample chamber, add immediately 1 ml of LB 
medium and transfer the cells to a sterile culture tube; 
- Incubate cultures for 60 minutes at 37°C in a moderate shaking to allow bacterial 
cells to restore their plasma membrane; 
- Plate aliquots of the electroporation mixture on agar plates supplemented with the 
appropriate antibiotics and incubate at 37°C over night. 
 
1.10 COLONIES SCREENING BY PCR AND RESTRICTION ENZYMES 
DIGESTION 
 
 
This protocol is designed to quickly screen for plasmid inserts directly from E. coli 
colonies. Even though blue/white screening can be used to  determine if inserts are 
present, these techniques are used to determine insert size and/or orientation in 
the vector. The procedure of screening by PCR is identical to a standard PCR, but 
the template is the colony itself instead of a DNA sample. If the restriction sites are 
maintained in the final plasmid after the cloning procedure, we also perform a 
control digestion  with the same restriction enzymes used to cut both vector and 
fragment in order to verify if the results is exactly the expected one. 
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1.11 COLONY BACTERIAL CULTURE 
 
Escherichia Coli may be grown on solid media or in liquid one. Lysogeny Broth    
( LB) is the most commonly used medium in molecular biology for E.coli cell 
culture. LB broth contains the enzymatic digestion product of casein known as 
peptone (some vendors term it Tryptone), yeast extract, and sodium chloride. 
Peptone is rich in amino acids and peptides. Its composition reflect the casein. In 
addition to amino acids and peptides, yeast extract also contains nucleic acids,  
lipids and other nutrients which are needed for bacterial growth. 
For our culture we used LB medium with the following composition: 
- liquid LB: yeast extract 0,5 %, bacto tryptone 1 %, NaCl 1 %; 
- solid LB: yeast extract 0,5 %, bacto tryptone 1 %, NaCl 1 %, agar 1,5%. 
The medium is then added with specific antibiotic, depending on the resistance 
carried by the plasmid: 
 
Kanamycin 50 μg/ml 
Chloramphenicol 50 μg/ml 
Ampicillin 50 μg/ml.   
 
1.12 MINI- MIDI- and MAXI-PREP 
Plasmids are used  to carry a specific DNA sequence inside the cell, but for their 
use  as vectors they need to be isolated from the rest of the bacterial genome. 
To purify our plasmids we used QIAGEN Plasmid Kits. These protocols are 
designed for preparation of up to 20 μg of plasmid DNA with QIAGEN Plasmid 
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Mini-Kit, up to 100 μg of high- or low-copy plasmid DNA with the QIAGEN Plasmid 
Midi-Kit  and up to 500 μg using the Maxi-Kit. 
Briefly, all of the QIAGEN Plasmid Kits protocols are based on the same steps. 
Bacterial lysates are cleared by centrifugation. The cleared lysate is then loaded 
onto the anion-exchange tip where plasmid DNA selectively binds under 
appropriate low-salt and pH conditions. RNA, proteins, metabolites, and other 
low-molecular-weight impurities are removed by a medium-salt wash and ultrapure 
plasmid DNA is eluted in high-salt buffer. The DNA is then concentrated and 
desalted by isopropanol precipitation and collected by centrifugation. Table below 
shows LB culture volume that we use for each kit, depending on the type of 
plasmid: 
 
 
                            High copy plasmid          Low copy plasmid 
QUIAGEN Plasmid mini-kit         3 ml              Not recommended 
QUIAGEN Plasmid midi-kit        25 ml                   100 ml 
QUIAGEN Plasmid maxi-kit      100 ml                    500 ml 
 
DNA concentration can be evaluated by both UV spectrophotometer at 260 nm or 
quantitative analysis on an agarose gel. 
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1.13 SEQUENCING PCR 
 
DNA sequencing includes different methods and technologies used for determining 
the order of the nucleotide bases in the DNA molecule. Nowadays chain-terminator 
method (also called Sanger method) is the technique of choice. The key principle 
of the Sanger method is the use of dideoxynucleotides triphosphates (ddNTPs) as 
DNA chain terminators. The ddNTPs lack the 3’-OH terminal group, so when they 
are randomly incorporated, they block the reaction lengthening. 
To obtain our sequences we use BigDye Terminator v3.1 Cycle Sequencing Kit 
(Applied Biosystem) which permits sequencing in a single reaction because each 
of the four dideoxynucleotide chain terminators is labelled with a dye that emits 
light at a specific wavelength. All of the newly synthesized and labelled DNA 
fragments are heat denatured and separated by size with a resolution o f one 
nucleotide, using a capillary electrophoresis instrument called ABI PRISM® 3130 xl 
Genetic Analyzer (Applied Biosystem). The outcome of the electrophoresis 
automatic sequencing is an electropherogram with unequal peak height, color and 
shape for each of the four nucleotides. DNA sequences of high quality typically 
result in a read length of 650 to 750 bases with an accuracy of 99%, characterized 
by sharp peaks and little to no background. 
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This is the protocol for a sequencing reaction: 
                   Final Concentration 
DNA            plasmidic DNA 300-400 ng       Cycle 1  95°C x 2.30'     
            PCR products 15-20 ng                   95°C x 30''      
Buffer 10X            1X              Cycle 2  50°C x 20''     
FW or Rv primer 3,2 µM  0,5 µl                     x 25    60°C x 4'         
Big dye terminator    1 µl                     Cycle 3  72°C x  7'      
H2O to 10  µl 
 
 
1.14 DNA PURIFICATION FROM SEQUENCING REACTION  
 
Before loading PCR products from a sequencing reaction on the capillary 
electrophoresis instrument, they have to be purified. Instead of ammonium acetate, 
which is specific in removing dNTPs, we use sodium acetate (0.3M final conc, pH 
5.2) that is suitable for routine DNA precipitations. 
This is the protocol we follow: 
 
- 1/10 V NaAc and 2V 100% cold EtOH added to the reaction; 
- incubation for 20 min. at room temperature; 
- precipitation of DNA by centrifugation; 
- washing  with 70% cold EtOH; 
- resuspension in 12 μl of denaturant fomamide; 
- denaturation for 5' at 95°C. 
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2. CELL CULTURE 
 
Animal or plant cells, removed from their tissues, will continue to grow if supplied 
with the appropriate nutrients and conditions. When carried out in a laboratory, this 
process is called cell culture and it occurs in vitro. Cells in culture may be 
genetically identical (homogenous population) or may show some genetic variation 
(heterogeneous population). A homogenous population of cells, derived from a 
single parental cell, is called clone. Therefore all cells within a clonal population are 
genetically identical. 
Freshly isolated cultures from mammalian tissues are known as primary cultures. 
At this stage, cells are usually heterogeneous but still closely represent the 
parental cell types in the expression of tissue specific properties. After several 
sub-cultures onto fresh media, cell line will either die or ‘transform’ to become a 
continuous cell line. Such cell lines show many alterations from the primary 
cultures including change in morphology, chromosomal variation and increase in 
capacity to give rise to tumors in hosts. 
For our experiments we used the following cell lines: 
HELA cells: human epithelial cells from cervical carcinoma. HeLa are adherent 
cells which normally grow flat and stuck down firmly on the tissue culture flask. 
SH-SY5Y cells: is a human derived neuroblastoma cell line, originally cloned from 
SK-N-SH. The cells differentiate by extending neurites to the surrounding area. 
The dividing cells can form clusters which are reminders of their cancerous nature, 
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but treatments such as retinoic acid and BDNF can force the cells to dendrify and 
differentiate. 
IMR-32 cells: is another human neuroblastoma cell line that when is differentiated 
mimics large projections of the human neurons. 
Neuro-2A cells: is a murine neuroblastoma cell line, established from a 
spontaneous tumor of a strain A albino mouse. 
 
These cell lines grow in 100 mm Ø cell culture dishes, at 37°C and 5% CO2, using 
10 ml of DMEM or RPMI complete medium. 
HELA and IMR-32 and growth medium:                   Final concentration 
 
-Foetal bovine serum (FBS) (Euroclone)                          10%  
-Glutamax (Gibco)                                              1% 
-Penicillin / 0.1 mg/ml streptomycin (Euroclone) 100X                1X 
-Fungizone (Euroclone)                                          1% 
-Dulbecco’s modified Eagle’s medium (DMEM) (Euroclone) to 500 ml                                                                                                                                                                                                                                        
 
SH-SY5Y and Neuro2A  growth medium: 
 
-Foetal bovine serum (FBS) (Euroclone)                          10%  
-Glutamax (Gibco)                                              1% 
-Penicillin / 0.1 mg/ml streptomycin (Euroclone) 100X                1X 
-Fungizone (Euroclone)                                          1% 
-Roswell Park Memorial Institute medium (RPMI) (Euroclone) to 500 ml 
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2.1  TRANSIENT TRANSFECTION 
 
 
“Transfection” means the introduction of foreign DNA into eukaryotic cells. 
Experimentally, this is most often done as transient transfection, in which the 
external gene is expressed only for a short period of time. In transient transfection, 
the gene introduced can be lost by the cell at any time, depending on 
environmental factors. 
We chose a very efficient transfection method based on the inclusion of the DNA to 
be transfected in liposomes, small membrane-bounded bodies similar to the 
structure of the cell and capable to fuse with the plasma membrane, releasing DNA 
inside the cell. 
Our immortalized cell lines were transfected with Lipofectamin 2000 (Invitrogen). 
One day before transfection, cells were plated to obtain 80% of confluence at the 
time of transfection. 
For each transfection sample, we prepare complexes as follows: 
6-WELL VASSELS: 1,25 μg of DNA and 4 μl of Lipofectamin 2000 in 250 μ l of final 
transfection volume 
100-mm PLATES: 10 μg of DNA and 32 μl of Lipofectamin 2000 in 500 μ l of final 
transfection volume 
  
First of all DNA was diluted in half of the appropriate transfection medium without 
serum and mixed gently. Lipofectamine 2000 is diluted in the other half of the 
appropriate transfection medium without serum, mixed gently and incubated for 5 
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minutes at 37°C. After 5 minutes of incubation, diluted DNA and diluted 
Lipofectamine were combined together and incubated for 20 minutes at 37°C to 
allow the DNA-Lipofectamine 2000 complexes to form. Such complexes were then 
added to each plate containing cells medium without serum. Transfection medium 
was replaced after 4-6 hours with complete medium. Transfected cells were grown 
at 37°C in a CO2 incubator for 24-48 hours until they were ready to assay for 
transgene expression. 
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3. RNA EXTRACTION AND ANALYSIS 
 
3.1 RNA EXTRACTION 
 
Several methods are used in molecular biology to isolate RNA from samples but 
the most common of these is guanidinium thiocyanate-phenol-chloroform 
extraction. The specific reagent that we used was TRI Reagent (Sigma-Aldrich). 
TRI Reagent solution combines phenol and guanidine thiocyanate in a monophasic 
solution to rapidly inhibit RNase activity. A biological sample is homogenized or 
lysed in TRI Reagent solution and the homogenate is then separated into aqueous 
and organic phases by adding chloroform and by centrifuging. RNA goes to the 
aqueous phase, DNA to the interphase, and proteins to the organic phase. Then 
the RNA is precipitated from the aqueous phase with isopropanol and finally it is 
washed with ethanol and solubilized in DEPC water. 
TRI Reagent (Sigma-Aldrich) protocol consists in: 
- cell washing with PBS; 
- lysis of the cultured cells with TRI Reagent: 1 ml TRI Reagent solution for 5–
10x106 cells or for 10 cm2 culture dish area; 
- addition of 200 ul of chloroform per 1 ml of TRI Reagent solution; 
- 5-10 minutes of incubation at room temperature after vigorously shaking; 
-centrifugation for 10 min at 12,000g and 4°C, followed by transfering of the 
aqueous RNA containing phase to a fresh tube; 
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- RNA  precipitation with 500 ul of isopropanol per ml of TRE Reagent used; 
- RNA pellet washing with 1 ml of 75% EtOH per ml of TRE Reagent used; 
- Resuspension with 30-50 ul of DEPCT water. 
 
The RNA final concentration was subsequently measured at the 
spectrophotometer, reading the Absorbance at 260 nm with 1 O.D., corresponding 
to 40 g/ml, for a cuvette 1 cm large (Lambert – Beer’s Law). 
Final concentration = absorbance value x dilution factor x 40 g/ml conversion factor  
As proteins absorb at 280 nm, measuring the 260/280 absorbance ratio it’s 
possible to value the RNA pureness. The ideal ration is between 1,8 and 2. 
The 260/230nm ratio is important to detect the presence of contaminants, such as 
phenol, ethanol or aromatic molecules. The best ratio is 2,2. 
To estimate the RNA integrity, it is possible to run 1 ug of RNA on 1% agarose gel 
electrophoresis in TAE buffer (0,04M Tris-acetate, 0,001M EDTA). 
 
 
3.2 REVERSE TRANSCRIPTION PCR (RT-PCR) 
 
The vast majority of cellular RNA molecules are tRNAs and rRNAs. Only 1 to 5% of 
total cellular RNA is mRNA. Separation of mRNA from the RNA pool is essential for 
the construction of cDNA. Most mRNA contain a poly(A) tails, while the structural 
RNAs do not, so poly(A) selection enriches the mRNA. 
To convert mRNA into double-stranded DNA we use ImProm-II Reverse 
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Transcription System (Promega). This procedure outlines the synthesis of cDNA 
for subsequent amplification using PCR. 
Reverse transcription reactions of up to 1μg of total RNA were performed in 20μl, 
comprised of components of the ImProm-II™ Reverse Transcription System. 
Briefly: 
RNA is combined with oligo(dT) primer that binds to poly(A) tails. The 
primer/template mix is thermally denatured at 70°C for 5 minutes and chilled on ice. 
A reverse transcription reaction mix is then assembled on ice to contain 
nuclease-free water, reaction buffer, reverse transcriptase, magnesium chloride, 
dNTPs and RNasin Ribonuclease Inhibitor. Following an initial annealing at 25°C 
for 5 minutes, the reaction is incubated at 42°C for up to one hour. Since no 
cleanup or dilution is necessary following the cDNA synthesis, the product may be 
directly added to amplification reactions. 
 
The first part of the reaction includes: 
RNA                     1 ug 
oligo dT                0,5 ug 
H2O nuclease free      to 10 ul 
To denature RNA secondary structures, this mix is incubated at 70 °C for 5min. 
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Then we added: 
                                                                                                     
Final concentration 
ImPromII 5X Reaction Buffer                                   1X 
MgCl2                                                       1,5 mM 
dNTPs mix                                                   2 mM 
RNasin Ribonuclease Inhibitor                                  20 U 
ImPromII Reverse Transcriptase                                1 ul 
H2O nuclease free to 10 ul 
The reaction is then incubated at 25°C for 5 minutes to allow reverse transcriptase 
binding, and at 42°C for 60 min. to allow elongation of cDNA. Finally, we increased 
temperature at 70°C for 15min to inactivate RT enzyme. 
 
3.3 QUANTITATIVE REAL TIME PCR 
 
Quantitative real time PCR is a technique used to amplify and simultaneously 
quantify a targeted DNA molecule. The quantity can be either an absolute number 
of copies or a relative amount when normalized with an endogenous gene (such as 
GAPDH or β-Actin). 
There are two common methods for products detection in real-time PCR: 
 
(1) non-specific fluorescent dyes (such as SYBR Green) that intercalate with any 
double-stranded DNA 
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(2) sequence-specific DNA probes (TaqMan probes) consisting of oligonucleotides 
labeled with a fluorescent reporter that permits detection only after hybridization 
with its complementary DNA target. 
In our experiments we always use SYBR Green (Biorad) as detec tion system. An 
increasing in DNA products during PCR leads to an increase in SYBR Green 
fluorescence that is measured at each cycle, allowing DNA concentrations to be 
quantified. 
Relative concentrations of DNA present during the exponential phase of the 
reaction are determined by plotting fluorescence against cycle number on a 
logarithmic scale (so that an exponentially-increasing quantity will show as a 
straight line). A threshold for detection of fluorescence above background is 
determined. The cycle at which the fluorescence from our sample crosses the 
threshold is called the cycle threshold, Ct. The quantity of DNA theoretically 
doubles every cycle during the exponential phase, and relative amounts of DNA 
can be calculated with the formula: 2- ΔCT , where ΔCT is the difference between the 
sample Ct and the housekeeping gene Ct. The reaction was performed with the 
thermalcycler iQ5 real-time PCR detection system (Biorad) and SYBR Green 
Supermix (Biorad), with following protocol: 
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Final concentration 
cDNA                                50 ng of retrotranscribed RNA 
SYBR Green 2X                                  1X 
Primer FW 10uM       0,5 uM 
Primer RV 10uM       0,5 uM 
H2O to 25 ul 
 
cycle 1  95°C x 2'         cycle 4  95°C x 1' 
cycle 2  95°C x 30''  cycle 5  74°C x 1'  
   95°C x 10''  cycle 6  x 43  74°C x 10''     
cycle 3  x 50  59°C x 20''                                         
                  74°C x 20'' 
 
Primers used in real time PCR reactions: 
mBactEx2real-FW 
GGCTGTATTCCCCTCCATCG 
mBactEx3real-RV 
CCAGTTGGTAACAATGCCATGT 
mLSD1-real-FW 
GCCTCAGCAGACACAGAAGG 
mLSD1-real-RV 
TGTTGTAAGGCGCTTCCAGC 
mRPSA FW 
ACCCAGAGGAGATTGAGAAGG 
mRPSA RV 
TGGGGAACTGCTGAATGGCC 
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mBDNF ORF FW 
ATGAGGGTCCGGCGCCACTC 
mBDNF ORF RV 
CAAGGACTGTGACCGTCCCG 
mBDNF exon II FW 
ATCCGGGCGATAGGAGTCC 
mBDNF exon II RV 
CACAGGGTTGGCTTTACAGC 
mNOVA1 x real FW 
GCCGGACTCGCGGAAAAG 
mNOVA1 x real RV 
TGAACAATTGTCTGTCCTCC 
mC-FOS x real FW 
GATGTTCTCGGGGTTGAAGC 
mC-FOS x real RV 
AGAAGGAGTCTGCGGGTGAG 
mEGR1 x real FW 
CCTTCAATCCTCAAGGGGAGC 
mEGR1 x real RV 
AACCGAGTCGTTTGGCTGGGA 
 
 
3.4 RELATIVE QUANTITY FLUORESCENT PCR (Rqf-PCR) and CAPILLARY 
GEL ELECTROPHORESIS 
 
To quantitatively measure the relative amount of each LSD1 isoform, we used a 
PCR-based method in which a fluorochrome-conjugated (FAM) forward primer 
(Sigma-Aldrich) and a reverse unmodified one were used to amplify all the 
expected isoforms in a single reaction. PCR products, mixed together with a 
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suitable internal ROX-conjugated size standard (500ROX Standard; Applied 
Biosystems), were separated by capillary electrophoresis under denaturing 
conditions, and the amount of each amplified product was measured as 
microsatellite sample, based on related fluorescence unit levels using the  
GeneMapper software. 
Capillary gel electrophoresis is an useful technique to accurately establish the 
length of the PCR product fragments. Since the matrix gel is made of 
polyacrylamide, it is possible to separate fragments that differ even from 1 bp. 
This is the protocol we followed: 
 
                                                                                                   
Final Concentration 
PCR product                                       up to 1ul 
Formaldehyde                                             11 ul 
Molecular weight marker                                  0,3 ul 
 
 
Each sample has to be denatured for 5 min. at 95°C before to be loaded on the 
capillary gel electrophoresis. 
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4. PROTEIN ANALYSIS 
 
Total protein extraction has been obtained from different cell lines, using  RIPA 
buffer or Low Stringency buffer (LS) as extraction method. Cells has been scraped 
from culture plate in 1 ml of PBS and centrifuged at 800g  for 5’ at 4°C. The pellet 
has been resuspended in 5-6 volume of LS or RIPA buffer, depending from the 
purpose of the extraction, incubated 30’ at 4°C in slow rotation and, after 
centrifugation at high speed for 30’, the supernatant containing soluble proteins 
was stored at -80 °C. 
Protein concentration has been quantified using the Bradford method (Pierce). 
 
Low Stringency lysis buffer: 50 mM Tris-HCl pH 7.5, 120 mM NaCl, 0.5 mM EDTA, 
0.5 % Nonidet P-40. 
RIPA lysis buffer: 50 mM Tris-HCl, 150 mM NaCl, 1.0 % NP-40, 0.5 % Sodium 
Deoxycholate, 1.0 mM EDTA, 0.1 % (w/v) SDS and proteases inhibitors). 
 
4.1 WESTERN BLOT 
 
Western blot or immunoblotting allowed us to determine, with a specific primary 
antibody, the relative amount of a protein in different samples. Samples are 
prepared from tissues or cells homogenized in a buffer that protects the proteins 
from degradation. Proteins are separated using SDS-PAGE. SDS is a detergent 
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that is present in the sample buffer, where along with boil ing and together with a 
reducing agent (normally DTT or B-ME to break down protein-protein disulphide 
bonds) it  disrupts the tertiary structure of the proteins. This brings the folded 
proteins down to linear molecules. SDS also covers proteins with a uniform 
negative charge, which masks the intrinsic charges of the R-groups. Indeed, SDS 
binds uniformly to the linear proteins (around 1.4g SDS/ 1g protein), so that their 
charge becomes  approximately proportional to their molecular weight. 
SDS is also present in the gel to make sure that once the proteins are linearized 
and their charges masked, they stay like this also during the running.  Gel matrix 
used for SDS-PAGE is polyacrylamide, which is a good choice because is 
chemically inert and, crucially, can easily be made up at a different concentrations 
to produce different pore sizes, giving a variety of separating conditions that can be 
changed depending on the needs. Once proteins are separated they have to be 
transferred to a nitrocellulose membrane for detection. Membrane is then 
incubated for 1h or over night in NaCl/Tris added with 0,3% Tween (TBST) and 4% 
(w/v) of skimmed milk that binds to any remaining sticky places. Afterwards, a 
primary antibody is added (in the same 5 % milk in 1X TBST solution) for 4h at 
room temperature or over night at 4 °C. Then the membrane is washed 3 times for 
5 min. in TBST and incubated with the specific HRP-coniugated secondary 
antibody.  Specific signal of the protein is detected with SuperSignal West Pico 
(Pierce). 
1,5 mm-thick polyacrylamide gel for SDS-PAGE is composed of: 
Materials and methods 
100 
 
                            Stacking (5%)             Separating   
40% Polyacrylamide   1,25 ml   variable 
1M Tris (pH 6.8)    1,25 ml   3,75 ml 
10% Ammonium persulfate  100 ul    150 ul 
10% SDS     100 ul    150 ul 
TEMED      10 ul      9 ul 
H2O          to 10 ml    to 15 ml 
 
Primary antibodies used: 
- monoclonal anti HA-probe (F-7) (Santa Cruz sc-7392) 
- monoclonal anti-FLAG clone M2 (Sigma F104) 
- polyclonal anti-GAPDH (NB 300-320) 
 
HRP coniugated secondary antibodies used: 
- donkey anti-rabbit IgG-HRP (GE Healthcare NA934V) 
- goat anti-mouse IgG-HRP (Santa Cruz  sc-2005) 
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5. ANIMALS 
 
The experiments were undertaken in accordance with the guidelines deﬁned by the 
European Communities Council directive (86/609/EEC) for the Care and Use of 
Laboratory Animals and every effort was made to limit the number of animals used. 
The experimental protocol was approved by the Ethics Committee of the 
‘University of Milan’. 
Behavioral experiments were performed with 12 weeks-old backcrossed C57BL/6 
LSD1 exon E8a knock-out and wild type male littermates, derived from multiple 
litters. The majority of tests were conducted using the same cohort for multiple 
tests, performed in order from least to most stressful. Phenotypic characterizations 
were performed on 3 weeks- and 3 months-old knock-out and wild type female 
mice. Mice were sacrificed by cervical dislocation in order to provide a fast and 
painless death without the effects of anesthesia. Immunohistochemical studies 
were done on 5 weeks-old  knock-out and wild type  male or female littermates, 
after fixation via transcardial perfusion. 
C57BL/6 mice were purchased from Charles River (Milano). Mice were housed 2-4 
per cage in an animal room with constant temperature (22 ± 1 °C) and a 12 hour 
light/dark cycle (lights on/off at 6:00 A.M/P.M.), with free access to food and water. 
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5.1 DNA EXTRACTION FROM MICE BIOPSY 
 
Mice genotyping were performed on DNA taken from fingers biopsy. We first 
incubated over-night at 58°C such small pieces of mice tissue, in 50 uL of a  
solution composed of: 
– 1 uL of proteinase K (10mg/mL), 
– 1 X PCR reaction buffer (10X) 
–  water to 50 uL 
We then ground fingers with the help of a tip and we incubated for 1h at 65°C. After 
that we denatured proteinase K at 95°C for 10 min. and we centrifugated to obtain 
a clear supernatant that we used as PCR template. 
  
5.2 PILOCARPINE TREATMENT AND SEIZURES ASSESSMENT 
 
Five weeks-old experimental mice were intraperitoneally injected (i.p.) with a single 
dose of 270 mg/kg of pilocarpine in sterile saline vehicle (0.9% NaCl). Control mice 
were age-matched with the treated mice and were administered a comparable 
volume of vehicle. We also pre-treated all of our mice with lithium chloride (3 
mEq/Kg), allowing a reduction of the pilocarpine dose required to induce status 
epilepticus and resulting in a higher percentage of animals developing seizures. 
On the day of injection, behavioral observation lasted minimally 1 h after 
pilocarpine injection, and pilocarpine-induced seizures were evaluated according 
to a modified version of the Racine scale, using categories 1–5. Categories one 
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and two (facial automatisms, tail stiffening and wet-dog shakes) were considered 
as a group to avoid subjectivity in assessing the seizures. All pilocarpine -treated 
mice displayed some or all of these behaviors. Category 3 (low-intensity tonic–
clonic seizure marked by unilateral forelimb myoclonus in addition to the symptoms 
above), category 4 (the addition of bilateral forelimb myoclonus and rearing), and 
category 5 (bilateral fore- and hind-limb myoclonus and transient loss of postural 
control) seizures were considered to be generalized, convulsive seizures. Category 
3–5 seizures were typically of 30–90 sec of duration and were separated by periods 
of relative inactivity of variable duration. The periods between category 3–5 seizure 
events were usually marked by continuous category 1 and 2 seizures. A mouse 
that experienced a minimum of three category 3–5 seizure events within 1 h 
following pilocarpine injection was considered to have undergone status epilepticus 
(SE). SE was then terminated in all mice by diazepam (10 mg/kg). Control  and 
pilocarpine-injected mice were housed individually in cages that were uniformly 
intermixed and monitored simultaneously. Following the pilocarpine treatment, 
mice were monitored for 1 to 7 hours for the occurrence of spontaneous category 
3–5 seizures and then sacrificed. Hippocampus, cerebellum and striatum of treated 
and control mice was removed and different protein expression as well as 
transcription profile were evaluated in order to find out differences between Exon 
E8a Knock-out mice and wild type ones, in a condition of neuronal activation. 
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5.3 WHOLE ANIMAL FIXATION VIA TRANSCARDIAL PERFUSION 
 
Although immersion fixation allows for the adequate cytological preservation of 
small pieces of tissue for routine histological stainings, we decided to preserve 
them with perfusion fixation. This method is  especially required for optimal fixation 
of central neural tissues, particularly if they are to be used in immunohistochemical 
or other specialized neurohistological procedures. 
Before starting with fixation we intraperitoneally administered 0,5 ml of 4% cloralio 
idrato to anesthetize mice. After one minute we assessed and assured 
surgical-plane anesthesia by toe pinch. We then wetted the fur of the ventral skin 
surface with 100% ethanol and we superficially cut the ventral skin with scissors, 
just below the zyphoid-process, being careful not to perforate the peritoneal 
membrane. After the exposition of the thoracic and peritoneal membrane surfaces, 
obtained by manually pulling the opposing skin segments rostrally and caudally, we 
cut the peritoneal membrane with scissors, just below the zyphoid-process to 
expose the diaphragm and visceral organs, being careful not to lacerate any 
significant vasculature. Performing a combination of blunt dissection and 
scissor-assisted dissection techniques, we opened the thoracic cavity by cutting 
the diaphragm from one lateral aspect to the other lateral aspect. Using thumb 
forceps, we gently grasped and held the right ventricular free-wall and visualized 
the delineation of the darker, blood-filled-coloration of right ventricle and the redder, 
muscular-coloration of left ventricle. First of all we performed an intracardiac 
injection with 200 ul of Vister Heparin,  a  strong blood anticoagulant,  then we 
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insert the needle of the infant infusion set, attached to pre-fix solution, into the left 
ventricular chamber and at the same time we carefully lacerated the right 
atrial-chamber with scissors: blood and heparinized pre-fix solution flew from the 
right atria laceration. The right ventricular chamber remain somewhat darkened in 
color when compared to the left ventricular chamber. The liver begins to blanch as 
blood is replaced with pre-fix solution. At the completion of the 5 min. of pre-fixing, 
we carefully changed-out the solution without dislodging the infusion needle from 
the left ventricle and we started  perfusion with 4% paraformaldehyde/PB for 10 
more minutes.  At the completion of the paraformaldehyde perfusion, we removed 
the needle from the left ventricle and we dissected brain. Tissue was immersed in 4% 
paraformaldehyde/PB and fixation continued by immersion with agitation for 10 -16 
hours at 4°C. 
        At the conclusion of fixation, we replaced fixative with PB 0.1 M pH 7.4 and we 
sliced the brain with microtome (Leica VT 1000 S) in coronal or parasagittal 
sections of 50 um width.  Sections were lied down in  PB 0.1 M pH 7.4 and some 
of them were conserved on a slide at 4°C for the immunostaining. On the contrary 
to perform post-embedding reactions we included brain in paraffin and then we cut 
10 um sections and we conserved them on gelatin-coated slices. 
Reagents: 
 
Phosphate Buffered (PB) 
To obtain 2X solution: 
A)  0.2M   NaH2PO4xH20     27,59 g/L 
B)  0.2M        Na2HPO4x7H20      56,615 g/L 
pH B solution was adjusted to 7.4 using A solution 
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Eparina Vister (Perfusant) 
5.000 U.I./ml solution 
 
Paraformaldehyde Fixative (Perfusant) 
Pre-fix solution 
1% Paraformaldehyde (Fluka) in PB, final pH 7.4 
Fix solution 
4% Paraformaldehyde (Fluka) in PB, final pH 7.4 
 
The paraformaldehyde is dissolved in PB with constant stirring. The fix solution is 
filtered. 
 
Intraperitoneal Anesthetic 
Cloralio idrato (Sigma 15307) 0,28 g in 7 ml 
Pump Set-Up 
5 min. of prefix- and 10 min. of fix-solution 
 
5.4 IMMUNOSTAINING 
 
Immunostaining is a general term that applies to any use of an antibody-based 
method to detect a specific protein in a sample. Immunohistochemistry (IHC) 
staining of tissue sections (or immunocytochemistry, which is the staining of cells), 
is the most commonly applied immunostaining technique. While some cases of 
IHC/ICC staining uses  fluorescent dyes (immunofluorescence), other 
non-fluorescent methods using enzymes such as peroxidase and alkaline 
phosphatase are also used.   
We performed both immunoperoxidase and immunofluorescent staining on LSD1 
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wild type and knock-out  brain slice, using different antibodies. 
Before starting with the immonoperoxidase staining we pre-treated brain slices to 
allow the  antibodies interaction. This is the protocol we followed: 
- NH4Cl 0,05 M/PBS for 20 min. to saturate aldeyde groups deriving from 
fix-solution and to avoid aspecific electrostatic interactions with the antibodies;   
- PBS washing; 
- H2O2 1% /PBS for 10 min. to block endogenous peroxidase; 
- PBS washing; 
- BSA 1% and Triton X-100 0,2% in PBS for 30 min. to block aspecific binding sites 
(with BSA) and to improve tissue permeability to the antibodies (Triton X-100 
0,2%); 
Afterward we performed immunostaining like this: 
- incubation with primary antibodies in BSA 0,1%, over night at room temperature 
or for 2 nights at 4°C but in constant shaking; 
- PBS washing to remove unbounded antibodies; 
- incubation with biotinylated secondary antibody for 75 min. at room temperature; 
- PBS washing; 
- incubation with Avidin-Biotin-Peroxidase complex (ABC/HRP complex) for 75 min. 
at room temperature in costant shaking. This method allows the weak specif signal 
to be amplified thanks to the binding between Avidin and Horseradish 
Peroxidase-conjugated Biotin molecules. Indeed, each Avidin molecules is able to 
bind 4 Biotin molecules. The solution is prepared 30 min. before the usage to let 
Biotin molecules interact with Avidin;   
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- PBS washing; 
- incubation in a solution of  Tris-HCl 0,05 M pH 7,4 with 3-3’ diaminobenzidine 
(DAB) 0,075% and H2O2 0,02%. In the presence of hydrogen peroxide, DAB is 
converted to an insoluble brown reaction product and water by the enzyme HRP 
(horse radish peroxidase).  The reaction is like this:    
                                                             
DAB + H202 ----------HRP----------> DAB ppt + H20 
 
So if we have HRP attached to the  antibody, which in turn is bound to an antigen 
in a particular area of a section, when we add DAB and H202, the reaction will 
proceed like any other enzymatic reaction and produce an insoluble brown DAB 
ppt and H20 in the area of the section where the antibody has bound antigen.  In 
some reactions, staining was intensified by adding nickel ammonium sulfate that 
gives reaction products a dark purple color. 
Sections were then collected on gelatin-coated slides, dried over night at 37°C and 
the day after they were dehydrated by an ascending alcoholic solution (alcohol 75º, 
96º, 100º), clarified in xilol and finally coverslipped with Permount to be observed 
with optical microscope.   
 
Primary antibodies used for the immunoperoxidase reactions: 
- monoclonal anti-Calbindin D-28K (Swant cat. 300) 
- polyclonal anti-Calretinin  (Swant cat. CR7699/3H) 
- polyclonal anti-LSD1 (AB 17721) 
- polyclonal anti-SOX2 (AB5603) 
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- monoclonal anti-VGLUT1 (MAB5502) 
- polyclonal anti-VGLUT2 (AB 72310) 
All of them were diluted in BSA 0,1%/PBS  0.01M, pH 7.4 
 
Secondary antibodies used in immunoperoxidase reactions: 
 
-  biotinylated goat anti-rabbit IgG antibody (BA1000) 
-  biotinylated horse anti-mouse IgG antibody (BA2000) 
-  biotinylated horse anti-goat  IgG antibody (BA9500) 
All of them were diluted in BSA 0,1%/PBS  0.01M, pH 7.4 
 
  
 
 
 
 
RESULTS 
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1. NEUROSPECIFIC LSD1 ALTERNATIVE 
SPLICING REGULATION  
 
 
 
Splicing efficiency of individual exons is determined by multiple features involving 
gene architecture, a variety of cis-acting elements within the exons and flanking 
introns, interactions with components of the basal splicing machinery 
(spliceosome) and  regulatory factors which transiently co-assemble with the 
spliceosome. The main goal of my project was to analyze the molecular 
mechanisms underlying the alternative splicing of the LSD1 neurospecific exon 
E8a. Alternative exons are often regulated according to cell-specific patterns and 
regulation is mediated by sets of cis-acting elements and trans-acting factors. For 
this reason, first of all we analyzed the intronic E8a flanking regions to find out the 
potential cis- and trans-acting factors involved in this process.  Such analysis was 
performed with the assistance of specific browsers that were able to predict with a 
good level of accuracy the factors involved in splicing regulation. After that, 
combining data obtained from database prediction with the existing evidences in 
literature we decided to experimentally validate the most promising regulators. 
Validation occurred by performing mini-gene splicing assays, that are commonly 
used in vivo to identify the intrinsic features of a gene that control exon usage and 
to find-out specific cis-acting elements and trans-acting factors that modulate 
alternative splicing in a cell-specific manner.  
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1.1 CHARACTERIZATION OF THE EXON E8a FLANKING INTRONS  
 
 
We know from literature that both in human and in mouse, 77% of the conserved 
alternatively spliced exons are flanked on both sides by long conserved intronic 
sequences. The average length of these regions is about 103 bases in the 
upstream intron and 94 bases in the downstream intron, while the average 
conservation percentage is about 88% [66]. Since they were found to be 
unexpressed in microarray experiments, many of these conserved intronic 
sequences are probably cis-regulatory elements with a function in alternative 
splicing modulation. 
In LSD1 genomic sequence, we observed a very high conservation degree in 
correspondence of the known 19 constitutive exons and a lower conservation in the 
intronic sequences, as expected. Nevertheless, we also noted a high conservation 
degree in correspondence of the alternative exons E2a and E8a, and within the 
E2a and E8a intronic flanking regions (Fig.1.1.1 A), according to what we found in 
literature. Using the UCSC Genome Browser (http://genome.ucsc.edu) we 
delineated a region of about 800-bp flanking the exon E8a, that was highly 
conserved among mammals. In particular, aligning this sequence using the 
GenomeVista browser (http://www.pipeline.lbl.gov), we observed 89% of identity 
with the mouse genome (Fig. 1.1.1 B), whereas with the rat genome we found 84% 
of identity. This observation immediately led us to think that E8a flanking intronic 
sequences were probably involved in alternative splicing regulation.  
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Starting from this observation we analyzed the selected region using SpliceAid2 
(http://www.introni.it), a human database of experimental RNA target motifs and 
splicing proteins, that gave us the possibility to find a great number of splicing 
factors potentially involved  in E8a alternative splicing regulation.  
Fig. 1.1.1 Alignment of human genomic LSD1 sequence with mouse genomic LSD1  
Fig. 1.1.1A   Schematic representation of the human LSD1 introns and exons from 1 to 19; asterisks indicate the location of 
annotated alternative exons (E2a and E8a). The “peaks and valleys” graphs represent percentage conservation at a given genomi c 
coordinate between the human sequence and the mouse one. The first  exon is numbered, as well as the last one and the 
alternatively spliced ones. Regions of high conservation are colored as exons (purple) or noncoding (pink). Conserved regions  are 
defined as regions with identity of 70% or higher. Fig. 1.1.1 B    Enlarged view of the alignment between human and mouse 
upstream and downstream introns around the alternatively spliced exon E8a.  
 
 
 
In particular we were interested in identifying NOVA1 binding sites because we 
knew that NOVA1 is a neurospecific splicing regulator and in literature there is the 
evidence of a physical interaction with the exon E8a, obtained by HITS-CLIPS 
experiments [67]. Thus, we looked for NOVA1 binding sites (YCAY) in the exon 
E8a flanking introns. Furthermore we were also interested in finding FOX1 binding 
sites (TGCATG) as well as nPTB ones (CT rich), because of their neuronal 
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restricted tissue-specificity and their demonstrated interaction with NOVA1 [67, 69].  
Fig. 1.1.2 shows that in the highly conserved 800 bp region surrounding the exon 
E8a, we found NOVA1 binding sites (YCAY) upstream and downstream the exon 
E8a, with a cluster of 7 sites within the first 100 bp of the downstream intron. Since 
NOVA1 positively regulates splicing when present in the downstream intron [68], 
our finding suggests that NOVA1 can have a positive role on exon E8a inclusion. 
We also found different nPTB binding sequences (CT rich) mainly located in the 
upstream intron. On the contrary no FOX1 binding sites were found inside this 800 
bp conserved region.    
 
 
Fig. 1.1.2 Cis-acting sequences involved in E8a splicing regulation 
Inside the 800 bp highly conserved region flanking the exon E8a we found several NOVA1 binding sites, YCAY elements  in brown 
in the picture, and different nPTB binding sites, represented by CT rich sequences in orange. No FOX1 binding sites were pres ent 
inside this restricted portion surrounding the exon E8a. 
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1.2  MINIGENE 800 SPLICING ASSAY 
 
 
In order to verify if the cis-acting elements that we found were really involved in 
splicing regulation and if they were sufficient  to induce exon E8a inclusion in the 
mature nLSD1 transcript, we performed functional studies using a Minigene 
reporter system where we cloned the 800-bp highly conserved portion mentioned 
above.  
Minigene constructs are important tools for the identiﬁcation and in vivo analysis of 
the cis-acting regulatory elements and trans-acting factors that establish splicing 
eﬃciency and that regulate alternative splicing. Expression of Minigene 
pre-mRNAs by transient transfection provides a rapid assay for loss-of-function and 
gain-or-function analyses of cis-elements and trans-acting factors that aﬀect 
splicing regulation. 
Minigene that we generated  contained the genomic 780-bp segment from LSD1 
gene that included the alternatively spliced small exon E8a and a portion of its 
ﬂanking intronic regions. Such genomic fragment was generated by PCR 
ampliﬁcation directly from genomic DNA of human placenta, using “hLSD1 cloning 
intron Fw” as forward primer and “hLSD1 cloning intron RV” as reverse primer. 
These primers contained also the NdeI restriction site in their 5’ ends to allow 
purified PCR product to be cloned inside the destination vector. 
The Minigene reporter vector that we used is an hybrid construct deriving from the 
low copy number pBlueScript II KS plasmid, where a Minigene cassette was 
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inserted at the level of its multiple cloning site, between the restriction sites PstI and 
BamHI (Fig. 1.2.1). This cassette contained  exons from α-globin and fibronectin 
genes under the control of the α-globin promoter and SV40 enhancer sequences, 
with a 3’ polyadenylation site derived from the α-globin gene. In particular, the 
cassette was composed of the first two exons E1 and E2, deriving only from the 
α-globin gene, followed by two chimeric exons: one of them  composed of the 
initial part of α-globin exon E3 and the final portion of fibronectin exon E24; the 
other one deriving from fusion between fibronectin exon E25 and the terminal part 
of α-globin exon E3. These two chimeric exons were linked together by the 
standard fibronectin intron, which contained the restriction site NdeI (Fig. 1.2.1). 
The presence of the chimeric exons allowed the amplification of  the Minigene 
transcripts only and not of the transcript  deriving from the genomic fibronectin and 
α-globin genes. This was possible thanks to the forward primer α2-3 and the 
reverse one Bra-2, which annealed on the junction of the chimeric exons. 
Moreover, the forward primer α2-3 was design to anneal with its 5’ end on the 
α-globin exon E2 and with the 3’ end on the initial α-globin exon E3. Thus only the 
mature and spliced  transcripts, and not the plasmidic DNA sequences, were 
amplified.  
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Fig. 1.2.1 pBSplicing plasmid.  
pBSplicing plasmid is composed of pBlueScript II  KS vector and the Minigene cassette with α-globin (black boxes) and 
fibronectin (grey boxes) exons. Arrows indicate primers position.  
 
To obtained the final Minigene 800 construct we cloned PCR genomic fragment of 
780 bp inside the NdeI restriction site of the pBSplicing plasmid (Fig.1.2.2), 
screening the insertion and the right orientation with forward and reverse FN1 
primers, together with a digestion with the enzymes NdeI and HindIII. Since 
minigene cassette is normally transcribed and then spliced by the cell machinery, 
using Minigene 800 reporter system we were able to study exon E8a alternative 
splicing and its inclusion frequency into the Minigene 800 mature transcripts. 
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 The presence in the 800 bp cloned genomic region of cis-acting elements 
promoting exon E8a inclusion allows the exon E8a to be included in the mature 
chimeric transcript. Furthermore, Minigene 800 assay gave us the possibility to test 
specific trans-acting factors  involved in exon E8a splicing modulation.   
 
 
 
Fig. 1.2.2 Minigene 800 reporter system 
Inside the minigene cassette we cloned exon E8a and its highly conserved 800-bp intronic sequence, using  NdeI restriction site.  
 
 
Since in vivo the inclusion of the exon E8a is restricted to the nervous system we 
used different neuronal cell lines as in vitro model of neuronal-like cells, and 
non-neuronal HELA cells as a negative control of inclusion.  
For transfection assays we plated the cells in 6-wells (35 mm) plates with 0,5 γ of 
Minigene and a filling vector to reach a total amount of 1,25 γ of DNA, using 
Lipofectamine as carrier (see “Materials and Methods” for details). 48 hours after 
transfection, total RNA was extracted from cells, retro-transcribed and the cDNA 
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was analyzed by PCR. To amplify the transcripts deriving from Minigene 800 we 
used fluorescinated primers α2-3F and Bra2R. PCR products were run on the 
agarose gel, to verify the quality of the reaction. As cDNA positive control we also 
amplified and run the endogenous β-actin gene, using the primers “hβ-actin Fw” 
and “hβ-actin Rv”. The output of the agarose gel electrophoresis  was a  unique 
band for all the amplicons deriving from the different Minigene 800 spliced 
transcripts. Indeed, the resolution power of the gel  did not allow the discrimination 
of more than one possible PRC product/s (Fig 1.2.3). 
 
Fig. 1.2.3 Agarose gel output obtained  by running Minigene 800 PCR products.  
The two possible  Minigene 800 splicing transcripts, deriving from the 12-bp exon E8a inclusion or not, generate two PCR amplicons 
that co-migrate in a unique band on the agarose gel. 
 
Thus,  to evaluate the presence of the exon E8a in the mature mRNA transcript 
deriving from Minigene 800, we ran PCR products on capillary gel electrophoresis 
together with an appropriate molecular weight marker. Since the α23F primer was 
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fluorescinated, laser was able to read the size of each  amplicon and to compare it 
with the known bp-length of the marker fragments. Therefore we could discriminate 
the presence or not of the exon E8a into the amplicons because of a length 
difference of 12 bp (the amplicons containing the exon E8a were 12 bp longer than 
those without the exon). The final outcome of the capillary gel electrophoresis 
consisted in peaks of different height, separated 12 bp one from another.  
This kind of analysis is also quantitative, because the fluorescence intensity 
depends on the quantity of the obtained fluorescinated amplicon. Thus, it was 
possible to evaluate the relative percentage amount of each transcript (containing 
or not the exon E8a) using the value of the height or the area underlined each 
peak. In particular, to calculate the percentage of exon E8a-containing transcripts  
we used the following formula: [height of the exon E8a-containing peak /( height of 
the exon E8a containing peak+height of the peak without E8a)] X 100.  
First of all we transfected pBSplicing vector to demonstrate that the hybrid cassette 
was correctly spliced by the endogenous cell machinery (Fig.1.2.4). 
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Fig. 1.2.4 Output of the Mnigene constitutive splicing. 
pBsplicing outcome in Hela and in SH-SY5Y cells: only one 247bp peak is generated from splicing of the sole  Minigene cassette. 
Numbers above each graph represent  length of the amplicons expressed in base pairs. Numbers besides the graph stand for  
fluorescence intensity. 
 
pBSplicing vector was correctly spliced  both in HeLa and in SH-SY5Y cells and 
the amplicon deriving from the mature mRNA cassette was about 247 bp-long (Fig. 
1.2.4 ). 
Then we transfected our Minigene 800 reporter plasmid  to investigate exon E8a 
inclusion.  
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Fig. 1.2.5 Output of the capillary gel electrophoresis in HELA and in SH-SY5Y cells. 
A) Minigene 800 splicing outcome in HELA cells: only one 247bp peak is generated from splicing cassette because no exon E8a 
inclusion occurs. B) Minigene 800 essay in SH-SY5Y cells: 247 bp peak  derives from the constitutive splicing while 258bp peak 
represents transcripts containing the exon E8a. Numbers above each graph represent length of the amplicons expressed in base 
pairs 
 
From HELA cells transfection with the Minigene 800 reporter we obtained the same 
result of the transfection with the sole pBSplicing vector, indicating that exon E8a 
was never included in non-neuronal cells (Fig. 1.2.5  A). On the contrary, when we 
transfected Minigene 800 reporter plasmid in SH-SY5Y cells, we identified two 
peaks: one deriving from the minigene cassette costitutive splicing and one, 12 bp 
longer, deriving from the exon E8a inclusion in the mature cassette transcript (Fig. 
1.2.5  B).  
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We performed Minigene transfection assay in only one non-neuronal cell line 
(HELA) and in three different neuronal cell lines (SH-SY5Y, Neuro2A and IMR32) 
in order to evaluate which one of them had the highest basal percentage of exon 
E8a containing mature transcripts.  
Figure 1.2.6 shows the result deriving from at least three independent transfection 
assays. We calculated the average percentage of exon E8a inclusion and the 
standard deviation (with the formula [standard error/ √n+ where n is the number of  
results), for each cell line.  
Exon E8a was included in all the neuronal-like cells lines that we used, with the 
highest percentage in SH-SY5Y (11,08 ± 2,35 %), followed by N2A (4,5 ± 0,36 %) 
and IMR32 (2,08 ± 0,38 %), but it was never included in HeLa cells.  
Fig. 1.2.5 Percentage of exon E8a inclusion in Minigene 800 mature transcript.  
Overexpressing the same amount of  Minigene 800 construct in different neuronal and non -neuronal cell l ines we found that 
SH-SY5Y were the best performing neuronal-l ike cellular model. 
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Since Minigene 800 cassette was correctly spliced only in the neuronal context, we 
can say that the cloned genomic sequence contains the cis-acting elements 
necessary to direct neuro-specific splicing inclusion. Furthermore, exon E8a was 
included only in a fraction of mature transcript, likewise in the endogenous LSD1 
transcripts where LSD1-8a splicing isoform does not replace the ubiquitary one  
but coexists with it.  
It is also very interesting to note that although neuronal-like SH-SY5Y cells do not 
express endogenous LSD1-8a, exon E8a is included in the Minigene 800 
transcript. Thus, we could conclude that the splicing mechanism regulating exon 
E8a inclusion in our reporter system is not as tightly regulated as the one acting on 
the endogenous transcript, possibly due to the lack of additional negative 
cis-elements or to the increased availability of positive cis-acting sequences.  
 
1.3 ROLE OF NOVA1 IN REGULATING EXON E8a SPLICING  
 
As described above, NOVA1 was shown in HIT-CLIPS experiments to be able to 
bind in vivo exon E8a-containing LSD1 transcripts [67]. Moreover, this neurospecifc 
pre-mRNA splicing factor has a lot of binding sites in the exon E8a downstream 
intron and it was reported in literature to preferentially regulate the inclusion of 
phosphorylated exon, exactly like the exon E8a (unpublished data from our 
laboratory). Thus, using Minigene 800 reporter system we assayed NOVA1 
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involvement in the exon E8a splicing regulation.  
First of all we searched for NOVA1 endogenous expression during perinatal stage 
of rat brain development when the exon E8a-containing LSD1 isoform has the 
highest level of expression. Performing a qrf-PCR (Fig.1.3.1 up) and a RT-PCR 
(Fig.1.3.1 down) on rat brain cortex at different developmental stages we 
demonstrated that LSD1-E8a and NOVA1 have a similar expression pattern.   
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Fig. 1.3.1  LSD1-8a isoform and NOVA1 expression during different perinatal stages of 
development. 
The relative amount of LSD1-8a  isoform was measured by rqf-PCR; cDNA were obtained from total RNA of rat embryonic cortex 
(E18.5) and postnatal rat cortex (PN). The first graph represent the relative percentage of LSD1 -8a isoform with respect to the sum of 
the four. The second graph shows NOVA1 quantification by qRT-PCR on total RNA extract from the indicated rat cortex samples, 
normalized on endogenous B-actin gene expression.  
 
Since we knew that SH-SY5Y cells endogenously expressed NOVA1 (data not 
shown) and  this neuronal-like cell line showed the best basal percentage of E8a 
inclusion in LSD1 transcripts deriving from Minigene 800 assays, we investigated if 
the over-expression of NOVA1 could modulate exon E8a usage. Therefore we 
cloned mouse NOVA1 cDNA in pCMV-Tag1 expression vector in order to obtain a 
fusion protein between the  amino terminal protein tag (FLAG) and NOVA1 
protein.  
Fig. 1.3.2 Western Blot analysis of FLAG-NOVA1 expression in HELA cells 
The molecular weight marker (M) is the Protein SHARPMASS Broad (EuroClone). Western was decorated with anti-Flag antibody.  
 
Starting from the Image clone containing mouse NOVA1 cDNA, we performed a 
PCR using the primers “NOVA BclI FW” and “NOVA HindIII RV”, which contained in 
Results 
 
126 
 
their 5’ ends the specific restriction sites BclII and HindIII respectively. We then cut 
the PCR product, with the enzymes BclII and HindIII, and the vector with the 
enzymes BglII (compatible with BclII) and HindIII, in order to ligate the insert in the 
backbone vector. Finally, to control the expression of the protein we transfected 
HELA cells and we performed Western Blot analysis, using anti-FLAG Ab 
(Fig.1.3.2). 
In order to evaluate if NOVA1 was able to induce exon E8a inclusion in Minigene 
800 reporter transcripts, we co-transfected Minigene 800 with or without NOVA1 
expression plasmid both in neuronal (SH-SY5Y) and non-neuronal (HELA) cell line 
as control. 
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Fig. 1.3.3 Percentage of exon E8a inclusion in Minigene 800 mature transcript. overexpressing 
NOVA1 protein 
Overexpressing NOVA1protein together with the Minigene 800 construct in neuronal (SH-SY5Y) and non-neuronal (HELA) cell lines 
we found that only in a neuronal -like cells NOVA1 was able to induce a significative increasing of the exon E8a inclusion. A Student’s 
t test (l Stat t I ≥ T ɒ/2)  was applied to percentage values of exon E8a inclusion by comparing Minigene 800 with Minigene 
800+NOVA1 in SH-SY5Y cells. *p<0.05; **p<0.01; ***p<0.001. 
 
 
Several experiments of equimolar transfection with NOVA1 and Minigene 800 
vectors gave an increase of exon E8a inclusion in neuronal-like cells, from 11,08% 
± 2,35 to 18,94% ± 3,25 (Fig. 1.3.3; Minigene 800 vs Minigene 800+NOVA1, 
11,08% ± 2,35 vs 18,94% ± 3,25, two tailed t test p=4,4*10-13). On the contrary we 
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never observed E8a inclusion in non-neuronal cells (Fig. 1.3.3). Thus we can say 
that the overexpression of NOVA1 in neuronal-like cells is able to enhance exon 
E8a inclusion in the mature Minigene 800 transcripts but other neuronal splicing 
factors, not present in HELA cells, are most probably required.  
We also repeated transfection assays increasing NOVA1:Minigene 800 ratio to 
understand if the inclusion trend reflected the amount of transfected NOVA1. Fig. 
1.3.4 shows the results that we obtained about the percentages of exon E8a 
inclusion in Minigene 800 transcript with different amounts of NOVA1. These data 
confirm a positive trend of NOVA1 dose-dependent effect in regulating exon E8a 
inclusion (Fig. 1.3.4; Minigene 800 vs Minigene 800+NOVA1 1x, 11,08% ± 2,35 vs 
17,75% ± 2,68,  two tailed t test p=0,000016; Minigene 800 vs Minigene 
800+NOVA1 2x, 11,08% ± 2,35 vs 18,83% ± 1,82,  two tailed t test 
p=0,00000086;  Minigene 800 vs Minigene 800+NOVA1 3x, 11,08% ± 2,35 vs 
23,35% ± 0,78,  two tailed t test p=0,00000011). 
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Fig. 1.3.4 Percentage of exon E8a inclusion in Minigene 800 mature transcript. overexpressing 
dif ferent amount of NOVA1 protein. 
Overexpressing one-fold, two-fold and three-fold NOVA1protein relative to Minigene 800 amount in neuronal (SH-SY5Y) cell line, we 
found a positive trend of the dose-dependent effect of NOVA1 in promoting exon E8a inclusion. A Student’s t test (l  Stat t I ≥ T ɒ/2)  
was applied to exon E8a percentage of inclusion values by comparing Minigene 8'00 with Minigene 800+NOVA11x/2x/3x. *p<0.05; 
**p<0.01; ***p<0.001. 
 
 
Moreover, to further prove NOVA1 involvement in exon E8a splicing regulation we 
analyzed  the effect of knocking down NOVA1 in SH-SY5Y cells.  
To this aim we designed and generated a shRNA molecule against NOVA1 in order 
to interfere with its expression. NOVA1 target sequence was composed of 19 
nucleotides but each of the two complementary shRNA strand contained both 
sense (green) and anti-sense (yellow) sequences, separated one from the other by 
Results 
 
130 
 
the 9 nucleotides of the hairpin loop. This allowed the right folding of the shRNA 
transcript in a typical harpin structure. Furthermore at the 5' ends of each 
complementary shRNA strand we inserted  restriction sites for BglII and XhoI for 
the directional cloning inside pSuper.gfp/neo vector. Such vector is suitable for 
shRNA molecules cloning because of the presence of the H1 promoter that is 
recognize by RNA-pol III. 
 
(BglII)         hairpin                   (XhoI)                                                                                                            
5'-GATCCCC-TGATGGGATCAACTTGCAA-TTCAAGAGA-TTGCAAGTTGATCCCATCA-TTTTTC-3'        
    
3'-GGG-ACTACCCTAGTTCAACGTT-AAGTTCTCT-AACGTTCAACTAGGGTAGT-AAAAAGAGCT-5' 
 
                                                                   
NOVA1 shRNA sequence was designed according to the 8 conventional Reynolds 
parameters to increase interfering efficiency. Each parameter has a score and the 
total final score for a shRNA molecule has to be at least 6/8. 
The score of our shRNA molecule was 7/8. After the annealing of the 2 
complementary strands in buffer STE they were cloned in pSuper.gfp/neo vector 
linearized with BglII and XhoI. 
In order to evaluate if the shRNA was able to induce NOVA1 silencing throught 
RNAi we co-transfected a 6-wells plate of SH-SY5Y cells with NOVA1 plasmid and 
two increasing amount of siRNA molecule in order to obtain NOVA1:siRNA ratio of 
1:1 and 1:3. Then by real time PCR we quantified NOVA1 transcript amount in 
each samples after treating them with DNAse to degradate cDNA deriving from 
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NOVA1 plasmid. NOVA1 level of expression was normalized on endogenous 
RPSA transcript. Fig.1.3.5 shows that samples overexpressing NOVA1 and siRNA 
molecule had a reduction of NOVA1 expression of about 55-60% compared to cells 
transfected only with NOVA1. However siRNA silencing effect was not 
dose-dependent (Fig. 1.3.5; NT vs NOVA1, 1 ± 0 vs  2,32 ± 0,09,  two tailed t test 
p=0,0066; NOVA1 vs NOVA1+siRNA 1:1, 2,32 ± 0,09 vs 0,42 ± 0,02,  two tailed t 
test p=0,0014;  NOVA1 vs NOVA1+siRNA 1:3, 2,32 ± 0,09 vs 0,44 ± 0,02,  two 
tailed t test p=0,0024). 
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Fig. 1.3.5 Level of NOVA1 expression in SH-SY5Y cells, transfected with different amount of shRNA 
molecule 
NOVA1 expression  was normalized over the RPSA expression level. The endogenous amount of NOVA1 transcript (NT)  was set 
to 1 and in all the other conditions NOVA1 level was represented as expressi on fold change relative to 1. Nova1 expression was 
significatively increased when it was over-expressed in SH-SY5Y cells (NOVA1 lane) , while it resulted significatively decreased in 
presence of different amounts of siRNA molecule. No differences in the level of NOVA1 silencencing were found  using onefold or  
threefold siRNA molecule relative to NOVA1. A Student’s t test (l  Stat t I ≥ T ɒ/2)  was applied to normalized Nova1 fold expression 
change  by comparing the endogenous amount of NOVA1 transcript  (NT) with the overexpressed NOVA1 amount (NOVA1) . The 
same Student’s t test  was applied to normalized Nova1 fold expression change  by comparing the overexpressed NOVA1 amount 
(NOVA1)  with the overexpressed NOVA1 and siRNA 1:1 or 1:3. *p<0.05; **p<0.01; ***p<0.001. 
 
Since we confirmed that siRNA molecule was able to strongly reduce NOVA1 
expression, we overexpressed  NOVA1 and its small interfering RNA together with 
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Minigene 800 reporter plasmid in SH-SY5Y cells, to verify if NOVA1 was really able 
to modulate exon E8 inclusion. To this aim, we preserved 1:3 ratio between NOVA1 
and siRNA molecule. 
Fig. 1.3.6 Percentage of exon E8a inclusion in Minigene 800 mature transcript. overexpressing 
NOVA1 protein and siRNA molecule  
Overexpressing NOVA1 and three-fold amount of siRNA molecule, exon E8a percentage of inclusion into Minigene 800 mature 
transcripts was significatively decreased. A Student’s t test (l Stat t I ≥ T ɒ/2)  was applied to exon E8a percentage values by 
comparing  Minigene 800+NOVA1  with Minigene 800+NOVA1+siRNA 1:3. *p<0.05; **p<0.01; ***p<0.001. 
 
These preliminary experiments of siRNA transfection with Minigene 800 vector 
revealed  that exon E8a splicing is responsive to NOVA1 level of expression (Fig. 
1.3.6; Minigene 800+NOVA1 vs Minigene 800+NOVA1+siRNA 1:3, 18,94% ± 3,25 
vs  14,73% ± 0,87,  two tailed t test p=0,035). This is in accordance to what we 
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found about a dose-dependent inclusion of the exon E8a mediated by increasing 
the amounts of NOVA1. 
Taken together the experiments performed so far showed that NOVA1 is involved 
in regulating exon E8a splicing but it is not sufficient alone to promote exon E8a 
expression in a non-neuronal cellular context, indicating that other neurospecific 
splicing factors have to cooperate with  NOVA1 to allow  exon E8a inclusion.  
 
1.4 SEIZURES-DEPENDENT CO-REGULATION OF NOVA1 EXPRESSION AND 
EXON E8a INCLUSION  
 
We know from literature that alternative splicing may be affected by some 
mutations associated with human epilepsy [78], and NOVA1 expression level has 
been found to be modulated in response to epileptic seizures [77]. This finding 
suggested the interesting possibility that also the neuronal LSD1 expression might 
be regulated by seizures, since the neurospecific exon E8a inclusion is under the 
partial control of NOVA1. 
Thus we speculated that farmacologically induced epileptic seizures could be a 
good model to study the regulation of NOVA1 expression and the neuronal LSD1 
alternative splicing responsiveness.  
To this aim we performed the well characterized LiCl/Pilocarpine treatment to 
induce tonic-clonic seizures in 15 C57BL/6 mice of 5 weeks. We used other 15 
identical mice as control. Mice were treated by Lithium 24 hours prior to Pilocarpine 
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(250 mg/Kg, i.p.) and 10-15 minutes after the pilocarpine injection they experienced 
multiple seizure events. Diazepam was then delivered in order to block tonic-clonic 
convulsion after one hour from the onset of seizures. Animals were sacrificed 7 
hours after Pilocarpine injection and  their hippocampus was rapidly collected and 
liquid nitrigen frozed. We used Pilocarpine because it is a selective muscarinic 
acetylcholine receptor agonist that provokes seizures indirectly, by over-stimulation 
of the cortical glutamatergic neurons. We also knew that this was the only 
farmacological treatment inducing significant changes in the levels of Nova1 
mRNAs [77]. 
We then analysed the exon E8a inclusion in mature LSD1 transcripts of treated 
mice to investigate if it was modulated by pharmacologically induced neuronal 
activation (Fig. 1.4.1). Using a couple of fluorescinated primers (mFAMex2 FW and 
mLSD1ex9 RV), we quantitatively evaluated LSD1 neurospecific splicing thanks to 
relative quantity fluorescent-PCR (rfq-PCR) on cDNA deriving from hippocampal 
area of control and Pilocarpine-treated animals. In this brain area, which is the most 
affected by seizures, we observed a strong reduction of exon E8a inclusion 
frequency, from 38,92% ± 1,33 to 27,73% ± 1,94 (Fig. 1.4.1 A; control vs 
pilocarpine treated mice, 38,92% ± 1,33 to 27,73% ± 1,94, two tailed t test p= 
0,0067). Importantly, the levels of LSD1 gene transcription, measured by 
qRT-PCR, were not affected by seizures (data not shown). 
The same RNAs were analyzed by means of qRT-PCR for the expression level of 
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NOVA1. We also checked for BDNF expression level, as experimental control of 
transcriptional response to seizures. As shown in Fig. 1.4.1 B, BDNF transcription 
underwent the expected transcriptional burst in treated mice compared to controls 
(BDNF expression level in controls vs Pilocarpine-treated mice, 1 vs 44,32 ± 13,94, 
two tailed t test p= 0,0000037), while in the same time window NOVA1 showed a 
small but statistically significant expression decreasing compared to control (Fig 
1.4.1 B, NOVA1 expression level in controls vs Pilocarpine-treated mice, 1 vs 0,77 
± 0,33, two tailed t test p= 0,022)  
 
Fig. 1.4.1 Analysis of the exon E8a percentage of inclusion in LSD1 mature transcripts (A) and 
splicing regulators expression level (B) in pilocarpine-treated mice and controls.  
(A) Percentage of exon E8a-including LSD1 transcripts in 15 controls and 15 pilocarpine-treated mice; data obtained by rqf-PCR. A 
Student’s t test (l  Stat t I ≥ T ɒ/2)  was applied to  the exon E8a inclusion percentage by comparing controls with Pilocarpine-treated 
mice. *p<0.05; **p<0.01; ***p<0.001. (B) Fold expression change of NOVA1 and BDNF in Pilocarpine-treated mice compared to 
controls. Gene expression was normalized over the endogenous RPSA expression level. The amount of NOVA1 and BDNF 
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transcripts in not treated mice  was set to 1 and  their level in Pilocarpine treated animals was represented as expression fo ld 
change relative to 1. A Student’s t test (l  Stat t I ≥ T ɒ/2)  was applied to normalized Nova1 and BDNF fold expression change  by 
comparing  their expression level in not treated mice with their corresponding level after Pilocarpine treatment. *p<0.05; **p<0.01; 
***p<0.001. 
 
This result let us to hypothesize a direct involvement of the alternative splicing 
mechanism modulating exon E8a inclusion in neuronal LSD1 transcripts as 
responsive to seizures, through a positive splicing regulator such as NOVA1.  
 
 
 
1.5 ROLE OF nPTB IN REGULATING EXON E8a SPLICING  
 
In addition to NOVA1 binding sites in the exon E8a downstream intronic portion,  
the 800-bp conserved region harbors also many CT-rich sequences mainly located 
inside the exon E8a upstream intron. By means of yeast two-hybrid system NOVA1 
interacting proteins were isolated and among them an RNA binding protein closely 
related to the polypyrimidine tract-binding protein (nPTB) was identified [71]. The 
expression of nPTB is enriched in the brain, both in glia and in neurons. 
Furthermore we know that nPTB interacts with NOVA1 in cell lines and colocalizes 
with NOVA1 within neuronal nuclei [71].  
For all these reasons we decided to investigate a possible role of nPTB in exon E8a 
splicing regulation.  
In the model of in vitro generation of neurons from mouse embryonic stem cells we 
could follow the expression kinetic of exon E8a during neuronal differentiation. In 
Results 
 
138 
 
particular LSD1-E8a transcript appears at DIV7. In the same cell model, it has been 
observed that the expression of Nova1 and nPTB occurs at DIV5 preceding of 
about two days the expression of LSD1-E8a isoform [72]. These observations 
suggested a possible involvement of nPTB in regulating exon E8a splicing. 
First of all by RT-PCR we analyzed the kinetic expression of nPTB in rat cortical 
neurons at different embryonic developmental stages. nPTB expression level was 
normalized on B-actin one (Fig.1.5.1). We observe that nPTB is expressed in the 
same developmental stages of LSD1-E8a and NOVA1, even if it follows an 
opposite temporal kinetic: when the exon E8a-containing isoform and NOVA1 
expression increase, nPTB expression decreases.   
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Fig. 1.5.1  LSD1-8a isoform and nPTB expression during different perinatal stages of development. 
The relative amount of LSD1-8a  isoform was measured by rqf-PCR; cDNA were obtained from total RNA of rat embryonic cortex 
(E18.5) and postnatal rat cortex (PN). The first graph represent the relative percentage of LSD1 -8a isoform with respect to the sum of 
the four. The second graph shows nPTB quantification by qRT-PCR on total RNA extracted from the indicated rat cortex samples, 
normalized on B-actin.  
 
To deeply investigate the effective role of nPTB in exon E8a splicing regulation we 
transfected Minigene 800 reporter vector with or without nPTB expression plasmid, 
which was kindly sent us from M. Baralle laboratory. The nPTB plasmid that we 
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used contained  indeed a “humanized” version of the wild-type nPTB ORF, 
obtained by the optimization of the nPTB codons content at the third position. 
Increasing C+G content at such position they were able to obtain a much more 
efficient translation in vitro and in vivo to evaluate nPTB overexpression effects 
[73]. 
So far we have performed only few experiments with nPTB expression plasmid and 
the Minigene 800 reporter system but we have found that nPTB is able to induce 
exon E8a inclusion into the mature Minigene 800 transcript only in neuronal-like 
cells, exactly like NOVA1. Fig. 1.5.2 shows that transfecting the same amount of 
nPTB and Minigene 800, in SH-SY5Y cells we obtained an increasing in the 
percentage of exon E8a-containing transcript from 11,08% ± 2,35 to 21,2% (Fig. 
1.5.2, Minigene 800 vs Minigene 800+nPTB in SH-SY5Y cells, 11,08% ± 2,35 vs 
21,2%). On the contrary in HELA cells nPTB had no effect on exon E8a inclusion. 
This is a preliminary result deriving from only one experiment, thus it needs to be 
confirmed; however it sheds a new light on another neurospecific splicing factor 
that most probably modulates exon E8a alternative splicing in a neurospecific way. 
We could observe, indeed, that nPTB and NOVA1 had a very similar effect on 
splicing regulation: they are both necessary but not sufficient to induce exon E8a 
inclusion. Thus it will be very interesting to investigate their combinatorial effect on 
splicing regulation in neuronal and non-neuronal cells, in order to find out which is 
the condition  that manages exon E8a alternative splicing.  
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Fig. 1.5.2 Percentage of exon E8a inclusion in Minigene 800 mature transcript. overexpressing 
nPTB protein. 
Overexpressing nPTB protein together with the Minigene 800 construct in neuronal (SH-SY5Y) and non-neuronal (HELA) cell lines, 
we found that only in a neuronal-like cells nPTB was able to induce an increasing of the exon E8a inclusion.  
 
 
1.6 RNA SECONDARY STRUCTURE AND ITS INVOLVEMENT IN EXON E8a 
SPLICING MODULATION   
 
As reported in the introduction, several studies [61, 62, 63] so far have 
demonstrated that also the RNA secondary structure per se can affect alternative 
splicing, mainly through the regulation of  the cis-regulatory elements availability.  
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Interestingly, a deep analysis of the 800-bp highly conserved intronic region 
flanking the exon E8a led us to the identification of a 21-bp sequence that is 
complementary and inverted to the exon E8a-containing one. This sequence starts 
about 300 nucleotides downstream the exon E8a and it is higly conserved among 
mammals as well, even if it is an intronic portion (Fig.1.6.1).  
The discovery of this conserved complementary and inverted region is quite 
intriguing since with a good chance it has a role in LSD1 RNA secondary structure 
folding and thus it may be involved in splicing regulation. 
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Fig. 1.6.1 An exon E8a complementary and inverted 21-nt sequence is present in the 800-bp highly 
conserved intronic regions, downstream the exon E8a. 
Exon E8a and its complementary and inverted sequence are in bolt and highlighted; the exon E8a including sequence is written in 
black and the exon E8a in purple while its 21-bp complementary downstream portion is red.  
 
To address this issue, using “mfold” web server 
(http://mfold.rna.albany.edu/?q=mfold/RNA-Folding-Form) we determined the 
predicted RNA secondary structure deriving from the 800-bp region that we cloned 
into Minigene 800. From the prediction we observed a perfect match between the 
exon E8a and its downstream complementary sequence, generating a quite long 
and stable stem structure (ΔG = 94.96 kcal/mol) (Fig. 1.6.2). Moreover, inside the 
whole 800-bp cloned sequence there are many different complementary regions 
that form stem structures interrupted only by few SNPs (not shown). Such tightly 
packed RNA secondary structure could be relevant in hiding and masking single 
strand cis-acting sequences recognized by splicing machinery.  
To test our hypothesis we generated another Minigene construct containing the 
same 800 bp region but lacking in  the sole 12-bp portion of the downstream intron 
complementary to the exon E8a. 
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Fig. 1.6.2 “mfold” output.  
The 21-bp exon E8a containing sequence and its downstream complementary and inverted regions form a stable stem structure 
during RNA  folding. 
 
In order to obtain the deletion of the 12-bp downstream sequence complementary 
to the exon E8a we followed the strategy in fig. 1.6.3. Using Minigene 800 as 
template, we amplified the upstream and downstream regions flanking the deletion 
by 2 independent PCR reactions, using primers “hLSD1 cloning intron FW” with 
“new 2 del pal hLSD1 RV” for the up PCR, and “new 3 del pal hLSD1 FW” with 
“hLSD1 cloning intron RV” for the down PCR. After purification of the two PCR 
products on the agarose gel, they were mixed together, annealed and used as 
template for another PCR, obtained with the external primers “hLSD1 cloning intron 
FW” and “hLSD1 cloning intron RV” (Fig. 1.6.3). These primers had the NdeI 
restriction site at their 5' end so the resulting amplicon was digested and cloned 
inside the NdeI unique site of the pBSplicing vector. Then we check for the right 
Exon E8a 
Complementary 
and inverted 
downstream 
region 
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insertion by digesting with HindIII restriction enzyme  and  by sequencing with  
forward and reverse FN1 primers. 
 
Fig. 1.6.3 Strategy used to obtain the 12-bp core deletion of the exon E8a downstream 
complementary sequence 
Using Minigene 800 as template, we amplified by PCR the upstream and downstream regions flanking the 12bp deletion (in red). We 
then annealed the 2 PCR products by means of protruding and complementary tails at 5' ends of the internal primers. The annealing 
was obtained by a slow air cooling of the denatured single strand molecules. Finally by a third PCR on such partially annealed 
substrate  we obtained the deleted fragment with the NdeI restriction sites at the ends.      
 
To understand if the stem structure deriving from the perfect matching between 
exon E8a   and its complementary downstream sequence could really affect exon 
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E8a splicing we  transfected  the new deleted Minigene 800 construct (Fig.1.6.4) 
in neuronal and non-neuronal cells.   
 
 
Fig. 1.6.4 Deleted Minigene 800 reporter system 
Inside the minigene cassette we cloned same 800-bp highly conserved intronic region used before but lacking in the sole 12-bp 
downstream core  region complementary to the exon E8a 
 
 
We first overexpressed deleted Minigene 800 alone to set the basal percentage of 
exon E8a inclusion into the mature deleted Minigene 800 transcript. As Fig.1.6.5 
shows, we found that the sole deletion of the exon E8a downstream 
complementary region was able to highly increase exon E8a inclusion to 85,75% ± 
2,26 (Fig. 1.6.5; percentage of exon E8a inclusion into deleted Minigene transcripts 
in SH-SY5Y, 85,75% ± 2,26; percentage of exon E8a inclusion into deleted 
Minigene transcripts in HELA, 0%). We observed this effect only in the 
neuronal-like SH-SY5Y cells, while in non-neuronal cells the inclusion remained 
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totally absent, exactly like in wild-type Minigene 800 over-expression. This result 
proves that the downstream complementary and inverted sequence, forming a 
secondary stem structure with the exon E8a, strongly inhibits its splicing inclusion. 
The exon E8a “trapping”  into a double strand RNA structure most probably 
prevent the binding of the neuro specific trans-acting factors that normally 
recognize single strand RNA sequences.   
Fig. 1.6.5 Percentage of exon E8a inclusion in deleted Minigene 800 mature t ranscript.  
Overexpressing the same amount of  deleted Minigene 800 construct in  neuronal (SH-SY5Y) and non-neuronal (HELA) cell lines 
we found again that inclusion occured only in SH-SY5Y cells, while HELA cells did not promoted exon E8a splicing. 
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However, in vivo, the endogenous exon E8a-containing LSD1 transcripts are non- 
deleted but the  neurospecific splicing occur at the same way. Thus it's clear that 
in vivo the exon E8a inclusion heavily relies on an unknown neurospecific 
trans-acting factor (or more than one), that promote exon E8a inclusion into the 
mature transcripts by preventing LSD1 RNA secondary stem structure formation. 
The 12-bp Minigene 800 deletion is able to recapitulate in vitro the best condition of 
LSD1 RNA structure folding that allows the exon E8a massive inclusion. 
Fig. 1.6.6 Percentage of exon E8a inclusion in deleted Minigene 800 mature transcript. 
overexpressing NOVA1 and nPTB proteins. 
Overexpressing separately the same amount of NOVA1and nPTB together with the deleted Minigene 800, in SH-SY5Y cells we 
observed a significative decreasing in the percentage of exon E8a inclusion. No effect was seen in HELA cells where the inclu sion 
remained totally absent even upon NOVA1 and nPTB over-expression. A Student’s t test (l Stat t I ≥ T ɒ/2)  was applied to exon e8a 
inclusion percentage values by comparing  deleted Minigene 800 with deleted Minigene 800+NOVA1in SH-SY5Y cells. *p<0.05; 
**p<0.01; ***p<0.001. 
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Together with the deleted Minigene 800, we then overexpressed NOVA1 and nPTB 
both in  SH-SY5Y and in Hela cells to understand if their positive role in exon E8a 
splicing inclusion could be related to LSD1 RNA structure folding. In non-neuronal 
cells neither NOVA1 nor nPTB were able to promote exon E8a inclusion inside 
deleted Minigene 800 transcript (Fig.1.6.6). On the contrary, in SH-SY5Y cells, 
NOVA1 and nPTB gave the same outcome: both of them did not induce again the 
expected increasing in the exon E8a inclusion percentage but their over-expression 
caused a decreasing in exon E8a alternative splicing, from 85,75% ± 2,26 to 
72,15% ± 2,21 and 59,7% respectively (Fig. 1.6.6; deleted Minigene 800 vs deleted 
Minigene 800+NOVA1, 85,75% ± 2,26  vs 72,15% ± 2,21, two tailed t test 
p=0,00000099; deleted Minigene 800 vs deleted Minigene 800+nPTB, 85,75% ± 
2,26  vs 59,7%). This may be explained by their partially blocking of the 
neurospecific unknown factor effect on preventing RNA stem structure folding. In 
the future it will be interesting also to elucidate the combiantorial effect of NOVA1 
and nPTB on the deleted Minigene 800 transcripts, both in neuronal and 
non-neuronal cell lines. 
  
1.7  SAM68: A PUTATIVE EXON E8a SPLICING REGULATOR 
  
Sam68 (Src-associated in mitosis, 68 kDa) is a nuclear KH-domain RNA binding 
protein implicated in a variety of cellular processes, including alternative pre-mRNA 
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splicing. Even if it is not a neurospecific splicing factor, it has been found to be 
involved in splicing regulation of many different neuronal pre-mRNA, such as 
Neurexin-1 [74] and neuronal mRNA that become translationally activated in 
response to electrical activity [75]. 
Sam68 recognizes and binds A- and T-rich sequences with particular affinity for the  
AAAATT stretch. This cis-acting site is not present inside the 800-bp intronic 
conserved region surrounding the exon E8a, but here we found clusters of A and T 
repetitions that could represent Sam68 binding sites. Moreover Sam68 was 
predicted by SpliceAid2 to be one of the most relevant trans-acting factor involved 
in regulating exon E8a inclusion, with a positive score ever higher than NOVA1. For 
all this reasons we decided to over-express Sam68 (Addgene plasmid 17690) in 
SH-SY5Y and HELA cells with Minigene 800 and its deleted version. In both the 
cell-lines Sam-68 did not show any significative effect on exon E8a splicing 
regulation. We also treated SH-SY5Y and Hela cells with Phorbol ester, which 
stimulates the Ras/Map kinase pathway, activating Erk and the phosphorylation of 
Sam68. Indeed, we found in literature that Sam-68 phosphorylation was crucial for 
its splicing activity [75]. However Phorbol esters treatment did not gave a positive 
outcome and the inclusion of the exon E8a was the same of the transfection with 
the sole Minigene 800 deleted or not. This means that Sam-68 is not involved in 
exon E8a splicing regulation. 
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1.8  EXON E8b  DISCOVERY AND ITS MODULATION BY FOX1 
 
 
We know from literature that at least 15% of NOVA1 targets may be under NOVA1 
and FOX1 combinatorial control, since FOX1-regulated splicing is defined by a 
position-dependent RNA-regulatory map similar to that of NOVA1 [67]. 
These observations suggested that additive or synergistic actions of NOVA1 and 
FOX1 may be favored. FOX1 protein is expressed in mammalian muscle, heart, 
and brain tissues. In the brain, this proteins is exclusively present in neurons [70], 
reproducing exon E8a neuronal pattern of expression. In addition, mutation or 
abnormal expression of FOX1 has been found in  patients with severe neurological 
diseases, including epilepsy and mental retardation [70]. Thus, recurring to 
Minigene reporter system we investigated the putative role of FOX1 in the exon 
E8a splicing regulation.  
Searching for FOX1 binding sites in the 800-bp highly conserved intronic region 
flanking exon E8a we didn't find TGCATG sequences. On the contrary we identified 
2 of these cis-acting elements at the end of the exon E8a downstream intron (Fig. 
1.8.1), far from the conserved 800-bp sequence that we cloned into Minigene 800 
vector but inside another highly conserved terminal region of the intron.  
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Fig. 1.8.1 FOX1 binding sites in the exon E8a downstream intron  
Inside the full length  exon E8a downstream intron we found 2 FOX1 binding sites (green boxes) at  the level of terminal highly 
conserved portion (pink).  
 
To investigated if the over-expression of FOX1 could have a role in the exon E8a 
splicing modulation we extended our Minigene 800 reporter plasmid (Fig.1.8.2), 
including the full length exon E8a downstream intron and the same conserved 
portion of the E8a upstream intron, for a total length of about 2750 bp. 
 
Fig. 1.8.2  Minigene 2750 reporter system 
Inside the minigene cassette we cloned the exon E8a with its conserved upstream intronic region and the full length downstream 
intron, using  NdeI restriction site.  
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Thus we amplified by PCR the genomic fragment of 2750 bp corresponding to the 
region of interest, using a couple of primers with AseI restriction site at their 5'end 
(AseI hLSD1-MG FW and AseI hLSD1-MG RV). Then we cloned purified PCR 
product in NdeI restriction site of pBSplicing vector, thanks to the compatibility 
between AseI and NdeI, and we check for the right insertion by sequencing with  
forward and reverse FN1 primers. 
In order to obtain FOX1 expression plasmid, starting from the pENTR-A2BP1 clone 
(Addgene plasmid 16176) containing human FOX1 cDNA, we performed a PCR 
using primers “FOX-1 cloning FW” and “FOX-1 cloning RV”, containing in their 5’ 
ends the restriction sites for XbaI and KpnI respectively. We then cut the PCR 
product and the pCGN vector with the enzymes XbaI and KpnI to ligate the insert in 
the backbone vector. Finally, we  checked for FOX1 expression performing 
Western Blot analysis with monoclonal anti-HA  antibody on a protein lysate 
deriving from transfected Hela cells (Fig.1.8.3). 
 
 
Fig. 1.8.3 Western Blot analysis of FOX1-HA expression in HELA cells 
The molecular weight marker (M) is the Protein SHARPMASS Broad (EuroClone). Western was 
decorated with anti-HA antibody.  
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In order to evaluate if FOX1 was able to modulate exon E8a inclusion in the new 
Minigene reporter transcripts, we co-transfected the new version of Minigene 2750 
reporter plasmid with or without FOX1 expression plasmid, both in neuronal 
(SH-SY5Y) and non-neuronal (HELA) cell lines. Several experiments of 
transfection of the Minigene 2750 reporter alone revealed that the inclusion of the 
exon E8a occured in 8,06% ± 1,55 of the Minigene 2750  transcripts (Fig. 1.8.4; 
percentage of exon E8a inclusion in SH-SY5Y cells, 8,06% ± 1,55; percentage of 
exon E8a inclusion in HELA cells, 0%), a slightly lower percentage compared to the 
Minigene  800.   As we expected exon E8a inclusion occured only in the 
neuronal-like cell line, while in HELA cells we didn't observe exon E8a containing 
transcripts (Fig. 1.8.4). Thus we can say that the presence of the full length exon 
E8a downstream intron has a small negative effect on the neurospecific exon E8a 
inclusion, may be due to the presence in the Minigene 2750 of cis -acting 
sequences that negatively compete for the exon E8a inclusion.     
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Fig. 1.8.4 Percentage of exon E8a inclusion in Minigene 2750 mature transcript. 
Overexpressing  Minigene 2750 construct in SH-SY5Y and HELA cells we found that exon E8a was inluded only in neuronal cells 
but with a lower percentage compared to the inclusion observed in Minigene 800 mature transcripts  
 
When we overexpressed FOX1 protein together with Minigene 2750 in SH-SY5Y 
and in HELA cells, we obtained a completely unexpected outcome: simply by 
running Minigene 2750 PCR products on the agorose gel, we didn't find the usual 
unique PCR band including amplicons with or without the exon E8a, but we 
observed that FOX1 was able to induce the generation of two distinct bands of 
different molecular weight (Fig. 1.8.5).  
This result was quite intriguing because for the first time it was present both in 
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HELA and SH-SY5Y cells, and it could have only one explanation: in presence of 
FOX1 another unexpected splicing event occured that induced the “exonization” of 
an intronic portion of LSD1.  
When we run the samples on the capillary gel electrophoresis we discovered that 
such new exon was composed of exactly 77 bp and we called it “exon E8b”.  
 
Fig.1.8.5 Effect of FOX1 over-expression on Minigene 2750 splicing products 
Both in HELA and SH-SY5Y cells, FOX1 over-expression together with Minigene 2750 reporter plasmid induced the generation of 
different splicing products which co-migrated in two distinct  bands on the agarose gel. Even if the visible outcome was the same in 
neuronal and non-neuronal cells, by running PCR products on the capillary gel electrophoresis we found which were exactly the 
splicing products generated in each cell l ine. The scheme on the right recapitulates the capillary gel electrophoresis output  shown in 
the picture below. 
  
Without over-expressing FOX1, in HELA cells only one amplicon was detectable 
(246-bp) deriving from the constitutive Minigene 2750 splicing, while in SH-SY5Y 
cells in addition to this we found also the 258-bp product that proved the basal 
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inclusion of the alternative exon E8a. These 2 amplicons, with a difference of only 
12-bp one from the other, co-migrated on the agarose gel in a unique band (Fig. 
1.8.5). 
Overexpressing FOX1, we observed the “exonization” of the 77-bp LSD1 intronic 
fragment that gave rise to the exon E8b. Thus, in HELA cells capillary gel 
electrophoresis gave two peaks: one coming from the constitutive Minigene 2750 
splicing (246-bp) and another longer one (323 bp) including the new exon E8b. In 
SH-SY5Y cells we even found 4 different peaks because the 77-bp new exon was 
included both in the constitutive transcript and in exon E8a including one (Fig. 
1.8.6). All the amplicons including the 77-bp exon E8b co-migrated in the upper 
bands of the gel (Fig. 1.8.5). 
 
Results 
 
158 
 
 
Fig. 1.8.6 Capillary gel electrophoresis output in a condition of FOX1 over -expression 
In HELA cells FOX1 overexpression together with Minigene 2750 induced the inclusion of only the exon E8b into the mature 
transcript. Thus in this cell line we can observe two peaks: one deriving from the canonical splicing event (246-bp) and one belonging 
to E8b-including transcript (323-bp). In SH-SY5Y cells, alternative splicing generated 4 different transcripts, deriving from single or 
simultaneous inclusion of the exon E8a or E8b. Black and grey boxes represent  Minigene exons; in purple the exon E8a; in green 
the exon E8b. 
 
Thus, over-expressing FOX1 protein, in SH-SY5Y cells we observed an inclusion of 
the exon E8b in 42,05% ± 1,95 of the mature LSD1 transcripts, while in HELA cells 
the percentage was 35,85% ± 1,2 (Fig. 1.8.7; exon E8a and exon E8b in SH-SY5Y 
cells, 8,06 ± 1,55 and 42,05% ± 1,95; exon E8a and exon E8b in HELA cells, 0% 
and 35,85% ± 1,2).  
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Fig. 1.8.7 Percentage of exon E8a and exon E8b inclusion in Minigene 2750 mature transcript upon 
FOX1 over-expression 
Over-expressing FOX1 together with  Minigene 2750 vector in SH-SY5Y and HELA cells, we found that exon E8a was included only 
in neuronal cells while FOX1 was sufficient  to promote exon E8b alternative splicing  both in neuronal and in non-neuronal cells.  
 
In order to understand which was exactly the intronic portion included into the 
Minigene 2750 mature transcript, we cut the two bands from the agarose gel (Fig. 
1.8.5) to perform a sequencing PCR reaction using forward and reverse FN1 
primers. We identified the new 77-bp exon at the end of the exon E8a downstream 
intron, nearby the 2 FOX1 binding sites that regulate its inclusion (Fig.1.8.8).  
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Fig. 1.8.8 Exon E8b nucleotide sequence 
Sequencing reaction let us to define the 77-bp exon E8b nucleotide sequence, which is highlighted in green. Exon E8b is nearby the 2 
FOX1 binding sites (in red), at the end of the exon E8a downstream intron. In bolt are indicated donor and acceptor splicing sites that  
flank the exon E8b. TGA is the premature STOP codon found inside the exon E8b. 
 
Fig. 1.8.8 highlights two important features of the exon E8b: the first one is that 
donor (5' end of the downstream intron) and acceptor (3' end of the upstream 
intron) splicing sites were GT and AG respectively, that are exactly the almost 
invariant sequences that usually identify an exon. The second important feature 
was the identification of the premature STOP codon “ TGA” at the 5' end of the 
alternative exon. This immediately led us to think about a degradation of all the 
exon E8b-containing transcripts by the surveillance cellular pathway of the 
Non-sense Mediated mRna Decay (NMD), that usually prevents the generation of 
truncated proteins.          
5'.....ACCTGAGATTCATCTTTGAGGGGAAGCCAGATACCTTGGGCTTCTT
ATTTTCCCATCCTGCCCTTATTCTTGGAAGGTCCTCAGGTTTGTTGACA.....3' 
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However the identification of the exon E8b inside Minigene 2750 transcripts is not 
suffcient to prove its existence in the endogenous LSD1 mature RNA and to 
speculate about its function. Thus we performed a PCR reaction on endogenous 
cDNA in order to identify the exon E8b. We designed  forward primer on the exon 
E8b and the reverse one on the exon 10 of LSD1, in order to clearly discriminate 
among possible PCR products that include introns in addition to the exons E8b, E9 
and E10 (Fig. 1.8.9). 
 
Fig. 1.8.9 PCR strategy used to search for endogenous exon E8b containing t ranscripts    
We designed forward primer on the exon E8b and the reverse one on the exon 10. Base pair length of each exon and intron is 
reported.c45-bp is the distance of the forward primer from the end of the exon E8b (in green). 73 -bp is the distance of the reverse 
primer  from the beginning of the exon 10.    
 
We performed PCR reactions for at least 50 cycles since the total amount of exon 
E8b-containing transcripts was supposed to be very low because of its degradation 
by NMD. We first used as reaction template cDNA obtained from Hela and 
SH-SY5Y cells, overexpressing FOX1 splicing factor. From this PCR we didn't find 
any endogenous exon E8b-containing amplicon. Also the treatment of the same 
FOX1 over-expressing cells with Puromycin (300 ug/ml), which blocks protein 
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synthesis and degradation, did not give any positive result (Fig.1.8.10 B). This 
means that neuronal and non-neuronal cell lines do not endogenously express 
exon E8b. 
We first identified exon E8b-containing transcripts in human brain tissues (neuronal 
tissue of Rett and Epileptic human patients) (Fig. 1.8.10 A). PCR reaction on these 
cDNAs, performed after DNase treatment, gave two different amplicons. By 
sequencing them we found that the lower band on the agarose gel (261-bp) 
originated from the amplification of only the exons between forward and reverse 
primers, while the upper band included also the 395-bp intron between exon E8b 
and exon E9 (Fig. 1.8.10 A). 
 
Fig. 1.8.10 Endogenous E8b containing transcripts  
Fig. 1.8.10 A Two are the endogenous populations of exon E8b-containing transcripts in Epileptic and RETT human patients. One of 
them is represented by the 261-bp amplicon including only the exons E8b, E9 and E10;  the other one is represented by the 656 -bp 
PCR product  coming from the inclusion of the intron E8b-9 in addition to the exons above. Fig. 1.8.10 B  Exon E8b is not 
expressed in HELA and SH-SY5Y cell l ines, treated or not with Puromycin. 
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This finding could not be the result of a DNA contamination because inside the 
LSD1 mature transcripts we always found the same E8b-9 intron. This means that 
in human brain there are not only LSD1 endogenous transcripts including the exon 
E8b but also mature transcripts with exon E8b and its downstream E8b-E9 intron. 
The function of these two new LSD1 splicing variants is not clear at  the moment, 
since we know that the presence of the premature STOP codon inside the exon 
E8b causes RNA degradation before protein synthesis.  
However we looked for their expression performing the same PCR on a multiple 
cDNA panel of human tissues (Ambion).  
Fig. 1.8.11 Exon E8b-containing transcripts in multiple human tissues 
PCR on human cDNA panel (Ambion), performed with forward primer on the exon E8b and reverse primer on the exon E10 of LSD1, 
shows that the only PCR amplicons detectable on the agarose gel correspond to the 656-bp LSD1 transcript including exon E8b and 
its downstream E8b-E9 intron. 
 
From the PCR above (Fig. 1.8.11) we found that the endogenous expression of the 
exon E8b-containing transcripts is not restricted to the brain but occurs in different 
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human tissue with unrelated embryonic origin. Furthermore the bp-length of the 
only amplicon that we obtained corresponded to a mature transcript including the 
exon E8b but also the E8b-E9 intron. We did not find any PCR product deriving 
from the sole exons inclusion. 
By UCSC genome browser we then performed a multiple alignment of the human 
exon E8b sequence with the same genomic portion of different mammals to find out 
its conservation degree. Fig. 1.8.12 shows only the 5' end of the exon E8b 
alignement and its intronic acceptor splicing site AG (inside the red square). The 
alignment clearly shows a very low level of conservation of the exon E8b among 
mammals, starting from the AG acceptor site which is not present in any other 
species with the exception of Rhesus. On the contrary the premature STOP codon 
“TGA” is conserved among mammals but most probably the absence of the 
acceptor splicing site causes the exon E8b not to be recognized by the cellular 
splicing machinery.  
This finding is in agreement with the lack of any detectable exon E8b-including 
transcript in mouse brain tissues (data not shown).  
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Fig. 1.8.12 Multiple alignment of the human exon E8b  
UCSC alignement of  the  5' terminal end of the human exon E8b and its intronic acceptor site (red box) with the same genomic 
region of different mammals. Horizontal traits are the nucleotide gaps. 
 
 
Taken together all these data show the existence of a new LSD1 alternative exon, 
that we called “exon E8b”, whose expression is restricted to human tissues. Such 
exon is not not neurospecifc, and its inclusion into LSD1 mature transcript is 
strongly positively regulated by FOX1, which is necessary and sufficient modulate 
exon E8b alternative splicing. The presence of a premature STOP codon inside the 
exon E8b causes the degradation of all the exon E8b-containing transcripts by the 
NMD, thus at the moment we can't say anything about its function but we think that  
it may be involved in regulating LSD1 expression level.  
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2. GENERATION OF EXON E8a-limited LSD1 
KO MICE 
 
To deeply investigate the biological implication of neurospecific LSD1 isoform in 
vivo, in collaboration with Dr. F. Altruda and Dr. E. Turco of the “Centre for in vivo 
functional genomics” in Turin, we generated exon E8a-limited-LSD1 knock-out 
mice to abolish the sole neuronal LSD1 expression. Using homologous 
recombination in mouse ES cells, we replaced exon E8a of mouse nLSD1 with a 
Neo selection cassette, flanked by two LoxP sites. The picture below shows the 
overall strategy that we used to generate exon E8a KO mice. 
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Fig. 2.0.1 Generation of LSD1-exon 8a Knockout mouse model. 
Our genetic modification was inserted in a targeting vector, which carried Neo resistant selection marker and homologous regi ons. 
The homologous regions defined the specific region of genomic integration. Targeting vector was then electroporated into 129/ SV 
mouse embryonic stem (ES) cells. Targeted ES cells were selected by antibiotics and expanded. ES cells were then injected into an 
early mouse embryo and the embryo implanted into the uterus of a C57BL/6 pseudopregnant mouse. Chimeric mice, which 
developed from the mixture of modified ES cells and cells of the host embryo, had the fur of two colours. These chimeric mice were 
mated with C57BL/6 wild type mice to obtain mice that derived from the modified ES cells. Such mice were hetorozygous for the 
deletion. By the breeding of male and female heterozygous animals  we obtained homozygous LSD1-E8a KO mice. 
 
 
 2.1 GENERATION OF pBlueScript II KS TARGETTING VECTOR  
 
A convenient method for subcloning the 20 Kb genomic fragment of LSD1  
surrounding neurospecific exon E8a, from the BAC clone into pBlueScript II KS 
vector is represented by homologous recombination via a process known as gap 
repair. To generate our gap-repaired plasmid we made use of 2 long homology 
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arms that significantly increased the frequency of subcloning and decreased 
unwanted recombination products. To this aim we designed two couple of PCR 
primers (primers A and B, C and D) and we used them to amplify two 1000 bp 
regions of the LSD1-8a BAC clone, flanking the 20 Kb fragment that have to be 
subcloned. The PCR products were purified using spin columns and digested with 
BamHI-EcoRI and EcoRI-SalI restriction enzymes. Restriction sites for these 
enzymes were included in the amplification primers to allow directional cloning of 
the PCR products into pBluescript II KS vector. The digested fragments were  then 
ligated to a BamHI- and SalI-cut pBlueScript II KS vector cointaining a TK (MC1TK) 
gene for negative selection in ES cells. The retrieval pBlueScript vector was 
subsequently linearized with EcoRI to create a double-strand break for gap 
repairing. When we electroporated linear pBlueScript II KS plasmid into 
electro-competent cells, which contained LSD1-8a BAC clone, we found that we 
were able to generate several  Ampr colonies in a single electroporation 
experiment. Some of these Ampr colonies were background colonies (derived  
from self-ligation of the linearized gap repair plasmid or from uncut DNA) but  the 
others contained gap-repaired plasmids with the expected genomic inserts (Fig. 
2.1.1). 
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Fig. 2.1.1 Subcloning a DNA fragment from a BAC clone into pBluescript II KS vector by using gap 
repair with short homology arms. 
The two homology arms (purple) used for subcloning have been PCR-amplified from LSD1 BAC clone DNA. They were obtained 
using primers A and B, and  primers C and D. Subsequently they were cloned into an MC1TK-containing plasmid to generate 
retrieval plasmid. The retrieval plasmid was linearized with EcoRI to create a DNA double-strand break for gap repair. The linearized 
pBluescript vector containing the two homology arms was then transformed into recombination -competent cells that carried the LSD1 
BAC clone. Gap-repaired plasmids were selected by their Ampicillin resistance. 
 
 
 
2.2 TARGETTING Neo CASSETTE AND LoxP SITES INTO pBlueScript II KS 
PLASMID 
 
The next step in generating exon E8a knock-out targeting construct was the 
introduction of NeoR gene flanked by 2 loxP sites into the subcloned pBlueScript II 
KS plasmid in order to replace the exon E8a. This was accomplished by introducing 
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a floxed Neomycin resistance (Neo) cassette (PL452) via homologous 
recombination. The floxed Neo gene in PL452 was expressed by a hybrid PGK–
EM7 promoter that allowed efficient Neo expression both in mammalian cells (PGK 
promoter) and in bacterial cells (EM7 promoter). To introduce the floxed Neo 
cassette at the correct location, we generated two 1Kb arms homologous to the 
targeting site. These homology arms, as described above, were generated by PCR 
amplification of E8a flanking regions, inside upstream and downstream introns, 
using LSD1-8a BAC clone as template. PCR primers were engineered to contain 
NotI and EcoRI (primers E and F) or BamHI and SalI (primers G and H) restriction 
sites for the directional cloning of the homology arms. Following PCR amplification, 
the products were purified, restriction digested, and ligated to the floxed Neo 
cassette, excised from PL452 with EcoRI and BamHI, and to a pEGFP vector 
linearized by NotI and SalI. After the purification of the Neo cassette together with 
flanking homology arms, obtained by NotI and SalI digestion of the pEGFP plasmid, 
we co-electroporated the cassette along with the gap-repaired subcloned 
pBlueScript II KS plasmid into EL350 cells. Transformants were selected by their 
kanamycin resistance, conferred in prokaryotes by Neo gene (Fig. 2.2.1). The 
obtained exon E8a knock-out targeting vector was subsequently linearized and 
electroporated into mouse 129/SV ES cells. Transformants were selected for their 
G418 and ganciclovir (Ganc) resistance and picked for Southern analysis. 
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                          Final LSD1 exon E8a KO targetting construct 
 
Fig. 2.2.1  An improved procedure for constructing LSD1 exon E8a KO-targeting vector 
pEGF targeting vector was constructed by ligating together the two PCR products generated by amplification of LSD1 BAC DNA wi th 
primers E-F and G-H (blue), and the floxed Neo selection cassette (black arrow: loxP site) deriving from PL452 vector. The targeting 
cassette was excised by NotI and SalI digestion. The gap-repaired pBlueScript plasmid and the excised targeting cassette were 
co-transformed into recombination-competent  EL350 cells.   
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2.3 BREEDING SCHEME FOR ES CELL CHIMERAS 
 
From “Centre  for in vivo functional genomics” we obtained 4 male and 1 female 
chimeras. 
Most of 129SV ES cells were male derived and so the sex ratio of chimeras was 
skewed in favour of males. Furthermore female chimeras do not generally transmit 
the ES cell genotype because XY ES cells rarely undergo meiosis in ovary, 
therefore it is not worth test-breeding them. Despite this we bred all the 5 mice with 
wild type C57BL/6 animals. The goal of test-breeding ES cell chimeras was the 
identification of mice that were able to transmit the ES cell genotype through their 
germ line. This was assessed by the coat colour of their pups. Indeed, ES cells 
derived from 129/SV substrain, produced agouti fur. When these ES cells are 
microinjected into C57BL/6 (black fur) blastocysts  the resulting mice will have 
patches of agouti (brown) and patches of black fur. However it is not unusual to get 
chimeras that are 90%-100% agouti, because it seems that 129 cells may grow 
faster than C57BL/6 cells in the developing mouse embryo. Secondly, the agouti 
pigment is a secreted protein, so the brown coat color may spread to cover areas 
that are derived from black cells. ES cell-mouse chimeras with high coat color 
contribution from the ES cells are likely to transmit through the germline more 
quickly than low coat color contribution chimeras. Thus, among the offspring all 
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pure black mice (non-agouti) were from the C57BL/6 component of the chimera 
and all yellowish-brown one (agouti) were from the ES cell component (Fig.2.3.1). 
 
 
Fig. 2.3.1  Chimeric mice breeding. 
We bred 4 male and 1 female chimeras (blue and white animals) with C57BL/6 willd type mice (white animals) but only male chimera 
1 and 5 gave rise agouti pups (blue in the picture), since their 129/SV mutated ES cells reached their reproductive apparatus. Here, 
during meiosis their gametes received or mutated or wild type allele, for this reason agouti pups had also to be  genotyped.  
 
 
Female chimera died before giving pups so we could verify the germline 
trasmission of the four male chimeras only. Among them, two animals did not 
transmitted the ES cell genotype and gave rise to a completely black offspring 
(chimera 2 and 4), on the contrary the other two chimeras (1 and 5) gave together 
82 brown (agouti) pups, because the 129 ES cells have contributed to the chimera's 
germline. All 82 brown pups were then genotyped to find out which ones received 
the targeted allele: since in ES cells only one of the two alleles were mutated in the 
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exon E8a locus of LSD1, only about 50% of the agouti mice should have inherited a 
mutated allele and become heterozygous mice. If we exclude from the count the 
animals that died before being genotyped, in the first-generation offspring (F1) we 
found 14 wild type and 10 eterozygous mice deriving from chimera 1, and 27 wild 
type and 23 eterozygous mice from chimera 5. (Fig.2.3.2) 
Fig. 2.3.2 F1 mice segregation 
White bars represent black pups from chimera 1 (45 pups) and 5 (13 pups) that were not genotyped because of their fur color . On the 
contrary, blue bars depict all the 82 agouti pups, that were genotyped and classified in wild type (vertical stripes) and ete rozygous 
(diagonal stripes). 
 
In order to generate exon E8a Knock-out mice we mated 11 heterozygous F1 males 
with 10 heterozygous F1 females and we obtained 292 F2 pups. 63 of them were 
knock-out, so the ratio was in accordance with the Mendelian low of segregation. 
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2.4 MICE GENOTYPING 
 
To identify homologous recombination events between the exon E8a of LSD1 and 
the Neomycin cassette, we first performed a PCR analysis of genomic DNA taken 
from finger biopsies. Results were then confirmed by RT-PCR on a representative 
litter of adult mice cerebellum (C) and cortex (X), tested for the sole exon E8a 
expression. We also performed an isoform relative quantification of all the four 
LSD1 splicing variants in representative adult mice's cerebellum (CB) using the  
Relative Quantity Fluorescent-PCR (Fig. 2.4.1). 
The targeting vector used to generate E8a-limited-LSD1 knockout mice contained 
a 800bp Neo-resistance cassette in place of the exon E8a (Fig. 2.4.1 A and B). 
With  the purpose of establish mice genotype by PCR, we designed a set of oligos 
that  let us discriminate between wild type, heterozygous and knock-out animals in 
the same reaction tube (Fig. 2.4.1 C). 
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Fig. 2.4.1  Strategy for specific inactivation of the exon E8a and its detection 
(A) Schematic representation of the mouse LSD1-8a gene and of the gene-targetting with Neo cassette. S indicates the 
transcriptional initiation site for LSD1-8a mRNA. Exons 8 and 9 are  two coding exons of wild type LSD1 gene, whereas E8a is the 
alternative neurospecific exon. Yellow regions indicate 1 Kb-long homologous  sequences used for construct the targeting vector. 
Primers 3, 6 and B are the oligos for routine genotyping of mice. LoxP sites are two 13 bp -long  inverted repeats required for 
Cre-mediated recombination.  (B) Structure of the mouse LSD1-8a locus in the mutated allele. Neo-cassette, flanked by 2 loxP sites, 
substitutes only the exon E8a. (C ) PCR performed with primers 3,6 and B on a representative litter of LSD1 mice, detecting wild type 
and mutated alleles.  (D) A representative litter of adult mice's cerebellum (C) and cortex (X),  tested for Exon 8a  expression by 
RT-PCR.The cDNA were amplified with primers  including only E8a.  (E) Isoform-relative quantification of LSD1 splicing variants in 
representative adult mice's cerebellum (Cb). rqf-PCR was performed on cDNA obtained from total RNA of the indicated samples. 
Amplicons were quantified by related fluorescence units (RFU) by GeneMapper software. E8a -including  LSD1 isoforms are shown 
in blue. 
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P3 and P6 primers hybridized inside the 5' and 3' homology regions (yellow in the 
picture) flanking the Neo cassette, while PB primer sat exactly on the junction 
between 5' loxP site (red region) and the 5' homology region. Wild type DNA gave 
only one amplicon of 579 bp, deriving uniquely from P3-P6 PCR that efficiently 
amplified this region when this was not distrupted by Neo cassette. Also knock-out 
mice  exhibited only one PCR product of 380 bp but generated by P3-PB PCR, 
because the presence of the Neo cassette allowed primer PB to anneal but at the 
same time prevented the low functioning P3-P6 PCR. On the contrary, 
heterozygous mice showed both the two amplicons of 579 and 380 bp,  because 
of the contemporary presence of  a wild-type and a mutated allele. 
We confirmed PCR results performing a semi-quantitative RT-PCR (Fig. 2.4.1 D) 
with a couple of primers annealing on the exon 8 (hmFAMex8 FW) and on the exon 
9 of LSD1 (mLSD1ex9 RV). cDNA was obtained by retro -transcription of the same 
amount of RNA deriving from cerebullum and cortex of representative wild type, 
heterozygous and knock-out litters. Our purpose was to demostrate the absence of 
exon E8a-containing isoform in the tissues of knock-out mice. As expected, wild 
type mouse showed two amplicons, since in CNS alternative splicing generates 
both ubiquitous isoform and the exon E8a-containing one. On the contrary, 
knock-out animal gave only one amplicon corrisponding to the sole ubiquitous 
LSD1 isoform, because of the exon E8a replacing with the  unspliceable 
Neo-cassette on both the alleles. As control we tested also an heterozygous mouse 
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that had about half the amount of the exon E8a containing amplicon compared to 
wild type one.   
Since RT-PCR performed around the exon E8a gave us a clear but limited 
information, we further supported our evidences by rqf-PCR with a couple of 
fluorescinated primers, the forward one on exon 2 (mFAMex2 FW) and the second 
one on exon 9 (mLSD1ex9 RV), that amplified in the same reaction all the four 
splicing variants of LSD1. Thanks to the qrf-PCR we were able to evaluate each 
PCR amplicon as single peak on the electropherogram and to compare different 
peaks' height in each sample to have a full-scale picture of what was the amount of 
the alternative splicing products (Fig. 2.4.1 E). In figure 2.4.1E  cerebellar amount 
of the 4 different LSD1 splicing isoforms is shown for each genotype and, as 
expected, WT mice presented all the four isoforms but KO mice were totally lacking 
in LSD1-8a as well as in LSD1-2a8a variants (blue picks). Heterozygous mice 
confirmed the positive exon E8a replacing with an intermediate amount of the 
above-mentioned transcripts. 
Furthermore, by qRT-PCR performed with a couple of primers that amplified all the 
LSD1 transcripts we demonstrated that total LSD1 amount was the same in the 
three different mice genotypes (Fig. 2.4.2). 
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Fig.2.4.2 Level of total LSD1 expression in the three different m ice genotypes.  
qRT-PCRs were performed using B-actin as housekeeping gene. Ct values obtained for LSD1 were normalized over the housekeeping gene to 
correct for sample variations. A Student’s t test (l  Stat t I ≥ T ɒ/2) was applied to  LSD1 normalized expression level by comparing 
heterozygous and wild-type mice LSD1 expression to the knock-out one. *p<0.05; **p<0.01; ***p<0.001.  Differences in the LSD1 level 
of expression are not statistically significative.     
 
We then confirmed this evidence by immunostaining a whole brain section with an 
anti-panLSD1 antibody (policlonal anti-LSD1 (AB 17721)) and we  found that also 
LSD1 protein level did not change in knock-out mice compared to wild-type ones 
(data not shown). 
Together these results suggest that the homologous recombination between exon 
E8a and Neo-cassette succesfully occured in our mice and that only the exon E8a 
containing isoforms were turned off. Moreover the presence of the Neo-cassette 
did not affect total LSD1 transcription efficiency, without leading to unexpected 
effects due to low LSD1 protein dosage. 
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2.5 BACKCROSS BREEDING TO MAKE A CONGENIC STRAIN 
 
The exon E8a-limited-LSD1 KO mice that we obtained by breeding heterozygous 
F1 mice inevitably had a mixed genetic background, deriving from 129 ES cells 
strain and C57BL/6 strain of the blastocysts that we used. This represents a 
drawback because the effects of neuronal LSD1 knocking down are subjected to 
variation in phenotype depending  from the background genotype on which they 
are examined. For this reason we transfered the E8a knock-out allele into a fully 
C57BL/6 genotype, in order to recreat a congenic strain. Our aim, indeed, was to 
obtain E8a-limited-LSD1 KO mice genetically identical to C57BL/6 ones, except for 
the chromosomal region surrounding the mutated alleles. We chose C57BL/6 as 
inbred strain since these mice are widely used  in research, available in large 
numbers and their genome has been completely sequenced, assembled and 
notated. To make our congenic strain we backcrossed heterozygous 
E8a-limited-LSD1 mutants with C57BL/6 inbred mice and we selected 
heterozygous offspring from the first generation (N1) to cross back to the inbred 
strain for the next generation (N2): at each generation (N) the genetic diversity 
decreased and the mice contained more and more of the inbred genome. A mutant 
strain is consider congenic when it reaches 99,8% of identity with the inbred 
genome. At this point we simply bred heterozygous male and female backcrossed 
mice to obtain  congenic E8a-limited-LSD1 KO animals for analysis (Fig. 2.5.1). 
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Fig. 2.5.1 Mice backcrossing 
The picture shows the backcrossing of heterozygous mice, from a mixed genetic background to C57BL/6 congenic background. The 
exon E8a knocking-out  was performed in 129/SV cells (blue) that were then implanted into the blastocyst of a C57BL/6 
pseudopregnant female mouse (white). Thus, F1 heterozygous pups were C57BL/6 for 50% of their genome. To move our mutation 
in a congenic strain it was necessary to perform consecutive backcrossing with C57BL/6 wild type animals, in order to increase the 
percentage of C57BL/6 DNA that forms the genome of the offspring. When such percentage reached 98% we bred male and female 
heterozygous congenic pups to obtain backcrossed KO animals. 
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2.6 ACCELERATED BACKCROSS BREEDING 
 
In order to speed up backcross breeding we used MAX-BAX (Marker-Assisted 
Accelerated Backcrossing) system. It consists in a 384 SNPs panel of C57BL/6  
DNA  markers (Charles River) that is able to dramatically reduce the time required 
to fully backcross a mouse line. This reduction is ach ieved by selecting animals 
with preferred genetic background as breeders for the next generation, resulting in 
a fully backcrossed animal in only five generations (Tab. 2.6.1). 
 
Tab.  2.6.1 Congenic strain generation s trategies 
Using traditional random backcrossing methods, it takes 10 generations (upwards of 2.5 years) to produce a congenic strain. 
Selectively breeding individuals containing more of the recipient genome from each generatio n allows accelerated congenic strain 
production. Indeed, the animals carrying the locus of interest with the highest percentage of recipient versus donor strain DNA are 
preferentially bred. 
 
 
We performed  MAX-BAX analysis on tail snips of 8 N3-backcrossed heterozygous 
mice that showed an average recipient-strain's contribution percentage of 95,13%, 
with values ranging from 93,47% to 97,40% (Tab. 2.6.2), according to the mean 
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values reported in “Speed Backcross” table 2.6.1. 
N3-1 N3-8 N3-10 N3-12 N3-13 N3-14 N3-15 N3-16
% of C57BL/6 94,01042 95,57292 97,39583 95,82245 94,66146 93,47258 94,14063 95,953
N3 mice analyzed
 
Tab.  2.6.2 MAX-BAX results 
Table shows the percentage of C57BL/6 recipient genome present in each of the 8 mice analyzed. In yellow the 4 mice with a 
C57BL/6 percentage higher than 95% that we used to carry mice backcrossing on. 
 
Thanks to these results we decided to continue accelerated backcrossing to N5 generation using only the 
4 mice with C57BL/6 contribution percentage higher than 95% (yellow in table 2.6.2). At the end of 
backcrossing we bred 6 heterozygous N5 male with 13 N5  female mice and so far we have obtained 
about 230 pups, with 1:1 ratio between male and female animals (Fig. 2.6.3 A). 29,5% of them were 
homozygous E8a-limited-LSD1 knock-out animals; the percentage is in according to the Mendelian 
frequency (Fig. 2.6.3 B). The great majority of them survived to adulthood and was fully fertile. 
 
Fig. 2.6.3 Sex and genotype ratio in backcrossed mice 
(A) Sex ratio 1:1 is respected in backcrossed pups, with 118 females (pink bar) and 112 male mice (blue bar). (B) Genotype 
segregation is accordance with Mendelian low, with 61 wildtype (vertical stripes), 101 heterozygous (diagonal stripes) and 68 
knock-out mice (horizontal stripes) 
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3. CHARACTERIZATION OF E8a-limited LSD1 
KO MICE 
 
 
 
 
It's becoming increasingly clear that it is almost always impossible to predict the 
resultant phenotype deriving from a gene inactivation because it often differs from 
the reasearchers expectations. Indeed, our E8a-limited LSD1 knock-out KO mice 
do not have an obvious phenotype; on the contrary they rather seem to not have a 
peculiar phenotype, since they are not sicken, they do not die prenatally or right 
after birth, neither during the first days or weeks of life. The phenotype of a 
knock-out mouse is always a very critical aspect to point out. For this reason we 
approached this issue from different points of view. First of all we looked at the 
internal organs with a macroscopic and microscopic histophatological examinations 
of KO and WT animals, then we characterized them with brain-specific 
immunostainings and finally we evaluated their behavioural and biochemical 
response to a specific chemoconvulsant treatment. 
 
 
3.1 NECROSCOPIC  EXAMINATION 
 
Mice examined: 
2  WT female and 2 KO female mice 
Developmental stage: 3 weeks (1 WT and 1 KO)  and 3 months (1 WT and 1 KO) 
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To begin with knock-out and wild type mice characterization we decided carry out a 
complete necroscopic internal organs examination, in terms of size, shape, volume, 
reciprocal position contacts and histopathological evaluations. To this aim, in 
collaboration with  Dr. Eugenio Scanziani of Mouse and Animal Pathology Lab. 
(Filarete foundation, Milan) we performed routine macroscopic analysis and 
microscopic histological studies of the complete mice, with major organs dissection, 
weight and fixation in paraffin, followed by a regular Hematoxylin and Eosin 
staining. 
The following organs and tissues were fixed: 
- representative samples from glossy detectable lesions 
- CNS 
- Thoracic cavity: heart, lungs, thymus, thyroid 
- Parenchymatous organs of the abdominal cavity 
- Hollows organs of the abdominal cavity 
- Genital tract 
- salivary glands and lymph nodes 
 
The CNS, after a short fixation, was submitted to transversal sectioning by using a 
“mouse brain matrix”. Six slices of 2 mm of thickness were obtained. All samples 
were processed for paraffin blocks embedding. For histopathological analysis, 4 
um-thick tissue sections were stained with Hematoxylin and Eosin. 
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Table below summarizes values obtained for the weight of the major internal 
organs of each mouse analyzed. 
brain liver kidney (Dx) kidney (Sx) total body
F 59 0,50 1,17 0,16 0,17 20,85
F 65 0,57 1,34 0,20 0,19 27,90
F 156 0,46 0,62 0,07 0,07 12,34
F 160 0,43 0,49 0,07 0,07 14,20
weight (g)
 
Tab.  3.1.1 Summary of the organs weight 
 
No statistically significant differences existed in the total body weight of the 
age-matched knock-out and wild type mice as well as in the weight of all the 
isolated organs (Tab. 3.1.1). Macroscopic examination of the vital organs didn’t 
reveal any abnormality. No relevant pathologies were found by necroscopy, except 
for a moderate mesenteric lymphadenomegaly in the 3 months-old WT animal. No 
inflammation, hemorrhage, fluid accumulation or any unfavourable changes were 
seen in the mutated animals tissue sections. Histopathologic analysis of the tissues 
showed that all the vital organs from the knock-out and control groups were normal 
in the main. 
Medical report obtained from the necroscopic analysis is posted here: 
Brain:  the gross morphology of brain from E8a knockout animals do not differ 
from that of wild-type brain. 
Heart, lungs, thymus, thyroid, and salivary glands:  these tissues do not show any 
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anomalies. 
Liver: rare and small foci of cellular of extramedullary hematopoiesis were noted in 
the liver of  all the animals but the damage was considered very mild and 
non-specific, and could have been due to a great number of aetiological factors 
such as  immunologic insult. 
Kidneys: rare and minimal findings of necrosis of tubular epithelial cells was 
osserved in kidneys of 3 weeks old KO mouse. Small perivascular 
lympho/plasmacytic infiltrates with one tube atrophy of epitelial cells were noted in 
wild type mice. 
Spleen, pancreas and lymph nodes: normal 
Stomach: focal eosinophilic infiltrate was seen in lamina propria of almost all the 
mice 
Small intestine: from moderate to severe, diffuse lympho/plasmacytic infiltrate in 
lamina propria with a high number of flagellate protozoa (most likely Giardia) in the 
intestinal lumen of all the mice, except for the 3 weeks-old knock-out mouse 
Large intestine: from moderate to severe, diffuse lympho/plasmacytic infiltrate in 
lamina propria with a moderate number of pyriform protozoa (most likely 
Tritrichimonas) in all the mice. Large number of rod shape, elongated organisms 
within the lumen of intestinal crypts in 3 weeks-old mice. 
Uterus: no pathological findings 
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Ovaries: some corpora lutea in 3 months old mice. 
Taken together necroscopy and histopathological analysis showed no particular 
evidences in mutant mice compared to the controls, both in CNS and in the other 
organs/tissues. Only “spontaneous” pathological findings have been recorded and 
in this regard it was worth noting the intestinal parasites seen in all animals. In 3/4 
cases protozoan flagellate were present and in 2/4 case pinworms, but these 
findings were unrelated from the exon E8a involvement.   
 
3.2 IMMUNOHISTOCHEMICAL CHARACTERIZATION 
 
Animals examined: 
3 WT and 3 KO mice 
Developmental stages: 6 weeks 
 
Since we know from existing data of our laboratory [12] that LSD1-E8a expression 
is restricted to CNS but the gross brain morphology of E8a knock-out animals did 
not differ from that of wild-type ones, a closer inspection of distinct brain areas was 
necessary to look more carefully into possible  alterations in the organization of 
mutant mice brain. Thus, in cooperation with prof. Silvia De Biasi of the 
Biomolecolar science and Biotechnology department (University of Milan) we 
performed immunohistochemical analysis using several neuronal markers. 
We started from evaluating Calbindin-D28K (CB) and Calretinin (CR) distribution as 
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they are two calcium-binding proteins of great interest in neuroanatomy and 
neuropathology to characterize different subpopulations of inhibitory neurons in  
normal developing and adult nervous system. We immunostained cortex, 
hippocampus and cerebellum areas of 6 weeks-old knock-out mice and we 
immediately detected very deep differences compared to wild-type animals, in 
particular in Calbindin staining which was the most informative one. For all the 
markers and the brain areas considered, we obtained a remarkably consistent and 
reproducible labeling pattern in all the mice. In the following descriptions, 
indications regarding labeling intensities always referred to differences observed in 
the distribution of one marker between in the same section of mutant and control 
mice. 
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CALBINDIN IMMUNOSTAINING 
Cerebellum 
    Wild-type mouse                        Knock-out mouse 
 
Fig. 3.2.1 Changes in calbindin D28k (CB) immunoreactivity in the cerebellum of E8a-limited-LSD1  
knockout mice (B,D,F) compared with wild-type mice (A,C,E). 
Parasaggital sections of the cerebellum are stained with antibodies against calbindin to detect Purkinje cells. Purkinje cell s that 
normally constitute a monolayer (PCL) between the molecular layer and the granule cell layer (A,C,E) are highly disorganized in the 
nLSD1 -/- cerebellum (B,D,F) 
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In cerebellum, Purkinje cells express calbindin whereas basket, stellate and Golgi 
cells are not calbindin-D28K immunoreactive. These cells are, almost all, calretinin 
negative. On the contrary granule, Lugaro and unipolar brush cells present an 
opposite immunoreactive profile: they are all calretin positive but lacking in 
calbindin. The developmental pattern of apparence of these proteins seems to 
follow the maturation of neurons. Calbindin appears early, shortly after the 
cessation of mitosis when neurons become ready to start migration and 
differentiation. 
Calbindin immunostaining revealed anatomy disruption of the Purkinje and 
molecular layers of the cerebellum in Knock-out mice (Fig. 3.2.1 B, D, F) compared 
to wild-type animals (Fig. 3.2.1 A, C, E). Such alteration was expressed as overall 
disorganization, changes in dendritic arborization, reduction in cell soma size and 
decrease in the numbers of Purkinje cells (Fig. 3.2.1 E-F). Furthermore we also 
observed a very clear defects in the misalignment of the Purkinje cells  as well as 
a drastic reduction of the molecular layer staining in nLSD1 -/- mice ( Fig. 3.2.1 
C-D). 
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Neocortex 
        Wild-type mouse                      Knock-out mouse 
 
 
Fig. 3.2.2 Changes in calbindin D28k (CB) immunoreactivity in the cerebral cortex of 
E8a-limited-LSD1  knockout mice (B,D,F) compared with wild-type mice (A,C,E). 
(C, D) are high power views of all layers of the cerebral cortex while (E, F) are high power  views of layers I to V. The distribution 
pattern and morphology of CB-immunoreactive neurons are different in the control and nLSD1 knock-out mice. CB immunoreactivity 
in nLSD1 -/- mice is much lower than that of control mice (A, B) and the high power views show that the number of the 
CB-immunoreactive neurons in the nLSD1 -/- mice (D,F) is lower than those of the control mice (C,E). 
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In the neocortex there are basically two major classes of neurons: projecting 
neurons (~80% of neocortical neurons) and interneurons (~20%). Projecting 
neurons are represented by pyramidal cells which are located in all layers except 
for layer I and are excitatory (glutamatergic). Interneurons are subdivided into 
excitatory spiny stellate cells, located in the middle layers of the cortex, and 
inhibitory smooth non-pyramidal neurons, present in all layers. All or the majority of 
CB-immunoreactive cells in cortex are smooth non-pyramidal neurons. 
Numerous CB-immunoreactive neurons were observed in the cerebral cortex of 
wild-type mice (Fig. 3.2.2 A,C,E), which were divided into two categories: neurons 
expressing high levels of CB in their neurites and cell bodies (black arrowheads in 
Fig. 3.2.2 E), and those expressing CB only in their cell bodies (light brown dots). 
The former neurons were distributed in all layers of the cerebral cortex except layer 
I (Fig. 3.2.2 A, C) and had long CB-immunoreactive neurites that branched many 
times (black arrowheads in Fig. 3.2.2 E). The former seemed to express more CB 
than the latter. The latter type of neurons were localized in layers II and III and they 
outnumbered the former (Fig. 3.2.2 A, C). These two kinds of CB-immunoreactive 
neurons were also observed in nLSD1 -/- mice, but their morphology and 
distribution pattern were different. The number of neurons expressing high CB 
levels in their cell bodies and neurites was reduced significantly in nLSD1-/- mice  
(Fig. 3.2.2 B, D, E) and each individual neuron of this type showed lower levels of 
CB immunoreactivity than that in control mice. On high power, the lengths of 
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CB-immunoreactive neurites were also reduced in nLSD1-/- mice and they had 
fewer branches (Fig. 3.2.2 F). As for the former type neurons, the number of 
neurons expressing CB only in the cell bodies and their CB immunoreactivity was 
reduced in nLSD1-/- mice (Fig. 3.2.2 D, F). 
 
Hippocampus 
    Wild-type mouse                                      Knock-out mouse 
 
Fig. 3.2.3 Changes in calbindin D28k (CB) immunoreactivity in the hippocampus of 
E8a-limited-LSD1  knockout mice (B,D,F) compared with wild-type mice (A,C,E). 
Decreased calbindin D28k (CB) expression in the hippocampal region of neuronal LSD1 knock-out mice (B, D, F). C, D are high 
power views of the CA3 of Ammon's horn; E and F are high power views of the CA2 of Ammon's horn. The overall distribution 
patterns of CB-immunoreactivity and the morphology of CB-immunoreactive neurons are very different in the control and nLSD1 -/- 
mice (A-F) 
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In the hippocampal formation there is a heterogeneous population of non-pyramidal 
neurons most of which expressing GABA. Largely non-overlapping subsets of 
these GABAergic interneurons express distinct calcium binding proteins (CBPs) 
and the distribution of these CBP-positive interneurons in the hippocampal 
subfields has been well characterized in rodents. Calbindin immunostaining marks 
granule cells of the dentate gyrus and their mossy fibers  and axons. Furthermore 
calbindin fills in soma and dendrites of interneurons located at the border of stratum 
granulosum and rarely inside the hilus, but marks also and the superficial pyramidal 
cells of the CA1 region. 
The hippocampal region of control mice showed a highly specific CB expression 
pattern. Granule cells in the dentate gyrus expressed high levels of CB in their cell 
bodies, and relatively high CB immunoreactivity was observed in the neuropil of the 
molecular layer and in the polymorph layer (Fig. 3.2.3 A). In Ammon's horn of the 
anterior hippocampal region, cell bodies of pyramidal cells in CA1 showed CB 
immunoreactivity, but those of pyramidal cells in CA3 did not (Fig. 3.2.3 C). Instead, 
the neuropil of the stratum lucidum in CA3 expressed high levels of CB (Fig. 3.2.3 
C). As observed in the cerebral cortex, neurons and neuropil expressing CB in the 
hippocampal region of control mice showed differential CB expression pattern in 
the hippocampal region of nLSD1-/- mice. The CB expression levels of these 
neurons and neuropil was lower in the nLSD1-/- mice than that in control mice (Fig. 
3.2.3 B). The number of CB-immunoreactive neurons other than pyramidal cells in 
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CA2 was significantly lower and each neuron showed less CB immunoreactivity in 
nLSD1-/- mice than that in controls (Fig. 3.2.3 E, F). 
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CALRETININ IMMUNOSTAINING 
Cerebellum 
Wild-type mouse                              Knock-out mouse 
 
Fig. 3.2.4 Calretinin (CR) immunoreactivity in the cerebellum of E8a-limited-LSD1  knockout mice 
(B,D,F) compared with wild-type mice (A,C, E). 
Sections of the cerebellum are stained with antibodies against calretinin to detect granule, Lugaro and unipolar brush cells. These 
cells that normally constitute the molecular layer and the granule cell layer are very well -organized in the nLSD1 -/- cerebellum (B,D,F) 
and in wild type one (A,C,E) 
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Calretinin-positive cells in the cerebellar cortex are interneurons, in particular they are 
known as Lugaro, Golgi and unipolar brush cells. In both wild-type and knock-out mice 
the localization of CR expression was very similar (Fig. 3.2.4 A-F), indeed both the 
molecular and granular layers showed positive immunoreactivity (Fig. 3.2.4 A, B). Only at 
high power views Calretinin-positive interneurons seemed to be slightly lower 
immunoreactive in nLSD1 knock-out mice (Fig. 3.2.4 C, E) compared to wild-type (Fig. 
3.2.4 D, F) but  the difference is not significative. 
 
Neocortex 
  Wild-type mouse                                  Knock-out mouse 
 
Fig. 3.2.5 Calretinin (CR) immunoreactivity in the cerebral cortex of E8a-limited-LSD1  knockout 
mice (B) compared with wild-type mice (A). 
The distribution pattern and morphology of CR-immunoreactive neurons are te same in the control and nLSD1 knock-out mice. CR 
immunoreactivity in nLSD1 -/- mice is similar to that of control mice (A, B) and also  the number of the CR-immunoreactive neurons 
in the nLSD1 -/- mice (B) is comparable to that of the control mice (A). 
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CR+ neurons in neocortex are concentrated predominantly in cortical layers II and 
III, both in rodents and primates. The density of CR+ neurons decreases with 
increasing depth in neocortex and therefore they are quite rare in infragranular 
layers, when compared to the supragranular ones. Neocortex of nLSD1 mutants 
(Fig. 3.2.5 B) mice revealed at this magnification a slightly lower frequency of 
calretinin-positive neurons compared to wild-type one (Fig. 3.2.5 A), togheter with a 
general very mild tissue disorganization (Fig. 3.2.5 A). 
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Hippocampus 
   Wild-type mouse                                  Knock-out mouse 
 
 
Fig.3.2.6 Calretinin (CR) immunoreactivity in the hippocampus of E8a-limited-LSD1  knockout mice 
(B,D) compared with wild-type mice (A,C). 
Calretinin  (CR) expression in the hippocampal  dentate gyrus of neuronal LSD1 knock-out mice (B, D, F). C, D are high power views 
of the dentate gyrus. The overall distribution patterns of CR-immunoreactivity and the morphology of CR-immunoreactive neurons are 
quite similar in the control and nLSD1 -/- mice (A-D) 
 
Calretinin is expressed mainly in the soma and the proximal and distal dendrites of 
interneurons that are specialized to innervate either principal cell dendrites or other 
interneurons in all layers and subregions of the hippocampus. Calretinin 
immunostains with the highest density the stratum pyramidale of the CA1 region 
and the projections of the mossy fiber into the inner molecular layer. 
In our restricted views of the dentate gyrus (Fig. 3.2.6 A-D) there was a little 
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reduction of the calretinin immunoreactivity of the supragranular band in nLSD1 -/- 
mouse (Fig. 3.2.6 B) compared to wild-type mouse (Fig. 3.2.6 A), but such 
evidence was no more clear in the higher power views (Fig. 3.2.6 C-D) where we 
rather found in mutated mice a small decreasing in the number of immature 
interneurons compared to wild-type ones.   
 
 
VGLUTs IMMUNOSTAINING 
 
Glutamate is the predominant excitatory neurotransmitter in the central nervous 
system. It is stored in synaptic vesicles and released upon stimulation. The 
homeostasis of glutamatergic system is maintained by a set of transporters present 
in plasma membrane and in the membrane of synaptic vesicles. The family of 
vesicular glutamate transporters in mammals is comprised of three highly 
homologous proteins: VGLUT-1, VGLUT-2 and VGLUT-3. The expression of 
particular VGLUTs is largely complementary with limited overlap and so far they 
are the most specific markers for neurons that use glutamate as neurotransmitter. 
VGLUTs are developmentally regulated and determine distinct populations of 
glutamatergic neurons. 
VGLUT-1 is localized mainly in neocortex (layers I-III), enthorinal and piriform 
cortex, hippocampus, amygdala and subiculum. VGLUT-2 can be observed in 
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olfactory bulb, layer IV of the cerebral cortex, granular layer of the dentate gyrus, 
thalamus, hypothalamus and in the brain stem cells. In cerebellum, VGLUT-1 is 
expressed in parallel fibers and VGLUT-2 in climbing fibers and in Purkinje cell 
dendrites. VGLUT-1 is present at synapses with low release probability, which are 
known to exhibit long term potentiation (LTP), whereas VGLUT-2 is expressed in 
synapses that exhibit high release probability and long term depression (LTD). The 
third vescicular glutamate transporter VGLUT-3 is localized in a very limited 
numbers of glutamatergic neurons in multiple brain regions and so we didn't 
perform any immunostaining against this transporter to characterize our mutated 
mice. 
 
 
 
 
 
 
 
 
 
 
 
Results 
 
203 
 
VGLUT-1 IMMUNOSTAINING 
Cerebellum 
  Wild-type mouse                                   Knock-out mouse 
 
Fig. 3.2.7 Vesicular Glutamate Transporter 1  (VGLUT1) immunoreactivity in the cerebellum of 
E8a-limited-LSD1  knockout mice (B,D) compared with wild-type mice (A,C). 
Sagittal sections of cerebellum stained with antibody against VGLUT1 to mark distribution of parallel fiber terminals to Purkinje cells 
and of   mossy fiber terminals. These cells normally constitute the molecular layer and the granular layer, respectively. Parallel 
fibers are very well -organized in the nLSD1 -/- cerebellum (B,D) and in wild type one (A,C), while a mild general disorganization is 
visible in the granular layer of nLSD1 -/- mice (B,D) compared to wild type (A,C). 
 
 
In mouse cerebellar cortex there are three kinds of excitatory nerve terminals: axon 
terminals of climbing fibers, parallel fibers and mossy fibers. The parallel fibers that 
are derived from cerebellar granule cells are well known to use L-glutamate for their 
excitatory transmission and recently also mossy fibers have been supposed to 
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employ L-glutamate as transmitter. These two kind of exc itatory cells are 
immunostained by anti-VGLUT1 antibody. While no differences were seen in 
parallel fibers to Purkinje cells distribution between nLSD1 knock-out (Fig. 3.2.7 B) 
and wild-type (Fig. 3.2.7 A) mice, at high power views a general mild 
disorganization was found in the granular layer of knock-out mice (Fig. 3.2.7 D) 
compared to control mice (Fig. 3.2.7 C). Also Purkinje -cells monolayer, located 
between the molecular and the granular one, seemed more irregular and thinner in 
knock-out mice (Fig. 3.2.7 D) than in wild-type ones (Fig. 3.2.7 C). 
Hippocampus 
      Wild-type mouse                               Knock-out mouse 
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Fig. 3.2.8 Vesicular Glutamate Transporter 1  (VGLUT1) immunoreactivity in the hippocampus of 
E8a-limited-LSD1  knockout mice (B,D,E) compared with wild-type mice (A,C,D). 
Sagittal sections of hippocampus stained with antibody against VGLUT1 to mark all the hippocampal areas except for pyramidal cells 
and granule cells. In nLSD1 -/- cerebellum (B,D,E) and in wild type one (A,C,D) no differences were observed in VGLUT1 
immunoreactivity. 
 
In the hippocampus, VGLUT1 is the dominant transporter subtype in adult animals, 
whereas VGLUT2 is transiently expressed during early postnatal development. 
VGLUT1 immunoreactivity is normally detectable in all hippocampal regions except 
for pyramidal cell layers and for granule cell layer of the dentate gyrus, exactly as 
we found in all the stainings (Fig.3.2.8 A-F). No differences were observed in 
VGLUT1 immunoreactivity of nLSD1 knock-out mice hippocampus compared to 
wild-type one (Fig.3.2.8 A-F).   
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VGLUT-2 IMMUNOSTAINING 
Cerebellum 
    Wild-type mouse                                  knock-out mouse 
 
 
Fig. 3.2.9 Vesicular Glutamate Transporter 2  (VGLUT2) immunoreactivity in the cerebellum of 
E8a-limited LSD1 knock-out mice (B,D,F) compared with wild-type mice (A,C,E). 
Sagittal sections of cerebellum stained with antibody against VGLUT2 to mark distribution of climbing fibers and of mossy fiber 
terminals. These cells normally constitute the molecular layer and the granular layer, respectively. A general incre asing in VGLUT2 
staining was clear in knock-out mice (Fig. 3.X B, D, F) compared to wild-type ones (Fig. 3.X A, C, E). At high power view an 
increasing also in the number of climbing fibers and mossy fiber terminals were seen in the nLSD1 -/- cerebellum (F) compared to  
wild type one (E). 
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In cerebellar cortex VGLUT2 expression is strong in mossy ﬁbers located in the 
granule cell layer and in climbing ﬁber terminals in the molecular layer. Our 
knock-out and wild-type mice showed a different pattern of staining, with knock-out 
animals (Fig. 3.2.9 B, D, F) that were much more immunostained than wild-type 
ones (Fig. 3.2.9 A, C, E), both at the level of molecular and granular zone. In 
particular, Fig. 3.2.9 E and F highlighted a strong increasing in the number of 
climbing fibers in knock-out mice, as well as a stronger VGLUT2 affinity for mossy 
fibers terminals of the granule layer. 
Hippocampus 
     Wild-type mouse                              Knock-out mouse 
 
Fig. 3.2.10 Vesicular Glutamate Transporter 1  (VGLUT2) immunoreactivity in the hippocampus of 
E8a-limited-LSD1  knockout mice (B,D) compared with wild-type mice (A,C). 
An overall increasing in VGLUT2 staining was clear in all the hippocampal regions of knock-out mice (Fig. 3.2.10 B, D) compared to 
wild-type ones (Fig. 3.2.10 A, C). At high power views it was also more evident that VGLUT2 immunoreactivity in the dentate gyrus 
was higher in knock-out mice (D) than in control mice (C) 
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VGLUT2 immunoreactivity is routinely detected in nerve terminals in the pyramidal 
cell layer of the hippocampus, in the granule cell layer and in the outer two-thirds of 
the molecular layer of the dentate gyrus. 
A general increasing in VGLUT2 staining was observed in knock-out mice 
hippocampus compared to wild-typre one (Fig. 3.2.10 A and B). In particular, at 
high power view we saw much more immunoreactivity at the level of granule cell 
layer of the dentate gyrus of mutated mice (Fig. 3.2.10 D).     
 
SOX-2 IMMUNOSTAINING 
 
Since we were interested in understanding if nLSD1 could be involved in memory 
and learning pathways, we performed an immunostaining of the subgranular zone 
(SGZ) of the dentate gyrus with an anti-SOX2 antibody. We know that the dentate 
gyrus has an important role in learning and memory, since the subgranular zone  
is one of the two major sites in the hippocampus, along with the subventricular 
zone (SVZ), where adult neurogenesis occurs, and adult neurogenesis may play an 
important role in the acquisition of new memories. The subgranular zone is 
characterized by several types of cells, but the most prominent are neural stem 
cells (NSCs) in various stages of development. However, in addition to NSCs, there 
are also astrocytes, endothelial cells, blood vessels and other components, which 
form a microenvironment that supports the NSCs and regulates their proliferation, 
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migration, and differentiation. SGZ generates only one type of differentiated cells: 
granule cells, the primary excitatory neurons in the dentate gyrus which are thought 
to contribute to cognitive functions such as memory and learning. The progression 
from neural stem cell to granule cell in the SGZ can be described by tracing 
different biomarkers. Sox2 is a biomarker associated with neural stem cells and in 
the SGZ it is expressed by radial glia cells.                                                                                                                          
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Cerebellum 
Wild-type mouse 
 
Knock-out mouse 
 
Fig. 3.2.11 Sox-2 immunoreactivity in the hippocampus of E8a-limited-LSD1  knockout mice (B) 
compared with wild-type mice (A). 
The subgranular zone (SGZ) (black narrows) of the dentate gyrus is marked by the stem cell marker Sox-2. The number of Radial glia 
cells (indicated by the arrows) that normally constitute SGZ is lower  in nLSD1 -/- hippocampus (B) compared to the wild-type one 
(A). 
 
Radial glial cells are a subset of astrocytes which are typically thought as 
non-neuronal support cells, indeed they are astrocytic in their morphology. 
However, unlike most astrocytes, they also act as neurogenic progenitors; in fact, 
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they are widely considered to be the neural stem cells that give rise to subsequent 
neuronal precursor cells. Radial glial cells often divide asymmetrically, producing 
one new stem cell and one neuronal precursor cell per division. Both the number 
and the immunoreactivity of the Radial glia cells to Sox-2 marker were lower in 
nLSD1 -/- knock-out (Fig. 3.2.11 B) compared to wild-type mice (Fig. 3.2.11 A). 
 
 
3.3 PILOCARPINE TREATMENT RESPONSIVENESS 
 
Animals examined: 
35 KO and 35 WT mice 
Developmental stage: 5 weeks 
 
There is a reciprocal strong relationship between neuronal activation, neurogenesis 
in the SGZ and learning and memories. On the one hand, high rates of neuronal 
activation induce neurogenesis that may increase memory abilities.  On the other 
hand, learning and memories have a positive effect on cell survival and induce cell 
proliferation through increased synaptic activity and neurotransmitter release. 
Since our goal is to understand if nLSD1 could be involved in memory and learning 
pathway we performed the well characterized lithium-pilocarpine treatment to 
induce neuronal activation in wild-type and mutants mice. This treatment is 
commonly referred to as a model of Human Mesial Temporal Lobe Epilepsy (MTLE) 
but seizures in epilepsy are widely thought to develop from highly synchronized 
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neuronal activation.   
Pilocarpine treatment highlighted very different neuronal activation responsiveness 
in wild-type and knock-out mice, evaluated as number of seizures observed (Fig. 
3.3.1) and time of latency to seizures (Fig. 3.3.2) 
                                                                                
 
 
 
 
 
      Fig.  3.3.1 Time of  latency to seizures Fig.3.3.2 Number of  seizures experience 
  Black squares symbolize wild-type mice while black triangles are for knock-out mice; horizontal lines are the mean values obtained 
in each analysis   
 
After pilocarpine-induced neuronal stroke with the same pilocarpine dosage 
described in Results-chapter 1, in nLSD1 knock-out mice we observed an 
extension of the latent period in which usually seizures do not occur, compared to 
wild-type mice. Indeed, such time of latency in wild-type animals was about 10 min. 
and then almost all of the  animals experienced tonic-clonic seizures; on the 
contrary knock-out mice started to display the effects of the treatment only about 25 
min. after injection and only a small number of them had tonic clonic convulsion 
B 
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(Fig. 3.3.1).  Also the number of experienced seizures was significantly different 
between the two mice populations (Fig. 3.3.2): wild-type animals displayed 6 
seizure events on the average while mutated mice had about only 1 convulsion in 
the same period of treatment. 
Studying pilocarpine-evoked neuronal activation in nLSD1 knock-out mouse model 
is interesting also from the biochemical point of view. Indeed, unpublished data 
from our laboratory revealed a strong physical interaction between LSD1 protein 
and the Serum Response Factor (SRF), which is a positive transcription factor that 
binds to Serum Response Element (SRE) in the promoter region of target genes. 
We know from literature that SRF regulates the activity of many immediate -early 
genes; among them there are c-Fos and Egr-1, whose induction in the brain is 
strongly associated with neuronal activity. 
C-fos is an immediate-early gene that undergoes dramatic and transient 
expression in response to a diversity  of  stimuli but a striking activation in 
neurons is obtained by depolarization in vitro and by seizures in vivo. Also egr-1 
encodes for a transcription factor protein which has a distinct pattern of expression 
in the brain, where it has been demonstrated to be elicited by seizure activity. 
Since we found that LSD1 takes part to SRF transcriptional complex, we 
hypothesized that LSD1 might have a role in regulating its transcriptional activity at 
the level of above-mentioned immediate-early genes, which have in their promoter 
region more than one  SRF  Responsive Elements (SRE). 
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That being so, we evaluated by qRT-PCR the expression level of c-Fos and Egr-1 
gene on RNA taken from hippocampal region of wild-type and knock-out mice, 7 
hours after seizures onset. 
               Egr-1 expression                   cFos expression 
 
Fig.3.3.3 Level of hippocampal Egr1 and cFos expression in treated and not treated KO mice 
compared to WT  
qRT-PCRs were performed using RPSA as housekeeping gene. Ct values obtained for Egr-1 and cFos were normalized over the 
housekeeping gene to correct for sample variations in RT-PCR efficiency (dCt). In the charts, the level of expression of the two genes is 
presented as fold change relative to the resting WT mice condition. **are referred to p value<0,01  *** are referred to p value<0,001 
 
 
 
   
As we expected, the expression level of the two immediate early gene 
significatively changed after the Pilocarpine treatment, with a burst that proved their 
strong responsivness to seizures. However farmacologically-induced neuronal 
activation did not had the same effect on both the two mice populations. Wild-type 
mice, indeed, experienced a massive increasing in Egr-1 and cFos expression 
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compared to knock-out mice, who on the contrary showed a lower and restrained 
burst. Such significative difference in their responsiveness may be explained by 
their different genotype: knock-out  mice in fact are totally lacking in the 
E8a-containing isoform of LSD1, which is known to repress the transcription less 
than LSD1 ubiquitary isoform. Thus knock-out mice have much more repressive 
potential compared to wild type mice and this was clearly highlighted by this 
experiment. 
Knock-out mice characterization is still in progress and these results come from 
preliminary experiments that have to be performed more than one time to be 
significative. For this reason no discussion will be presented about these data.   
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Alternative splicing is considered one of the most powerful biological mechanisms 
that leads to diversification of gene function without a corresponding increase in 
gene number, giving rise to evolutionary complexity especially for mammalian 
species. Notably, most of the splicing events occur in CNS-related transcripts and 
participate in fundamental nervous processes, from cell-related ones, such as axon 
guidance and synapse formation, to higher cognitive functions, including learning 
and memory [12].  
Although LSD1 and its epigenetic role in the central nervous system have been 
extensively investigated, LSD1 alternative splicing regulation as well as 
neurospecific LSD1 function in vivo  has not been elucidated yet. 
LSD1 is the first identified Lysine specific demethylase that removes methyl groups 
from mono- or di-methylated Histone 3 Lys4 (H3K4). It is known to be part of a 
repressing complex containing also the proteins CoREST and HDAC1/2. As LSD1 
is known to be a corepressor of the transcriptional silencer REST, its general 
function is to inhibit the expression of neuronal genes in non-neuronal cells. LSD1 
gene contains two alternative exons: exon E2a and exon E8a. The inclusion in the 
mature transcripts of the alternative exon E8a is restricted to the  nervous system 
and the LSD1-E8a isoform is characterized by a less neuronal gene repressing 
action. The exon E8a is only 12-bp long and it codes for 4 aa that form a protruding 
loop in the LSD1 catalytic domain. Moreover exon E8a contains a Threonine 
residue that can be phosphorylated [12], and that is required to induce neuronal 
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maturation and neurite outgrowth and to abrogates neuronal LSD1-8a repressive 
activity [13]. All these observations suggest an important regulatory role played by 
the exon E8a inclusion into neuronal LSD1 protein. Thus, it is relevant to 
understand what are the main cis- and trans-acting factors  involved in exon E8a 
retaining inside the neuronal LSD1 transcripts.  
Here I will point out the main evidences that I  obtained from my PhD project about 
neurospecific LSD1 splicing regulation. 
 
 EXON E8a INCLUSION IS POSITIVELY REGULATED BY NOVA1 and 
nPTB 
We began our investigation of alternative splicing regulation by analyzing the 
intronic regions flanking the exon E8a, where we identified an extremely conserved 
800-bp sequence surrounding the alternative exon. We then cloned this sequence 
in a Minigene reporter system to study exon E8a inclusion in different cellular 
context. The Minigene vector is a good reporter model that let us to examine exon 
E8a inclusion in transcripts exclusively deriving from the reporter gene. Thanks to 
the high-resolution power of capillary electrophoresis, the assay allowed us to 
precisely detect exon E8a inclusion in the mature Minigene transcript and to 
quantitatively measure its percentages. With other techniques, like the 
polyacrylamide gel electrophoresis, the detection and quantitative analysis would 
have been more difficult and less precise and reproducible.  
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We observed exon E8a inclusion selectively in neuronal-like cells. This indicates 
that within this region are present the cis-acting elements necessary to positively 
drive splicing inclusion in the Minigene transcripts in the neuronal-like cells 
SH-SY5Y. Interestingly, this cell line, likewise all the other neuroblastoma cell lines 
we analyzed, do not express endogenous LSD1-8a transcripts. This apparent 
incongruity suggests that although in this cellular context are present several 
neuro-restricted trans-acting factors positively regulating exon E8a inclusion, within 
the analyzed genomic region are missing the negative regulatory elements that 
would recapitulate the endogenous splicing.  
Indeed, neuronal splicing is modulated by a subset of neuro-specific trans-acting 
factors whose function have been deeply elucidated during the last few years. 
Among these factors we started investigating the role of NOVA1 and nPTB. 
NOVA1 was found by R. Darnell group to be directly bound to an RNA containing 
the exon E8a nucleotide sequence [67] while nPTB was demonstrated to be part of 
the same NOVA1-multiprotein complex [69]. The bioinformatics analysis of the 
cis-acting elements recognized by these two factors indicated the presence of 
several consensus sequences inside the highly conserved region cloned into 
Minigene 800. Another important evidence suggesting the implication of both 
NOVA1 and nPTB in exon E8a alternative splicing is their developmental 
expression profile in rat brain cortex that closely overlaps with LSD1-8a.  
Using the Minigene 800 we were able to demonstrate a positive role of both 
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NOVA1 and nPTB in exon E8a splicing modulation. In particular in neuronal cells, 
the overexpression of NOVA1 factor was able to induce a dose-dependent 
increase in the exon E8a inclusion and in the same cellular context its 
down-regulation using an anti-NOVA1 ShRNA decreased exon E8a usage. 
Similarly, we found a positive effect mediated by nPTB over-expression in neuronal 
cells. 
In both cases, NOVA1 and nPTB alone are not able to induce exon E8a usage in 
non-neuronal cells, indicating that they are both necessary but not sufficient to 
mediate exon E8a alternative splicing. Their inability in promoting exon E8a 
inclusion in non-neuronal cells revealed that this splicing event needs other/s 
neurospecific factor/s present in SH-SY5Y but not in HELA cells. We are now 
evaluating if a combinatorial effect between NOVA1 and nPTB is required to 
promote exon E8a inclusion in HELA cells and to increase it in neuronal cells,  
both transfected with the Minigene 800 vector.  
Furthermore, the positive role of NOVA1 in modulating exon E8a alternative 
splicing was  supported by the identification of a pathological condition where 
NOVA1 and exon E8a were co-regulated. Indeed, in a mouse model of 
pharmacologically induced Mesial Temporal Lobe Epilepsy, we observed that upon 
Pilocarpine treatment both the percentage of exon E8a inclusion and the level of 
NOVA1 expression were reduced. This discovery is important because on the one 
hand it proves the involvement of the neuronal LSD1 isoform in one of the most 
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frequent neurological disorder in humans, opening the way to a possible treatment 
of this pathology, and on the other hand it corroborates also in vivo the positive role 
of NOVA1 in promoting exon E8a inclusion into mature LSD1 transcripts.  
Using the same splicing assay, we further tested the possible role of another 
important neurospecific splicing factor, Sam-68. Bio-informatic analysis using 
SpliceAid2 prediction tool, indicated Sam-68 as one of the most promising exon 
E8a splicing regulator, with a score even higher than that found for NOVA1. Both in 
neuronal and non-neuronal cells we did not see any positive effect on exon E8a 
alternative splicing, even upon treatment with TPA, a Phorbol ester which is known 
to induce Sam-68 phosphorylation by activating Ras-signalling pathway. All these 
experiments allowed us to conclude that exon E8a alternative splicing is not 
regulated by Sam-68. 
 
4. LSD1 RNA SECONDARY STRUCTURE PLAYS A PIVOTAL ROLE IN 
MODULATING NEUROSPECIFIC EXON E8a ALTERNATIVE SPLICING    
The identification of a downstream sequence complementary to the exon E8a, 
shed a new light on exon E8a splicing regulation. Pre-mRNAs are typically depicted 
in a linear fashion although a good portion of them exists in a double-stranded 
conformation originating higher-order structures. Often, such structures play 
important roles in regulating RNA metabolism. This is what happens to the 
neuronal LSD1 pre-mRNAs, where the exon E8a and its complementary and 
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inverted sequence, separated by 300 nucleotides, promote the generation of a 
stable stem structure that keeps the exon E8a sequence and the splicing acceptor 
and donor sites embedded inside it. Since the stem structure is thermodynamically 
very stable, it could interfere and negatively modulate splice-sites recognition. In 
principle, RNA secondary structures are able to inhibit spliceosome assembly 
because the recognition of a splice site, or enhancers or silencers typically 
depends upon interactions between trans-acting splicing factors and 
single-stranded cis-acting elements of the pre-mRNA.  
To test the hypotheses that the complementary/inverted downstream sequence 
negatively regulated exon E8a inclusion, we generated a deleted Minigene 800, 
missing the 12-bp core sequence of the complementary/inverted region. mFold 
browser predicted that this deletion would have strongly affected the secondary 
mRNA structure, “unmasking” exon E8a containing sequence. Indeed, when we 
transfected deleted Minigene 800 in neuronal cells we observed a strong 
increasing in the exon E8a inclusion. This result let us to conclude that the deletion 
perturbed the pre-mRNA secondary structure surrounding the exon E8a, allowing 
positive trans-acting spicing regulators to easily reach their binding sites.  
This effect was not observed in non-neuronal cells where the removal of the  
complementary sequence did not exert any positive effect. This result indicated 
that:  
 in non-neuronal cells it is not possible to have exon E8a inclusion because, 
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although the deleted Minigene 800 pre-mRNA is unfolded, these cells are 
lacking in the  neurospecific splicing factor/s that control/s exon E8a 
alternative splicing; 
 in neuronal cells, on the contrary, such neurospecific trans-acting factor (or 
more than one) is expressed but its function is inhibited by the inclusion of 
exon E8a in the double strand structure.  
Intriguingly, the overexpression of NOVA1 or nPTB with the deleted Minigene 800 
did not further increase exon E8a inclusion, as expected, suggesting that their 
positive effect might be exerted by inhibiting or contrasting exon E8a trapping into 
the double strand RNA structure. Thus, we postulated that the small but significant  
exon E8a inclusion that we observed over-expressing NOVA1 or nPTB with 
Minigene 800, was induced by their ability to partially “unlock” Minigene 800 stem 
structure, allowing the other neurospecific positive splicing regulators to partially 
play their role.  
In the future it will be interesting to discover this neurospecific trans-acting factor (or 
complex) that is sufficient to strongly drive exon E8a inclusion. This might clear the 
way to find new possible involvement of LSD1 in physiological or pathological  
condition with a deregulated expression of such splicing regulator. 
 
 LSD1 HAS A NEW ALTERNATIVE EXON, THAT WE CALLED “EXON 
E8b”, WHOSE INCLUSION IS PROMOTED BY FOX1   
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The discovery of this new alternative exon occurred serendipitously when we 
evaluated the effect of FOX1 on neurospecific LSD1 alternative splicing. Using an 
extended version of the Minigene 800, named Minigene 2750, including the full 
length downstream intron with the 2 FOX1 binding sites at the 3' end, we found that 
FOX1 was completely unable to modulate exon E8a alternative splicing but it had 
an important role in promoting the “exonization” of a 77-bp downstream intronic 
sequence. Importantly, exon E8b inclusion occurred almost at the same level in 
neuronal and non-neuronal cells, thus we can say that FOX1 is  sufficient per se  
to regulate exon E8b alternative splicing. Indeed, exon E8b inclusion was not 
affected by NOVA1 nor by nPTB. This 77-bp “exonized” fragment had all the 
features of an exon, such as canonical acceptor and donor splicing sites, and is 
was proximal to cis-acting FOX1 binding sequences that regulated its inclusion. 
The exon E8b sequence analysis revealed that, if included in LSD1 mature 
transcript containing exon E8 or exon E8a, it introduced a premature STOP codon. 
This would predict that all the endogenous exon E8b-containing mRNA should be 
rapidly degraded by the Non-sense mRNA Mediated Decay (NMD). Such 
degradation does not occur for hybrid exon E8b-including Minigene transcripts, 
since minigene-derived transcript are not translated. As expected for  transcripts 
regulated my NMD, their identification in vivo was very difficult. Indeed, to detect 
them we had to perform PCRs with more than 50 cycles. We found exon 
E8b-including transcripts only in human tissues and in particular in brain tissues 
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from RETT and Epileptic patients. Analyzing these RNA we noticed the presence of 
another mRNA population presenting a longer exon E8b that included the entire 
downstream intron fused to exon E9. This second LSD1 splicing variant arose in 
many different human tissues when we screened an Ambion human RNA panel, 
although only upon more than 50 PCR cycles. We conclude that in human tissues 
there are two new LSD1 splicing variants: one containing the sole exon E8b and 
the other one with the exon E8b and its downstream intron. Importantly, we found 
exon E8b only in human tissues and not in mouse or rat. This is in agreement with 
the fact that the acceptor splice site is present only in Human and in Rhesus and 
the exon E8b nucleotide sequence is not highly conserved. Thus, so far about the 
exon E8b we have discovered that: 
3. it exists not only inside the Minigene 2750 transcripts but also in the 
endogenous LSD1 mRNAs; 
4. it is present only in human LSD1 transcripts;  
5. its expression is not restricted to central nervous system; 
6. its splicing is tightly regulated by FOX1; 
7. when present in LSD1 transcripts, it induces in vivo degradation of the 
mRNA by the Non-sense Mediated mRNA Decay (NMD); 
8. it is included, although not preferentially, together with the exon E8a in a 
small percentage of LSD1 splicing transcripts; 
Its very low endogenous expression level, makes it difficult to  study its functional 
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role. At the moment we can only say that its inclusion into LSD1 mature transcripts 
could be a tool at cells disposal to finely tune LSD1 transcripts amount, providing a 
new human-restricted level of regulation of LSD1 expression. In support of this 
hypothesis we know that there are pathological conditions in which LSD1 levels are 
deregulated. For instance, while in the majority of tumors LSD1 is upregulated, in 
some cases it is downregulated. This is the case of breast carcinomas, where 
LSD1 reduction enhances the metastatic spread of the tumor [79]. LSD1 was also 
found to be progressively downregulated during human embryonic stem cells 
differentiation, indicating that LSD1 may be involved in maintaining pluripotency 
[80]. All these findings are consistent with a possible role of the exon E8b in the 
negative regulation of LSD1 expression. Furthermore exon E8b was found in 
Minigene 2750 reporter system to be modulated by FOX1, an important splicing 
factor involved in a lot of phenotypes exhibiting mental retardation, epilepsy and 
autism. Thus in the future we will investigate pathological conditions characterized 
by the concomitant deregulation of FOX1 and LSD1.  
In conclusion, we can say that the discovery of the human-restricted exon E8b  
may be a very important step forward for the LSD1 characterization. Indeed, it is 
interesting  that an extremely conserved enzyme like LSD1 has a neurospecific 
splicing isoform present only in mammals and a newly discovered alternative exon 
expressed only in human transcripts. This means that the exons E8a and E8b 
could have given their small but significative contribution  to phylogenetic 
Discussion 
 
226 
 
evolution from yeast, where LSD1 initially appeared, to human. Now all we have to 
do is understand their function. 
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